JPH0453848B2 - - Google Patents
Info
- Publication number
- JPH0453848B2 JPH0453848B2 JP56501991A JP50199181A JPH0453848B2 JP H0453848 B2 JPH0453848 B2 JP H0453848B2 JP 56501991 A JP56501991 A JP 56501991A JP 50199181 A JP50199181 A JP 50199181A JP H0453848 B2 JPH0453848 B2 JP H0453848B2
- Authority
- JP
- Japan
- Prior art keywords
- amplifier
- activity
- response
- fraction
- modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000694 effects Effects 0.000 abstract description 80
- 239000000427 antigen Substances 0.000 abstract description 76
- 108091007433 antigens Proteins 0.000 abstract description 76
- 102000036639 antigens Human genes 0.000 abstract description 76
- 230000004044 response Effects 0.000 abstract description 66
- 210000000265 leukocyte Anatomy 0.000 abstract description 46
- 239000000126 substance Substances 0.000 abstract description 27
- 239000000284 extract Substances 0.000 abstract description 26
- 210000000987 immune system Anatomy 0.000 abstract description 22
- 231100000430 skin reaction Toxicity 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 17
- 206010040914 Skin reaction Diseases 0.000 abstract description 12
- 230000028993 immune response Effects 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 12
- 230000035483 skin reaction Effects 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000009885 systemic effect Effects 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 8
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000004727 humoral immunity Effects 0.000 abstract description 4
- 239000000385 dialysis solution Substances 0.000 abstract description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 241000159243 Toxicodendron radicans Species 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000009290 primary effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 238000000502 dialysis Methods 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 238000010828 elution Methods 0.000 description 20
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 13
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 12
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 12
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 12
- 239000001099 ammonium carbonate Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 206010060708 Induration Diseases 0.000 description 8
- 229940026309 histoplasmin Drugs 0.000 description 8
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 8
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108010023197 Streptokinase Proteins 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 229960005202 streptokinase Drugs 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108010074506 Transfer Factor Proteins 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000002563 Histoplasmosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex⢠Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229940124644 immune regulator Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical group OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940029403 aplisol Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007459 negative regulation of leukocyte migration Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 102000040811 transporter activity Human genes 0.000 description 1
- 108091092194 transporter activity Proteins 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000001467 vasoreactive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00Â -Â A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265Â -Â B01D15/36
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
è«æ±ã®ç¯å²
ïŒ () ååéã3500ããå°ããã
() ããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿æ§ã®ç©è³ªã
å®è³ªçã«å«ãŸãããã㊠() ããçœè¡çæœåºç©ã®éæç©ããã²ã«æ¿Ÿéã
ãã³ãªã¯ã¿ãã·ã«ã·ã©ã³ã«ã©ã ãçšããéçžé«
é液äœã¯ãããã°ã©ãã€ãŒã§æ°Žäžã®ãšã¿ããŒã«
åŸé ã«ãã溶åºããããšã«ããåŸãããšãã§
ãããã€ãŸãã () 次ã®ããããã®ãšã¿ããŒã«æ¿åºŠç¯å²ã0.0ã
0.4ïŒ ã36ã40ïŒ ã72ã76ïŒ ã85ã89ïŒ ã94ã
95ïŒ ã97ã99ïŒ ããã³100ïŒ ãæãã溶åºç»å
ãšããŠåèšåŸé ãããããã溶åºããããšãã§
ããããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã0.0ã0.4ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ã
æãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒ
é ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã36ã40ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã72ã76ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã85ã89ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã94ã95ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã100ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæã
ã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ãã
ã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé ã®
ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã97ã99ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãâãµãã¬ããµãŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé ã®ã¢
ãžãŠã¬ãŒã¿ãŒã ïŒ ããçœè¡çæœåºç©ãããããçäœã®å ç«ç³»ã®
çŽæ¥ãŸãã¯éæ¥å¿çã«åœ±é¿ããæ§è³ªãæããå ç«
ç³»ã¢ãžãŠã¬ãŒã¿ãŒã補é ããæ¹æ³ã§ãã€ãŠããã®
ã¢ãžãŠã¬ãŒã¿ãŒã¯ããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿
æ§ã®ç©è³ªãå®è³ªçã«å«ãŸãããããŠ(1)ããçœè¡ç
æœåºç©ãéæååééççŽ3500ã®éæèã§éæ
ãã(2)éæç©ãã²ã«æ¿ŸéããŠè€æ°åã®åç»ã«åç»
åãã(3)ã¢ãžãŠã¬ãŒã¿ãŒç¢ºèªåç»ãéžæããŠé
ãã(4)éããããã¢ãžãŠã¬ãŒã¿ãŒç¢ºèªåç»ãéçž
ã¯ãããã°ã©ãã€ãŒã«ã©ã ã«ä»ãã(5)ã«ã©ã ãæ°Ž
äžã®ãšã¿ããŒã«åŸé ã§æº¶åºããããšãç¹åŸŽãšã
ããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒã®è£œé æ¹æ³ã ïŒïŒ 掻æ§æåãšã㊠() ååéã3500ããå°ããã () ããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿æ§ã®ç©è³ªã
å®è³ªçã«å«ãŸãããã㊠() ããçœè¡çæœåºç©ã®éæç©ããã²ã«æ¿Ÿéã
ãã³ãªã¯ã¿ãã·ã«ã·ã©ã³ã«ã©ã ãçšããéçžé«
é液äœã¯ãããã°ã©ãã€ãŒã§æ°Žäžã®ãšã¿ããŒã«
åŸé ã«ãã溶åºããããšã«ããåŸãããšãã§
ãããã€ãŸãã () 次ã®ããããã®ãšã¿ããŒã«æ¿åºŠç¯å²ã0.0ã
0.4ïŒ ã36ã40ïŒ ã72ã76ïŒ ã85ã89ïŒ ã94ã
95ïŒ ã97ã99ïŒ ããã³100ïŒ ãæãã溶åºç»å
ãšããŠåèšåŸé ãããããã溶åºããããšãã§
ããããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒãå«æãããã
ãã以åæŽé²ãããæåã«å¯Ÿããããå ç«ç³»å¿
çãå¢å€§ãããã¯æžå°ãããå»è¬çµæç©ã çºæã®èæ¯ ããå ç«ç³»ã¯ããããŠè€éã§ãçŸåšã§ãå®å šã«
ã¯ç解ãããŠããªããçŸåšã§ã¯ïŒçš®ã®äž»èŠãªæ
æ§ãããªãã¡ã埪ç°æäœã«ãã€ãŠä»²ä»ããã液äœ
æ§å ç«ãšãå称ã®ãšãããªã³ã现èã«ãã€ãŠä»²ä»
ããã现èæ§å ç«ãšããããšèããããŠãããäœ
液æ§å ç«ã¯ãããéå ç«å絊è ã«è¡æž å ç«ã°ãã
ãªã³ã«ãã€ãŠéæ¬ããããã®ãããªè¡æž ã仲ä»ã
ã茞éã«ãã€ãŠå ç«å¿çãçããããã¯å€ãã®å Ž
åå³æçã«çããã现è仲ä»å ç«ã¯æªæ¢¢è¡çœè¡ç
ã«ãã€ãŠèŒžéãããã现èã«ãã€ãŠèŒžéãããå
ç«å¿çã¯ãæ°æéãšããæéãçµãŠç·©åŸã«çºçŸã
ãã 现è仲ä»å ç«ã®ä»£è¡šçãªçºçŸã¯é 延åéææ§å
å¿ã§ãããæ¬æ现æžã§ã¯DHãšç¥ãããDHç®è
åå¿ã¯ãé©åœãªæåãç®äžæ³šå°ãããå Žåã«èªã
ãããã24ã48æé以å ã«ãå±æçççïŒçºèµ€ïŒ
ããã³è «è¹ãšè¥åïŒç¡¬çµïŒããæåæ§ã®é«ãåäœ
ã«èªããããæåæ§ã®çšåºŠã¯åå¿ã®ãµã€ãºããã³
匷床ã«ãã€ãŠæž¬å®ããããDHåå¿ã¯ãŸããç¹åŸŽ
çãªçµç¹åŠçæèŠããšãã«ççé åã«ãããè¡ç®¡
åšå²ã«ãªã³ãçããã³åçã®æµžæœ€ãçãããDH
åå¿ã®éšäœã«ã¿ããã现èã¯ãæªæ¢¢è¡çœè¡ç矀ã«
ç±æ¥ãããã®ã§ããã 现è仲ä»å ç«ã®æ©æ§ã¯ããŸã å®å šã«ã¯ããã€ãŠ
ããªããå¿çã仲ä»ãã现èã¯ãæåã®ææŠã«ã
ãŸããŸãªæ¹æ³ã§å¿çã§ããããã®çš®ã®å¿çã«ã¯ã
äžããããæåã«å¯ŸããŠç¹ç°çãªæåæ§ããã€çŽ°
èã®å¢æ®ãåçš®ã®å ç«æ©èœã仲ä»ãã现èããšã
ã°æäœã®èªå°ããã³å¢å ãç°ç©çŽ°èãè «çã«å¯Ÿã
ãåå¿ãå«ãŸããããããã®å¿çãã¿ãŒã³ã®è³ªã
ãã³éã¯å€ãã®å åãããšãã°èžè ºãå¯è ç®è³ªã®
ãã«ã¢ã³ãã€ã³ã¿ãŒããšãã³ããã®ä»ã®çŽ°èæ§å¿
çã®å¥å¹äœããšãã°ãã¹ã¿ãã³ãã»ãããã³ãã
ãã¹ã¿ã°ã©ã³ãžã³ã«ãã€ãŠåœ±é¿ãããã æ¬çºæã¯ãçœè¡çã®éææœåºæ¶²ããåé¢ããã
现è仲ä»å ç«å¿çã«åŒ·åã«åœ±é¿ããå ç«ç³»ã¢ãžãŠ
ã¬ãŒã¿ãŒã®çºèŠã«åºã¥ããã®ã§ãããããã¯ãç¹
ç°çæåã«å¯Ÿããéå°åå¿ãŸãã¯äžé©åœãªåå¿ã«
ããåçš®èšåºçç¶ã®æ²»çããã³ããçš®ã®ã¢ã¬ã«ã®
ãŒçç¶ã®ç·©åã«æçšã§ããã åŸæ¥æè¡ 1954幎ãH.S.Lawrenceã¯ãããã«ã¯ãªã³æå
æ§äŸäžè ã®çœè¡çãã調補ãã溶解質ãããã«ã¯
ãªã³éåå¿å絊è ã«ãã®æåæ§ãéã¶ããšãã§ã
ãããšãå ±åãããJ.Clin.Invest.33ã951
ïŒ1954ïŒãããã®ä»äºã«ã€ããŠã®æè¿ã®ç·èª¬ãšããŠ
LawrenceãH.S.ïŒThe Harvey Lactures68ã
239ïŒ1974ïŒããŸããã®æç¹ã§ã®è«æãéãããã®
ãšããŠã¯ãM.S.AscherãA.A.GottliebãC.H.
Kirkpatrickç·šïŒTransfer FactorïŒBasic
Properties and ClinicalApplicationsã
Academic PressãInc.ãNew YorkïŒ1976ïŒãã
ã³A.Kahnãç·šïŒImmune Regulators in
Transfer FactorãAcademic PressãInc.ã
New YorkïŒ1976ïŒãããããã®æåæ§ã®èŒžéã¯
çœè¡ç溶解質äžã®å åã«ãããã®ãšæšæž¬ãããã
ã®åŸã茞éå åãšããæ©èœçãªå称ãä»ããã
ïŒB.AmosãH.Koprowskiç·šïŒCellâBound
Antibodiesäžã§NajarianãJ.S.ãFeldmanãJ.D.
ã®è«æã«å¯Ÿããæ¹è©ã§LawrenceãH.S.ã«ããïŒã
ãã®èŒžéå åã«ããçŸåã¯ããã§ããã¿ãããã
ãã®ããã掻æ§ã®æ ¹æºãåé¢ããæ§ç¶ãæããã«
ããç 究ã¯åŸã ã«ããé²ãŸãªãã€ãã 茞éå åãæ確ã«ããã«ã¯ãïŒåã®æ£è ãããª
ãã¡äžããããæåã«å¯ŸããŠDHåå¿ã瀺ãããš
ãããã€ãŠããäŸäžè ãšãåäžæåãææŠãããŠ
ãDHåå¿ãèµ·ãããªãïŒãã®æåã«å¯Ÿãã现è
仲ä»å ç«ããããªããšèããããïŒããšãããã€
ãŠããå絊è ã確å®ããå¿ èŠããããäŸäžè ã®è¡
液ãã調補ããçœè¡çãç Žå£ãã现èå 容ç©ãé
æãããæ¿çž®ããéæç©ãé©åœãªç·©è¡æ¶²ã«ãšãã
å絊è ã®åè ãŸãã¯ä»ã®äŸ¿å©ãªéšäœã«ç®äžæ³šå°ã
ããçŽïŒæ¥åŸãå絊è ã®åäžéšäœãŸãã¯ä»ã®éšäœ
ã«ããã®æåãç®äžæ³šå°ããŠææŠããããå žåç
ãªDHåå¿ã¯çŽïŒé±åŸã«èŠ³å¯ãããããã®ããã«
ããŠèŒžéãããå ç«ã¯ãå絊è ã«ïŒå¹Žéãããä¿
æããããšããã 茞éå åã®ç²Ÿè£œããã³åå®ã®äœæ¥ã¯ãããã«äŒŽ
ãæ§é çãªããååŠçåºæºããªãããããŸã粟補
åŸã«èªããããçŸåãæåã®éæç©ã«ããèªå°ã
ããçŸè±¡ãšè³ªçã«ç°ãªãå Žåãå€ããããé²æ©ã
劚ããããŠããã茞éå åã®èªã粟補ãã¬ãã¬ãŒ
ã·ãšã³ã«ã€ããŠãçšãããããŸãDHç®èåå¿ä»¥
å€ã®åºæºã§ã¢ãã¿ãŒãããŠæç®äžã«çŸããããã
ã®èªããå®éãåäžã®çååŠçå®äœãæããŠãã
ã®ãããããã¯åäžã®çååŠçæ©èœãè¡šã掻æ§ã«
察ããŠçšãããŠããã®ããæçã§ã¯ãªããæ¬æ现
æžã«ãããŠã¯ã茞éå åã®èªã¯Lawrenceã«ãã€
ãŠåé¢ãããLawrenceã«ãã€ãŠæåã«ç¹åŸŽã¥ã
ããã掻æ§ããªãã¡ç¹å®ã®æåã«å¯Ÿããå ç«ãé«
床ã®æåæ§ããã€äŸäžè ããæåæ§ããããªãå
絊è ãžèŒžéããèœåããã€ç²çœè¡ç溶解ç©ã«éå®
ããŠçšããããšã«ããã ãã茞éå åã®ãããŸã§ã®åå¥åã§ã¯ãåçš®ã®
掻æ§ç©è³ªã®ååšãæããã«ãããŠããã
VandenbarkãA.A.ããJ.Immunol.118ã636
ïŒ1977ïŒãã¯ãçœè¡çæœåºæ¶²ã®éæç©ãSephadex
â25ïŒPharâmaciaãInc.ãUppsalaãSweden
ã®åæšåïŒã¯ãããã°ã©ãã€ãŒã«ä»ããçµæãå ±
åããŠãããin vivoã«ãããçç©æŽ»æ§ã¯å åŠå¯
床254nïœãŸãã¯280nïœã«ç€ºãïŒåã®äž»ããŒã¯ã«
ã®ã¿èªãããããïŒã€ã®ããŒã¯ãã©ã¯ã·ãšã³ã¯ã
æååå¿æ§äŸäžè ãããããŸã§ã¯éåå¿æ§ã§ãã€
ãå絊è ã«ãææãªç®èè©Šéšåå¿æ§ã茞éãããš
å ±åãããŠãããä»æ¹ã®ããŒã¯ã¯èªçºæŽ»æ§ïŒæå
ãå ããªãå Žåã®ç®èåå¿ïŒãçãããŸãæåãš
çµåãããšç®èåå¿ãææã«å¢å€§ããããåããŒ
ã¯ãã©ã¯ã·ãšã³ã¯çé»éæãŸãã¯ïŒïŒ é ¢é žããã
ã¯ïŒïŒ ã¡ã¿ããŒã«ã®æº¶åªç³»ãçšãããªã¯ã¿ãã·ã«
ã·ã©ã³æš¹èå å¡«ã«ã©ã äžéçžã¯ãããã°ã©ãã€ãŒ
ã«ãã€ãŠããã«åå¥åããããããããªãããã
ã®ååå¥ååŸã®çç©æŽ»æ§è©Šéšã®çµæã¯å ±åãããŠ
ããªãã GottliebãA.A.ãïŒTransfer FactorïŒBasic
Properties and Clinical Applicationsã263é ïŒ
ã¯çœè¡çéæç©åç»åã®ã¢ãã¿ãªã³ã°ã®æ段ãšã
ãŠããã¬ã¹ã«ãã³ãçšãããããã¬ã¹ã«ãã³
ãHoffmanâLaRocheãInc.ãNutleyãN.J.ã
BohlenãP.ãïŒArch.BiochemãBiophys.155ã
213ïŒ1973ïŒãã¯äžçŽã¢ããåºãæããç©è³ªãšåå¿
ãã匷ãè¢å ããã€çæç©ãäžããããã«ãã€ãŠ
ã¿ã³ãã¯ããã³ä»ã®äžçŽã¢ããåºããã€ååç©ã®
é«æ床å®éãå¯èœã§ãããéæãããçœè¡çæœåº
ç©è³ªãSephadex â10ïŒPharmaciaãInc.ã
UppsaleãSwedenã®åæšåïŒã«ã©ã ã§åç»åã
ããšãããçç©æŽ»æ§ã¯ããã¬ã¹ã«ãã³åå¿æ§äž»ã
ãŒã¯ã«ã€ããŠèªãããããæåãå ããŠãå ããª
ããŠããé 延åéææ§åå¿ãèªãããããã®å¿ç
ã¯æåååšæã®æ¹ã幟å倧ããã€ãã éæãããçœè¡çæœåºç©ã¯GottliebãA.A.ãã«
ããããã«åç»åãããJ.Reticuloendothelial
Soc.21ã403ïŒ1977ïŒã«å ±åãããŠãããæœåºç©ã¯
ãŸãã衚瀺ãããéæååéããããçŽ12000ã
ãã³3500ã®éæèãçšããŠãååéåå¥éæã«ä»
ãããåŸè ã®èãééãããååéç¯å²3500æªæº
ã®ç©è³ªãåç»ãååéç¯å²3500ã12000ã®ç©è³ª
ãåç»ãšåã¥ãããäž¡åç»ãSephadex â10
äžã²ã«éã«ä»ãããçç©æŽ»æ§ã¯ãã®å Žåããã
ãã¬ã¹ã«ãã³åå¿æ§ããŒã¯åç»ã«èªãããããã
ãããªããã掻æ§ã¯äŸäžè ã®å ç«ç¶æ ã®æ©èœã§ã¯
ãªãããã§ãã€ããããããïŒçš®ã®ç°ãªãäœçšã
èªããããã第äžã®äœçšã¯ãæåã®æ·»å ãªãããŸ
ãäŸäžè ããã³å絊è ã®å ç«ç¶æ ãšã¯ç¡é¢ä¿ãª
DHåå¿ã®èªå°ã§ãã€ãããã®çš®ã®æŽ»æ§ãæ¬æ现
æžã§ã¯ãã®ã¡ã«å®çŸ©ããããã«ã€ã³ããŠãŒãµãŒãš
åŒã¶ã第äºã®æŽ»æ§ã¯ãäŸäžè ãæåæ§ãæããã
ãããŸã§æŽé²ãããããšã®ãªãæåã«å¯Ÿããç®å
åå¿ã®å¢å€§ã§ãã€ãããã®ãããã¬ã¹ã«ãã³åå¿
æ§ã¯ãããã°ã©ãã€ãŒåç»ã«èªãããã掻æ§ã¯ã
å絊è ããã§ã«æåæ§ãæããæåã«å¯ŸããDH
åå¿ãå¢å€§ããããã§ãã€ãããããã®å Žåãã
äŸäžè ã®æåæ§ãšã¯ç¡é¢ä¿ã®ããã§ãã€ããã
ã©ã¯ã·ãšã³ãããã«ããããã·ã¢ãã¿ã€ãã¯ãã
ãã°ã©ãã€ãŒã«ãã€ãŠåç»ãããšãããæ·»å æå
ãªãã«DHåå¿ãçããçç©æŽ»æ§ã¯ãããã¬ã¹ã«
ãã³ãšã®åå¿ã§æ€ç¥ãããäž»ããªãããããã©ã¯
ã·ãšã³ã«ã¯ãªãã€ãã ããã«J.Immunol.124ã885ïŒ1980ïŒã«ã¯ã
GottliebãA.A.ãã«ãããã€ã³ããŠãŒãµãŒïŒæå
ãæ·»å ããªãã§DHåå¿ãçããïŒããã³ã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒå絊è ãæåæ§ãæããæåã®å
åšäžã«DHåå¿ãçããïŒããé·ã150cmã
Sephadex â10ã«ã©ã ã§åç»åããå Žåã®ããŒ
ã¿ã瀺ãããŠãããã¢ã³ããªãã¢ã€ã¢ãŒã¯äž»ãã
ã¬ã¹ã«ãã³åå¿æ§åç»ã«ååšããããã€ã³ããŠãµ
ãŒã¯ãã®åç»ã«ã¯ãªãã€ããããã«ããããã·ã¢
ãã¿ã€ããçšããŠåç»ããããã¢ã³ããªãã¢ã€ã¢
ãŒã®æŽ»æ§ã¯ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ã«çãŸã€
ããå¯Ÿç §æ¯èŒè©Šéšã«ããããã®æŽ»æ§ã¯ãåäžåŠçœ®
ãæœããèµ€è¡ç溶解ã«ãããŸãåäžç²Ÿè£œæäœãè¡
ã€ãé£å¡©æ°Žã«ããªãããšã確èªãããã GottliebãA.A.ãã¯ãImmune Regulators in
Transfer FactorãA.KahnãC.Kirkpatrickã
Hillç·šãAcademic PressãInc.ãNew York
ïŒ1979ïŒã339é ããšé¡ããè«æäžã§ãããŒã¿ã¯ç€º
ããŠããªããããµãã¬ããµãŒãšåŒã°ããå¥ã®æŽ»æ§
ããªãŒã°ã¡ã³ã¿ãŒæŽ»æ§ããããããã·ã¢ãã¿ã€ã
ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠåé¢ã§ããããšã瀺
åããŠããããªãŒã°ã¡ã³ã¿ãŒã¯ïŒ³éæåç»ã«çºèŠ
ãããåžžã«äž»ããã¬ã¹ã«ãã³åå¿æ§åç»ã«ååšã
ãããã®ãªãŒã°ã¡ã³ã¿ãŒã¯ã以åã«BCGã«æŽé²
ãããç¡æäœæ£è ã«å šèº«æäžãããšæå¹ã§ãããš
èãããããããã«ãéæåç»ã«èªãããããµ
ãã¬ããµãŒæŽ»æ§ã¯ãããããã·ã¢ãã¿ã€ãã¯ãã
ãã°ã©ãã€ãŒã«ãããŠãããã¬ã¹ã«ãã³åå¿æ§ç©
質ã®å Žåããé«ãå¡©æ¿åºŠã§æº¶åºãããšè¿°ã¹ãããŠ
ãããéæçœè¡çæœåºç©ã®åç»åãè©Šã¿ãããä»
ã®ç 究ãšããŠã¯ãWilsonãG.B.ããJ.Lab.Clin.
Med.93ã819ïŒ1979ïŒãã®in vitroã«ãããŠçœè¡ç
ã®éèµ°ã«åœ±é¿ããïŒçš®ã®æŽ»æ§ãããªãã¡ïŒçš®ã®æ
åéäŸåæ§æŽ»æ§ïŒæåãªãã§å¿çãçããïŒãïŒ
çš®ã®æåäŸåæ§ç¹ç°çã€ã³ããã¿ãŒããã³ïŒçš®ã®
æåäŸåæ§ãšã³ãã³ãµãŒã«ã€ããŠã®å ±åãããã
æåäŸåæ§ã€ã³ããã¿ãŒã¯ãé©åœãªäŸäžè ç¹ç°æ§
ã®æåã®ã¿ãin vitroã®çœè¡çéèµ°ã®ææãªé»å®³
ãçããã®ã§ã茞éå åãšå ±éã®æ§è³ªããã€ãŠã
ããæåäŸåæ§ã®çœè¡çé走匷åã¯ãæåç¹ç°æ§
ã«é¢ããç¹åŸŽã¥ãããªãããŠããªããããããªã
ããäžèšæŽ»æ§ãããå ç«ç³»ã®in vivoæ©èœã«äœã
ãã®é¢ä¿ãæããã®ãã©ããããŸããã®æ²»ççæ
çšæ§ãšã®é¢é£ã«ã€ããŠã¯ãå šãç¥ãããŠããªãã çºæã®èŠçŽ æ¬çºæã¯ããå ç«ç³»ã®ã¢ãžãŠã¬ãŒã¿ãŒã«é¢ã
ãããã詳现ã«ã¯ãæ¬çºæã¯ïŒïŒååéã3500
ããå°ãããïŒïŒããã¬ã¹ã«ãã³ã«æ¬è³ªçã«å
å¿æ§ã®ç©è³ªãå®è³ªçã«å«ãŸãããããŠïŒïŒãã
çœè¡çæœåºç©ã®éæç©ããã²ã«æ¿Ÿéããã³ãªã¯ã¿
ãã·ã«ã·ã©ã³ã«ã©ã ãçšããéçžé«é液äœã¯ãã
ãã°ã©ãã€ãŒã§æ°Žäžã®ãšã¿ããŒã«åŸé ã«ãã溶åº
ããããšã«ããåŸãããšãã§ããããå ç«ç³»ã¢ãž
ãŠã¬ãŒã¿ãŒã«é¢ããããã«ãŸãæ¬çºæã¯ãã®ãã
ãªããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿æ§ã®ç©è³ªãå®è³ª
çã«å«ãŸãªããããçäœã®å ç«ç³»ã®çŽæ¥ãŸãã¯é
æ¥å¿çã«åœ±é¿ããæ§è³ªãæããå ç«ç³»ã¢ãžãŠã¬ãŒ
ã¿ãŒãããçœè¡çæœåºç©ãã補é ããæ¹æ³ã«é¢
ãããã®æ¹æ³ã¯(1)ããçœè¡çæœåºç©ãéæååé
éççŽ3500ã®éæèã§éæãã(2)éæç©ãã²ã«æ¿Ÿ
éããŠè€æ°åã®åç»ã«åç»åãã(3)ã¢ãžãŠã¬ãŒã¿
ãŒç¢ºèªåç»ãéžæããŠéãã(4)éããããã¢ãžãŠ
ã¬ãŒã¿ãŒç¢ºèªåç»ãéçžã¯ãããã°ã©ãã€ãŒã«ã©
ã ã«ä»ãã次ãã§(5)ã«ã©ã ãæ°Žäžã®ãšã¿ããŒã«åŸ
é ã§æº¶åºããããšãç¹åŸŽãšããæ¹æ³ã§ãããæ¬æ
现æžã«ãããã¢ãžãŠã¬ãŒã¿ãŒã®èªã¯ãåç©ããã
ã¯ããçäœããã®éšåãŸãã¯ããããåŸãããæ
åã®ãäžèšçäœã以åã«æŽé²ãããããšãããæ
åã«å¯Ÿããå¿çãããªãã¡äžèšåç©ãããã¯ãã
ã®å ç«ç³»æ©èœã«ç¹ç°çã«åž°ããããšãã§ããå¿ç
ã«ãçŽæ¥ãŸãã¯éæ¥çã«äœçšããç©è³ªãšå®çŸ©ãã
ãããããã€ãŠãå ç«å¿çã«å¯Ÿããäœçšãå«ãã
äžè¬çäœçšãæããç©è³ªã¯ãããã«å®çŸ©ããã¢ãž
ãŠã¬ãŒã¿ãŒã®èªã«ã¯å å«ãããªããæ¬æ现æžã«è¿°
ã¹ãã¢ãžãŠã¬ãŒã¿ãŒã¯DHç®èåå¿è©Šéšã«ãããŠ
掻æ§ãçºçŸããããããã€ãŠããã®äž»äœçšã¯çŽ°è
仲ä»å ç«ç³»ã«å¯Ÿãããã®ãšèãããããããããª
ãããããã«è¿°ã¹ãã¢ãžãŠã¬ãŒã¿ãŒã¯å šå ç«ç³»ã«
åºç¯ãªäœçšãæããäœæ¶²æ§å ç«ç³»ã«ãäœçšããã
ãšããããæ¬æ现æžã«ãããŠè«ããã«éãã茞é
å åãã€ã³ããŠãŒãµãŒãã¢ã³ããªãã¢ã€ã¢ãŒãã
ã³ãµããã¬ããµãŒã®èªã¯ãããããç®èåå¿ã«ã
ããDHå¿çã«é¢é£ããããããã®æŽ»æ§ãšå®çŸ©ã
ããã 茞éå åã®èªã¯äžè¿°ã®ç²çœè¡çæœåºæ¶²ã®æœåºç©
ã瀺ãã茞éå å掻æ§ã¯ãäžããããæåã«å¯Ÿã
ãŠæåæ§ãæããããšãããã€ãŠããäŸäžè ã®çœ
è¡çãã茞éå åãã¬ãã¬ãŒã·ãšã³ã調補ããå
äžæåã«æåæ§ã®ãªãããšãããã€ãŠããå絊è
ã«ç®äžæ³šå°ããå Žåã«çºçŸãããå絊è ã«ãã®åŸ
ãã®æåãææŠããããšDHå¿çã芳å¯ãããã
å絊è ã¯ãæ£åžžæã茞éå å掻æ§ã泚å°ããªãå Ž
åãå¿çãçããªãã茞éå åã¯ãäžããããæ
åã«ä»¥åæŽé²ãããŠããªãå絊è ã«ãäœçšãèªã
ãããããšãããäžè¿°ã®ã¢ãžãŠã¬ãŒã¿ãŒã§ã¯ãª
ãããããã茞éå åã®äœçšã¯äžããããæåã«
é¢ããŠç¹ç°çã§ããããããã«è¿°ã¹ãã¢ã³ããªã
ã¢ã€ã¢ãŒããã³ãµãã¬ããµãŒã¯ãå絊è ã以åã«
æŽé²ãããæåã«éç¹ç°çã«äœçšããã ã€ã³ããŠãŒãµãŒã¯ãæåã®æ·»å ãªããäŸäžè ã
ãã³å絊è ã®æåæ§ãšã¯ç¡é¢ä¿ã«DHå¿çãçã
ã掻æ§ãšå®çŸ©ãããã ã¢ã³ããªãã¢ã€ã¢ãŒã¯ãå絊è ãæåæ§ãæã
ãæåã®æ³šå°åŸã«ãæ£åžžãã倧ããªå¿çã®ç£çã
ç¹åŸŽãšãããã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ã¯äŸäžè ã®
ç¹ç°çå ç«æåæ§ã«ã¯äŸåããªãã ãµãã¬ããµãŒæŽ»æ§ã¯ãå絊è ãæåæ§ãæãã
æåãšãµãã¬ããµãŒãåæã«æ³šå°ããå Žåãå絊
è ã«æ£åžžããå°ããDHå¿çãçãããšããçµæ
ã«ãã€ãŠèŠ³å¯ãããã æ¬çºæã«ãããŠãããå ç«ç³»ã®ã¢ãžãŠã¬ãŒã¿ãŒ
ã¯çœè¡çæœåºæ¶²ã®éæç©ããåé¢ããããïŒçš®ã®
ã¢ãžãŠã¬ãŒã¿ãŒã¯ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ãæ
ããïŒçš®ã¯ãµãã¬ããµãŒæŽ»æ§ãæãããã¢ã³ããª
ãã¢ã€ã¢ãŒã¯ãç¡æäœç¶æ ããã³å ç«æ©èœäœäžç¶
æ ã®æ²»çã«å±æçãŸãã¯å šèº«çã«çšããŠæçšãšè
ããããäžæ¹ããµãã¬ããµãŒã¯å±æçæäœäº¢é²ç¶
æ ããšãã°ãããã«ããé害ã®æ²»çã«æçšã§ã
ãããããã®ã¢ã³ããªãã¢ã€ã¢ãŒã¯ã¢ã³ããªãã¢
ã€ã¢ãŒïŒãïŒãšåœåããããµãã¬ããµãŒã¯ïŒ³âãµ
ãã¬ããµãŒããã³ïŒ¬âãµãã¬ããµãŒãšåœåããã 奜ãŸããæ æ§ã®è©³çŽ°ãªèª¬æ æ¬çºæã¯å ç«å¿çãã¢ãžãŠã¬ãŒãããæ©èœãã
ã€ç©è³ªã®çºèŠã«åºã¥ããã®ã§ãããçŸåšã®æè¡ã§
ã¯ãããåäœã以åã«æŽé²ãããæåã«å¯Ÿããå¿
çãå¢åŒ·ãŸãã¯æå¶ããã¢ãžãŠã¬ãŒã¿ãŒã®åå®ã
å¯èœã§ãããããããªããããã®çš®ã®ç©è³ªã«ãã€
ãŠãåçš®ã®ä¿®é£Ÿãããæ©èœãçŸãããããšãã°ã
åå¿ã®ç¹ç¶ãæåæ§ã®éŸå€ãããã³ççããªã³ã
çå¢æ®ãããã¯åŸªç°æäœç£ççã®å¿çã®çš®é¡ã§ã
ãããã®çš®ã®ä¿®é£Ÿæ©èœã¯ãããæ€ç¥ããã³å®éã
ãããã«çšããè©Šéšç³»ã«ãã€ãŠå®çŸ©ãããããšã¯
æããã§ãããæ¬çºæã®ã¢ãžãŠã¬ãŒã¿ãŒã«ã¯DH
å¿çã®ã¢ã³ããªã€ãã¢ã€ã¢ãŒããµãã¬ããµãŒãå«
ãŸããã°ããã§ãªããä»ã®é©åœãªè©Šéšç³»ã§æ€ç¥ã
å®éãããå ç«ä¿®é£Ÿã®ä»ã®è¡šçŸãå å«ãããã æ¬æ现æžã«è¿°ã¹ãã¢ãžãŠã¬ãŒã¿ãŒã¯ããããã€
ãŠãå ç«ç³»ã®æåéã®çŽ°èéäŒéã®èªç¶æ段ãæ§
æããã¢ãžãŠã¬ãŒã¿ãŒç©è³ªã®ç³»ã®äžéšã§ãããª
ãããã®å Žåãå ç«å¿çã®ç¶æ ã¯çµ¶ããåœé¢ã®æ
åææŠã®ã¬ãã«ããã³æŽ»æ§ã«å¿ããŠã¢ãã¿ãŒã
ãã修食ãããããããã€ãŠãæ¬çºæãããã®çš®
ã®ã¢ãžãŠã¬ãŒã¿ãŒç³»ã®ååšãæããã§ãã以äžã
ä»ã®ã¢ãžãŠã¬ãŒã¿ãŒãçºèŠãããããšãããåŸ
ããä»ã®ç²Ÿè£œæè¡ããã³ä»ã®è©Šéšæäœãçšããä»
åŸã®ç 究ãããã®çš®ã®ã¢ãžãŠã¬ãŒã¿ãŒã®åå®ãã
ã³ç²Ÿè£œãå°ãã§ããããããããªãããæ¬çºæã¯
ãã®çš®ã®ã¢ãžãŠã¬ãŒã¿ãŒã®ååšãæããã«ããå
çš®ã®å ç«æ§é¢é£ç¶æ ã®æ²»çã«æçšãªæ°ãããäºæ
ããªãæ§è³ªãæããæ°çš®ã®ã¢ãžãŠã¬ãŒã¿ãŒã®åé¢
ããã³ç¹åŸŽã¥ããå§ããŠè¡ãããšã«ããããã®çš®
ã®çºèŠãžã®éãéããã®ã§ããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãäžããããæåã«å¯Ÿ
ããæåæ§ãæããå絊è ã®DHç®èåå¿ã«å¯Ÿã
ãŠä¿é²ããã³å¢åŒ·å¹æã瀺ãç¹ãç¹åŸŽãšãããæ
åãšãšãã«æäžãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã«ã
ã€ãŠçããåå¿ã¯ãç®äžæ³šå°åŸçŽïŒã14æéã§åŒ·
床ãããŒã¯ã«éãã以åŸæ¥éã«æ¶éããïŒäžæ¹ã
ã¢ã³ããªãã¢ã€ã¢ãŒïŒããªãå Žåã«ã¯ãæåã®æ³š
å°åŸ24ã30æéã§ãæ£åžžã®DHå¿çã¯ããŒã¯ã«é
ããïŒãæ¬çºæã®ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãæ¬çº
æã®ä»ã®ã¢ãžãŠã¬ãŒã¿ãŒããããªã¯ã¿ãã·ã«ã·ã©
ã³ã«ã©ã ãçšãïŒã100ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«
âæ°ŽåŸé ã§æº¶åºããéçžã¯ãããã°ã©ãã€ãŒã«ã
ãåé¢ã§ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ã«ã©ã ã
ããå°ãªããšãæ°Žäž15ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«ã§
溶åºããããã®ã¢ããªãã¢ã€ã¢ãŒã®å€§éšåã¯æ°Žäž
çŽ15ïŒ ïŒïœïŒïœïŒããçŽ20ïŒ ïŒïœïŒïœïŒãšã¿ããŒ
ã«ïŒããŒãã³ãšã«ããŒæ¿åºŠæž¬å®è£ 眮ã®èªã¿åãæ¿
床ïŒäžã«æº¶åºããããåŸããã溶åºç»åã®å±æç
枬å®å€1.3324ã1.3326ããèšç®ããããšã¿ããŒã«
æ¿åºŠã¯ïŒã0.4ïŒ ã§ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒ
ã¯ããã¬ã¹ã«ãã³ãšã¯ã»ãšãã©åå¿ãããããã¬
ã¹ã«ãã³åå¿æ§ã®äž»ããŒã¯ãšã¯éçžã¯ãããã°ã©
ãã€ãŒã§åé¢ããããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ã
衚瀺ã®ååééæéç3500ã®éæèãééããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒããæåã«å¯Ÿããå¿çã®
ä¿é²ããã³å¢åŒ·ãçããããä¿é²ã®çšåºŠã¯ã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒã«å¯Ÿããå¿çãããããããªãã
å°ãããåå¿éšäœã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒæå
ã«ããå Žåãããå±éãããããªãé·æéïŒïŒæ¥
ãŸã§ïŒç¹ç¶ãããé©ãã¹ãããšã¯ãæ倧å¢åŒ·æŽ»æ§
ãé©çæ¿åºŠã«ãããŠã®ã¿èªããããè³é©æ¿åºŠãè¶
ãããšå¢åŒ·äœçšãäœäžããã°ãããDHå¿çã®æ
å¶ãçãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãªã¯ã¿ãã·
ã«ã·ã©ã³ããå°ãªããšã45ïŒ ïŒïœïŒïœïŒãšã¿ããŒ
ã«â氎溶液ã«ãã€ãŠæº¶åºãããã®ã¢ã³ããªãã¢ã€
ã¢ãŒã®å€§éšåã¯æ°ŽäžçŽ45ïŒ ïŒïœïŒïœïŒãçŽ53ïŒ
ïŒïœïŒïœïŒãšã¿ããŒã«ïŒããŒãã³ãšã«ããŒæ¿åºŠæž¬
å®è£ 眮ã®èªã¿åãæ¿åºŠïŒäžã«æº¶åºããããåŸãã
ã溶åºç»åã®å±æç枬å®å€1.3428ã1.3440ããèš
ç®ããããšã¿ããŒã«æ¿åºŠã¯36ã40ïŒ ã§ããããã
ã¬ã¹ã«ãã³ãšã¯åå¿ãããçœè¡çæœåºæ¶²ã®éæç©
ããåé¢ãããä»ã®ã¢ãžãŠã¬ãŒã¿ãŒããã³ãã®æœ
åºæ¶²ã«ãããããã¬ã¹ã«ãã³åå¿æ§ç©è³ªã®äž»ããŒ
ã¯ãããéçžã¯ãããã¯ã©ãã€ãŒã«ãã€ãŠåé¢ã
ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®ååéããã³ãµã€
ãºã¯ã衚瀺ã®ååééæéççŽ3500ã®éæèãé
éããçšåºŠã§ããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒïŒããã³ïŒã¯ãæåã«
察ããå¿çã®å¢åŒ·ããããããåžéç 究ã«ãã
ã°ãã¢ã³ããªãã¢ã€ã¢ãŒïŒããã³ïŒã®æŽ»æ§ã¯åžé
ã«ãã€ãŠå¢åŒ·ããããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æŽ»
æ§ãå¢åŒ·ãããããããŒã¿ã¯å¹ŸåãããŸãã§ã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒïŒããã³ïŒã¯ããªã¯
ã¿ãã·ã«ã·ã©ã³ãããããããå°ãªããšã70ïŒ
ïŒïœïŒïœïŒã80ïŒ ïŒïœïŒïœïŒããã³89ïŒ ïŒïœïŒïœïŒ
ãšã¿ããŒã«â氎溶液ã«ãã€ãŠæº¶åºããããããã
ã®ã¢ã³ããªãã¢ã€ã¢ãŒã®å€§éšåã¯ã以äžã®ãšã¿ã
ãŒã«âæ°Žæ¿åºŠç¯å²ïŒããŒãã³ãœã³ãšã«ããŒæ¿åºŠæž¬
å®è£ å®è£ 眮ã®èªã¿åãæ¿åºŠïŒã§æº¶åºãããïŒã¢ã³
ããªãã¢ã€ã¢ãŒïŒã¯70ïŒ ïŒïœïŒïœïŒã74ïŒ ïŒïœïŒ
ïœïŒãã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯80ïŒ ïŒïœïŒïœïŒã
84ïŒ ãïŒïœïŒïœïŒãã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯89ïŒ
ïŒïœïŒïœïŒã94ïŒ ïŒïœïŒïœïŒãåŸãããå溶åºç»å
ã®å±æç枬å®å€1.3531ã1.3543ã1.3567ã1.3580
ããã³1.3592ã1.3596ããèšç®ããããšã¿ããŒã«
æ¿åºŠã¯ããããã72ã76ïŒ ã85ã89ïŒ ããã³94ã
95ïŒ ã§ããããããã®ã¢ããªãã¢ã€ã¢ãŒã¯ããã
ãããã¬ã¹ã«ãã³ãšåå¿æ§ã瀺ããããã¹ãŠãã
ããããŸãæ¬æ现æžã«è¿°ã¹ãä»ã®ã¢ãžãŠã¬ãŒã¿ãŒ
ãããéçžã¯ãããã°ã©ãã€ãŒã«ãã€ãŠåé¢ã§ã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒïŒããã³ïŒã¯ããã
ãã衚瀺éæååééççŽ3500ã®éæèãééã
ãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯DHåå¿ã«ãããŠæå
ã«å¯Ÿãå¢åŒ·å¿çãçããå šèº«äœçšãæããããæ
ããã«ãããŠãããã¢ã³ããªãã¢ã€ã¢ãŒïŒãé€ã
æ¬æ现æžèšèŒã®å¢åŒ·æ§ã¢ãžãŠã¬ãŒã¿ãŒã®å€§éšåã«
å ±éããŠããç¹ã¯ãæ倧å¿çã®ããã®è³é©çšéã
ããç¹ã§ãããã¯åé¢ããããµã³ãã«ãåžéããŠ
ãããªããå¹æãæ¯èŒããããšã«ãã確èªãã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãªã¯ã¿ãã·ã«ã·ã©ã³
ãã100ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«ïŒããŒãã³ãšã«
ããŒæ¿åºŠæž¬å®è£ 眮ã®èªã¿åãæ¿åºŠïŒã§æº¶åºãã
ããåŸããã溶åºåç»ã®å±æç枬å®å€1.3610ã
1.3620ããèšç®ããããšã¿ããŒã«æ¿åºŠã¯100ïŒ ã§
ããããã®ã¢ã³ããªãã¢ã€ã¢ãŒã¯ããã¬ã¹ã«ãã³
ãšåå¿ãããæ¬æ现æžã«èšèŒã®ä»ã®ã¢ãžãŠã¬ãŒã¿
ãŒãšã¯éçžã¯ãããã°ã©ãã€ãŒã«ãã€ãŠåé¢ã§ã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®ååéããã³ãµã€ãº
ã¯ã衚瀺éæååééççŽ3500ã®éæèãééã
ãçšåºŠã§ããã ãµãã¬ããµãŒã¯è¡šç€ºéæååééç3500ã®é
æèãééããéæç©ããåé¢ãããããµãã¬
ããµãŒã¯ãéçžã¯ãããã°ã©ãã€ãŒã«ããïŒã
100ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«âæ°ŽåŸé ã§æº¶åºããŠ
åå®å¯èœã§ãããå°ãªããšãéšåçã«ã¢ã³ããªã
ã¢ã€ã¢ãŒïŒããã³ïŒããåé¢ã§ããããµãã¬ã
ãµãŒã¯ãªã¯ã¿ãã·ã«ã·ã©ã³ããæ°Žäžãšã¿ããŒã«67
ïŒ ã100ïŒ ïŒïœïŒïœïŒã®ç¯å²ã§æº¶åºããã96ïŒ
ïŒïœïŒïœïŒã99ïŒ ïŒïœïŒïœïŒïŒããŒãã³ãšã«ããŒæ¿
床枬å®è£ 眮ã®èªã¿åãæ¿åºŠïŒã§æº¶åºããåç»ã«æ
çã«ååšããããã®åç»ã®å±æç枬å®å€1.3602ã
1.3606ããèšç®ããããšã¿ããŒã«æ¿åºŠã¯97ã99ïŒ
ã§ããããµãã¬ããµãŒã¯éçžã¯ãããã°ã©ãã€
ãŒã«ãããäž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãšã®å
é¢æ§ããå€æããŠãããã¬ã¹ã«ãã³ãšåå¿ããŠè¢
å ãçããããšã¯ãªããDHç®èåå¿ã®æå¶ã¯ã
ãµãã¬ããµãŒãå絊è ãDHå¿çã瀺ãè©Šéšæ
åã®æ³šå°åãŸãã¯ãã®æ³šå°ãšåæã«æ³šå°ããå Žå
ã«çºçŸãããæå¶ã¯å¯éæ§ã§ãçæéäœçšåã§ã
DHã®çºçŸããçŽ72æéé 延ããããã¢ã³ããªã
ã¢ã€ã¢ãŒïŒããµãã¬ããµãŒãšåæã«æ³šå°ãããš
æå¶ã¯èªããããªãã ãµãã¬ããµãŒã¯ã衚瀺éæååééç12000
ã®éæèãééããããéæååééçé3500ã®
èã§ã¯éæãããªãçœè¡çæœåºåç»äžã«ååšã
ãããµãã¬ããµãŒã®æŽ»æ§ã«äŒŒãŠããµãã¬ããµ
ãŒæŽ»æ§ã¯å¯éæ§ã§ãæå¶å¹æã¯çŽ72æéç¹ç¶ã
ãããµãã¬ããµãŒã¯ããããã·ã¢ãã¿ã€ãã¯ã
ããã°ã©ãã€ãŒã«ããäž»ããã¬ã¹ã«ãã³åå¿æ§ã
ãŒã¯ããåé¢ãããããšããå€æããŠãããã¬ã¹
ã«ãã³ãšåå¿ããªãã 以äžã®å®æœäŸäžã®æäœã¯ãããäŸäžè ããåŸã
ããææãããã³ããå絊è ã«å¯Ÿããè©Šéšã«ã€ã
ãŠè¿°ã¹ããã®ã§ãããçšããæäœããã³è©Šè¬ã¯ã
ããã®æ²»ççšã®ç¡èãéæ¯æ§çæç©ãåŸãããã
ãã«éžæãããç¹å®ã®æåã«å¯ŸããäŸäžè ããã³
å絊è ã®æåæ§ã¯ãããããè©Šéšããã äŸ ïŒ ç²Ÿè£œæäœ ïŒ¡ çœè¡çã®èª¿è£œ çœè¡çã¯ãå šè¡ãµã³ãã«ã®åç»åãŸãã¯çœè¡
çæ³³åã®ãããããçšããæšæºæ¹æ³ã§èª¿è£œã
ããåè ã®æ¹æ³ã§ã¯ãå šè¡ãµã³ãã«450mlã
MacrodexïŒPharmacia Corporationã
PiscatawayãN.J.ã®åæšåãççé£å¡©æ°ŽäžïŒ
ïŒ ïŒïœïŒïœïŒããã¹ãã©ã³70ïŒäž1xgã§æ²éã
ããŠåç»åããçœè¡çããèµ€è¡çãåé¢ããã
ãã®æ¹æ³ã§çŽïŒãïŒÃ109ã®çœè¡çãååãã
ããçœè¡çæ³³åã¯å€§éã®çŽ°èãåŸãå Žåã«å¥œãŸ
ããã€ããHaemoneticsïŒHaemonetics
Corp.ãBraintreeãMass.ã®åæšåïŒ30så现
èåé¢æ©ã䜿çšããããã®ç³»ã«ã¯ãæ«æ¢¢è¡ãã
ã®çœè¡çã®ååããã³æ²éã«ããæçµçœè¡çã
ã¬ãã¬ãŒã·ãšã³ããã®èµ€è¡çã®é€å»ãå¹æçã«
ããããã46.7ïŒ ã¯ãšã³é žäžãããªãŠã
ïŒHaemoneticsãBraintreeãMassãïŒ30c.c.ãã
ã³500mlã®ïŒïŒ ïŒïœïŒïœïŒVoltexïŒMcGaw
Co.ãIrvineãCalif.ã®åæšåïŒãé«ååéãã³
ãã³ãã¬ãã¬ãŒã·ãšã³ãäžå¡ãããããããã®
å Žåãã37âã§60åéã€ã³ããŠããŒãããã®
ã¡ãçœè¡çã«å¯ãã è¡æŒ¿ãåŸããããè¡æŒ¿ã
400xgã§15åéé æ²åŸã0.5Mé£å¡©æ°Žã§ïŒåæŽæµ
ããŠçœè¡çãååãããæŽæµåŸãçœè¡çãã¬ã
ããâ20âã§åçµä¿åããã现èåé¢æ©ãïŒå
äœåãããŠãçœè¡çã®å¹³ååéã¯ïŒÃ1010åã§
ãã€ãã  éæ çœè¡çæœåºæ¶²ã¯æ» èç¶æ ã§èª¿è£œãããçœè¡ç
ãã¬ãããïŒïœïŒéçé žã¢ã³ã¢ããŠã 10mlã«å
æžæ¿ãããã©ã€ã¢ã€ã¹âã¢ã»ãã³æµŽäžã§10åå
çµãè解ãããè¿ããã溶解ç©ããŸããéæå
åééç12000ã®ã»ã«ããŒã¹éæããŠãŒã
ïŒArthur H.ThomasãInc.ãChicagoãIll.ïŒã
çšããïŒïœïŒéçé žã¢ã³ã¢ããŠã ã«å¯ŸããŠéæ
ãããç·©è¡æ¶²ãïŒå亀æããéæ液ãåããŠå
çµä¹Ÿç¥ããå°å®¹éã®éçé žã¢ã³ã¢ããŠã ã«å溶
解ããéæååééç3500ã®ã»ã«ããŒã¹ããŠãŒ
ããçšããïŒïœïŒéçé žã¢ã³ã¢ããŠã ã«å¯ŸããŠ
ååãšåæ§ã«éæããã第ïŒã®éæã«ãããæ®
ç液ãæ¬æ现æžã§ã¯ïŒ¬åç»ãéæ液ãåç»ãš
åŒã¶ãååç»ã次ã®äœ¿çšãŸã§â20âã§åçµä¿å
ããã  ã²ã«é Sephadex â10ïŒPharmaciaãInc.ã
UppsalaãSwedenã®åæšåïŒãïŒïœïŒéçé ž
ã¢ã³ã¢ããŠã äžã§äžå€èšæœ€ãããã€ãã§ãªãŒã
ã¯ã¬ãŒãã§åŠçããã埮ç²æ«ãé€å»ããã®ã¡ã
1.5cmÃ151cmã«ã©ã ã«å å¡«ããïŒïœïŒéçé žã¢
ã³ã¢ããŠã ã§å¹³è¡¡åãããå溶解ããåç»ã®
ããã¬ã¹ã«ãã³åå¿æ§ç©è³ª400mgãBohlenãP.
ãïŒArch.Biochem.Biophys.155ã213ïŒ1973ïŒ
ã«ãããããå®éåºæºãšããŠã®ãŠã·è¡æž ã¢ã«ã
ãã³ã«åºã¥ãããã«ã©ã ã«è² è·ããããµã³ãã«
ã¯ïŒïœïŒéçé žã¢ã³ã¢ããŠã ã«ãããæµé13
mlïŒæã§æº¶åºãããïŒã«ã©ã 容éïŒ254mlïŒã
0.8mlã®ãã©ã¯ã·ãšã³ãšããŠæ¡éãããåãã©
ã¯ã·ãšã³100ÎŒããšã€ãŠã254nïœã«ããã玫
å€ç·åžåããã³ããã¬ã¹ã«ãã³ãšã®åå¿æ§ã調
ã¹ããçµæã¯ç¬¬ïŒå³ã«ç€ºããšããã§ããã äž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãåŸãããã
ãã®ãã¿ãŒã³ã¯äŸäžè éã§å€åã¯ãªãã€ããã
ãã¬ã¹ã«ãã³åå¿æ§ãšã®é¢ä¿ã§ã®ã¢ãžãŠã¬ãŒã¿
ãŒæŽ»æ§ã®äœçœ®ã¯äžé£ã®10ååžé液ã«ããã€ãŠ
DHå¿çã枬å®ããŠæããã«ãããDHå¿çã®
æ§è³ªã¯åžéã«ãã€ãŠå šãäºæãã¬æ¹åã«å€åã
ããããã¬ã¹ã«ãã³ããŒã¯ã®é åã®éåžéãµã³
ãã«ã¯ãæååç¬ã«å¯Ÿããå¯Ÿç §å¿çã«æ¯ã¹ãŠæ
åã«å¯ŸããDHå¿çãäœäžããã10-2ããã³
10-3ã®åžéã§ãé©ãã¹ãããšã«ãDHå¿çã¯å¯Ÿ
ç §ã«æ¯ãå¢åŒ·ããããããã«é©ãã¹ãããšã«ã
10-5ã®ãªãŒããŒã«åžéãããšDHå¿çã®æå¶ã
èªããããããã®ãããªç°åžžãªå¿çæ§ã瀺ãå
ç»ããæ¬æ现æžã§ã¯ã¢ãžãŠã¬ãŒã¿ãŒç¢ºèªåç»ãš
åŒã¶ããã®åç»ãéžã³ããã«ç²Ÿè£œããããã®ã
ããªå®éšãããåé¡ã®æŽ»æ§ïŒã¢ãžãŠã¬ãŒã¿ãŒç¢º
èªåç»ïŒã¯äž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãšã
ãã«å ç«ã€å°ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãå«
ãé åã«ååšããããšãããã€ãã次ã®ç²Ÿè£œå·¥
çšã§ã¯ãåç»ïŒïŒïŒãïŒïŒïŒïŒç¬¬ïŒå³ã«ç€ºãïŒ
ãéããåçµä¹Ÿç¥ããããã®åç»ã®äž¡åŽã«ãã
ã«åéåç»ãåºããã°æçµåçãæ¹è¯ãããå¯
èœæ§ããããæé©ã®åç»éžæã¯ãŸã 確å®ããŠã
ãªãã äžéšã®å®éšã§ã¯ããã€ãšçãïŒ80cmïŒ
SephadexGâ10ã«ã©ã ãçšããŠã²ã«éãè¡
ã€ããé·ãã«ã©ã ã®æ¹ãåé¢ãæ¹åãããç¹ã
é€ããçµæã¯ã»ãŒåæ§ã§ãã€ãããšãã«ãé·ã
ã«ã©ã ã§ã¯ãäž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ã
ãæåéäŸåæ§ã®ã€ã³ããŠãŒãµãŒãåé¢ãã
ãã ã²ã«éã«ä»£ããŠãæé€ååééç5000ã®ã¹
ã«ãã³åããªã¹ãã¬ã³ãžããã«ããŒã³
ïŒShodex â802ïŒïœãæåé»å·¥è£œïŒã®ïŒÃ25
cmã«ã©ã ãçšããæµé0.8mlïŒåã®æ°Žã§æº¶åºã
ãé«éã²ã«æé€ã¯ãããã°ã©ãã€ãŒã«ãã粟補
ããããšãå¯èœã§ãã€ãã  éçžã¯ãããã°ã©ãã€ãŒ ãªã¯ã¿ãã·ã«ã·ã©ã³ã®ã«ã©ã ãçšããïŒã
100ïŒ ïŒïœïŒïœïŒåŸé ã®ãšã¿ããŒã«æ°Žæº¶æ¶²ã§æº¶
åºããéçžé«å§æ¶²äœã¯ãããã°ã©ãã€ãŒã«ãã
ããã«ç²Ÿè£œãè¡ã€ããã«ã©ã ã«ãµã³ãã«30mg
ïŒããã¬ã¹ã«ãã³åå¿æ§ã«åºã¥ããŠïŒãè² è·ãã
æµé0.5mlïŒåã§æº¶åºããïŒmlåç»ãéããã
äžéšã®ãã¬ãã¬ãŒã·ãšã³ã§ã¯ããšã¿ããŒã«âæ°Ž
åŸé ã«ç¶ããŠã100ïŒ ãšã¿ããŒã«ã«ããåé床
ã§æº¶åºãè¡ã€ãã åãã©ã¯ã·ãšã³ãåçµä¹Ÿç¥ããççé£å¡©æ°Ž
0.5mlã«å溶解ãããåãã©ã¯ã·ãšã³0.1mlãã
ãããããå容è ãæåæ§ã瀺ãããšã確èªã
ãæåãšãšãã«ç®å 泚å°ãã24æéåŸã®ç®èå
å¿ã調ã¹ããçµæã第ïŒå³ã«ç€ºãã 第ïŒå³ã«ç€ºãåé¢ã«ãããæåã¹ãã¬ããã
ããŒãŒïŒSKïŒã«æåæ§ã瀺ããªãäŸäžè ãã
ç©è³ªãåŸããå容è ã¯ã¹ãã¬ãããããŒãŒã«æ
åæ§ã瀺ãããšãããã€ãŠãããå容è ããã¢
ãžãŠã¬ãŒã¿ãŒã®ãªãå Žåã«ç€ºãSKã«å¯Ÿããç®
èåå¿ã第ïŒå³ã«æ°Žå¹³ãªç·ãšããŠç€ºããããã®
ç·ããäžã«ããã°ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ãã
ã以äžã®å¿çã¯æ£åžžããäœãããµãã¬ããµãŒæŽ»
æ§ã瀺åãããåèã®ããã第ïŒå³ã«ãããã¬
ã¹ã«ãã³åå¿ç©è³ªãªãã³ã«åçš®ã®å°ååïŒã»ã
ããã³ããã¹ã¿ãã³ãã¢ã¹ã³ã«ãã³é žããã³ã
ã³ã¢ããããã³ãªã³é žãã€ããã³ãŒããŸã³ïŒã§
è¡ç®¡åå¿æ§ãççèªçºæ§ãŸãã¯æççæ§ãç¥ã
ããŠããç©è³ªãå«ãåç»ã®äœçœ®ã瀺ããå®ç·ã¯
ååç»ã®æº¶åºãããŸãŸã®æ¿åºŠã§ã®ç®èåå¿æ§ã
瀺ããŠããã ååç»ã®çµæããæ°çš®ã®åžé床ã§æäžããé
ååç»ïŒïŒãïŒïŒïŒïŒïŒãïŒïŒïŒïŒïŒãïŒïŒïŒ
ãšæ¯èŒãããåžé床ãé«ãã»ã©ãéã«ã10ã20
ã®éååç»ã§ã¯æ倧ã®ã¢ããªãã¢ã€ã¢ãŒæŽ»æ§ã
瀺ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æ倧掻æ§ã瀺
ãåç»ïŒããªãã³ã«åç»ïŒïŒã®åžéå¹æãã
SKã«å¯ŸããŠæåæ§ã瀺ãåäœã§æž¬å®ãããçµ
æã¯ãæåããã³ã¢ãžãŠã¬ãŒã¿ãŒæ³šå°åŸïŒïŒïŒ
ïŒããã³24æéã®çºèµ€ããã³ç¡¬çµé åã®çžŠæšªã
mmã§ç€ºãããã¢ãžãŠã¬ãŒã¿ãŒã¯ççé£å¡©æ°Žã§åž
éããããã®ããŒã¿ã¯ç¬¬ïŒè¡šã«ç€ºãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã®å ŽåïŒç¬¬ïŒå³ã®åç»
ïŒïŒãè©Šéšããå šåžé床ã§åŒ·ãä¿é²ããå¢åŒ·äœ
çšãèªããããæ€èšããå šæ¿åºŠã§è©Šéšéšäœã®é£œ
åã瀺ããŠãããããããªãããåç»ïŒïŒã§
ã¯ã10ã1000ååžéã§ã®ã¿ææãªå¢åŒ·ãèªãã
ãããããã€ãŠãã¢ã³ããªãã¢ã€ã¢ãŒïŒæŽ»æ§ã«
ã¯æçãªè³é©æ¿åºŠãåŸããããããçšåºŠã®ä¿é²
ãã¿ãããããã¢ã³ããªãã¢ã€ã¢ãŒïŒã»ã©æç
ã§ã¯ãªãã€ãã 第ïŒå³ã®éåžéãµã³ãã«ã«ã€ããŠã®æž¬å®ã§åŸ
ãããã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ã®ããšïŒããŒã¯
ã¯ãå¿ ããããå šãã¬ãã¬ãŒã·ãšã³ã«ãããã¢
ã³ããªãã¢ã€ã¢ãŒã®çã®äœçœ®ã瀺ããã®ã§ã¯ãª
ããããã«ã¯ããã€ãã®çç±ãããã第äžã«ã
äŸäžè ã«ããçœè¡çäžã®ã¢ãžãŠã¬ãŒã¿ãŒæ¿åºŠã
ç°ãªããã§ãããçœè¡çäžã«ä»ã®ç©è³ªãããã
ããããã¬ãã¬ãŒã·ãšã³ã«åœ±é¿ããå Žåãã
ããè©Šéšããå容è åŽã®çç©åŠé©ãªå€åãã
ããæåŸã«ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã®å Žåãæ¿
床ã«ãã€ãŠéã®å¹æã瀺ãããšãé¢ä¿ããããš
ãã«ç¬¬ïŒå³ã«ãããŠãåç»ïŒïŒãïŒïŒã®é åã§
掻æ§ãäœäžããã®ã¯ããã®é åã§ã¯ã¢ã³ããªã
ã¢ã€ã¢ãŒãäžèšè³é©æ¿åºŠã«ãã€ãçµæã§ããã
ãšã¯æçã§ãããé©åœã«åžéããå Žåãã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒã®æŽ»æ§ããŒã¯ã¯åç»ïŒïŒãïŒïŒ
ã®é åã«èªããããã¹ãã§ããããã®çµè«ã第
ïŒå³ã«ç¹ç·ã§ç€ºãããããã¯ã¢ã³ããªãã¢ã€ã¢
ãŒïŒæŽ»æ§ãè³é©åžéã«ãããŠæž¬å®ãããšããŠã®
æšæž¬æ²ç·ã§ããã åç»ïŒïŒãïŒïŒã«ã¯ïŒ³ãµãã¬ããµãŒæŽ»æ§ãã¿
ããããæåãšåæã«æ³šå°ãããšããµãã¬ã
ãµãŒã¯æ³šå°ïŒãŸãã¯24æéåŸã®DHå¿çã®çºçŸ
ãå¹æçã«é²æ¢ãããããã«å¯Ÿããæååç¬ã
泚å°ããå Žåã«ã¯ã24æéåŸã«æçãªDHå¿ç
ãèªããããã¢ã³ããªãã¢ã€ã¢ãŒïŒãŸãã¯ïŒã
ååšãããšããã§ã¯ããã€ãšåŒ·ãå¿çããèªã
ããããçµæã第ïŒå³ã«ç€ºããæ£è ã®å·Šè ã«ã
第ïŒå³ã«ç€ºã溶åºåŸé ã®åç»ãéãïŒïŒ10ãã
ã³ïŒïŒ100ã«åžéãããã®ããæ£è ã®è ã«ç€ºã
ãããã«HPâPKâïŒã«ã¯HPâïŒïŒåç»ïŒã
ïŒïŒãåãïŒãHPâPKâïŒã«ã¯HPâïŒïŒåç»
ïŒïŒãïŒïŒãåãïŒãHPâPKâïŒã«ã¯HPâ
ïŒïŒåç»ïŒïŒãïŒïŒãåãïŒãPPDãšæ··åããŠ
äžé£ã«ç®äžæ³šå°ãããPPDåç¬ã®å¯Ÿç §ã®æ³šå°
ã¯æ£è ã®å³è ã«è¡ã€ããHPâïŒããã³HPâ
ïŒã泚å°ããéšäœã§ã¯ããã®åç»äžã®ã¢ã³ããª
ãã¢ã€ã¢ãŒã«ãããå¯Ÿç §ã«æ¯ã¹ãŠççã®å¢åŒ·ã
芳å¯ããããããããªãããHPâïŒåŠçéšäœ
ã§ã¯ãååšãããµãã¬ããµãŒã®æŽ»æ§ããã®åç»
ã®ã¢ã³ããªãã¢ã€ã¢ãŒã®æŽ»æ§ãäžåããšæã
ããççã¯äœäžããããµãã¬ããµãŒæŽ»æ§ã¯å€§
éšåã®äŸäžè ã§ãéçžã¯ãããã°ã©ãã€ãŒã®ã
ãŒã«ããåç»ïŒïŒãïŒïŒã«ã¿ãããããµãã¬
ããµãŒæŽ»æ§ãåäžã®åç»ããšãã°ç¬¬ïŒå³ã®åç»
ïŒïŒã«èªããããå Žåããã€ããããããªã
ããå šãã¬ãã¬ãŒã·ãšã³ã§åžžã«åäžãã©ã¯ã·ãš
ã³ã«ãµãã¬ããµãŒæŽ»æ§ãã¿ãããã®ã¿ã§ãªãã
ãã®ãããªæŽ»æ§ã®ååšã¯äŸäžè éã§å·®ãã¿ãã
ãã éçžã¯ãããã°ã©ãã€ãŒã«ããåé¢ãã20ã
ã30ãŸã§ã®é åã®åãã©ã¯ã·ãšã³ã«ã€ããŠæ°çš®
ã®åžéãè¡ã枬å®ãããšãã¢ã³ããªãã¢ã€ã¢ãŒ
ïŒïŒïŒããã³ïŒã®ååšã確èªããããã¢ã³ããª
ãã¢ã€ã¢ãŒïŒã®æŽ»æ§ããŒã¯ã¯åç»ïŒïŒããã³ïŒ
ïŒãã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æŽ»æ§ã¯åç»ïŒïŒã«
éãŸããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æŽ»æ§ã¯äž»ãšã
ãŠåç»ïŒïŒããã³ïŒïŒã«ååšããããµãã¬ã
ãµãŒã¯åç»ïŒïŒããã³ïŒïŒã«èªãããããã¯ã
ããã°ã©ãã€ãŒã®ä»£è¡šççµæã第ïŒå³ã«ç€ºãã
第ïŒå³ã§ã¯ãå¯Ÿç §ã«å¯ŸããDHå¿çã®å€åã
ïŒïœÃïœïŒâïŒa*Ãb*ïŒã«ããç®èåå¿ã®çšåºŠã§
ããããããïœããã³ïœã¯åç»ïŒæåã®æ³šå°ã«
ãã€ãŠçããçºèµ€éšäœã®çŽåŸããããã«çŽäº€ã
ã軞ã«ãã€ãŠæž¬å®ããŠmmã§è¡šç€ºããå€ã§ããã
a*ããã³b*ã¯æååç¬ã泚å°ããŠçããå¯Ÿç §
éšäœã§ã®çžåœããçŽåŸã§ãããããªãã¡ããã®
ç®èåå¿ã®çšåºŠã¯æååç¬ãã³æåãšã¢ãžãŠã¬
ãŒã¿ãŒã®æ··åã«ãããç å€ã®é¢ç©ã®å·®ã«ã»ãŒçž
åœãããåç»ïŒïŒããã³ïŒïŒã«ã¿ãããå¯Ÿç §ã¬
ãã«ïŒããå°ããªå€ã¯ãµãã¬ããµãŒæŽ»æ§ããïŒ
ãã倧ããå€ã¯ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ã瀺
ãã第ïŒå³ã«ç€ºããå®éšã§ã¯å¥æ°çªå·ã®åç»ã®
ã¿æž¬å®ããŠããããšãèæ ®ãããšã第ïŒå³ã®ã
ã¿ãŒã³ã¯ç¬¬ïŒå³ã®å Žåã«é¡äŒŒããŠããã ãšã¿ããŒã«âæ°ŽåŸé ããšã¿ããŒã«æ¿åºŠ99.9ïŒ
ã«éããã®ã¡ã100ïŒ ãšã¿ããŒã«ã«ããæµé0.5
mlïŒåã§æº¶åºããïŒmlåç»ãéãããšãéçžã«
ã©ã ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã溶åºãããã
ã®æ¡ä»¶ã§ã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯åç»ïŒïŒã
ïŒïŒã«æ€åºãããèŠããã®æ¿åºŠãæ倧ã«ãªãã®
ã¯åç»ïŒïŒã§ãã€ãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãå絊è ãæåæ§ã
瀺ãæåã«å¯Ÿããå¿çãä¿é²ãå¢å€§ããããïŒ
Ã108ã®çœè¡çããäžè¿°ã®ç²Ÿè£œæ³ã§çæããçš
éã§ã以åã«æŽé²ãããæåã«å¯Ÿããå¿çãçŸ
æ£ã«ããäœäžããæ£è ã®DHå¿çãæ¹åããå Ž
åã«ããå埩ããããäžè¬çã«ãã¢ã³ããªãã¢
ã€ã¢ãŒïŒã«å¯Ÿããå¿çã¯åžéã«ãã€ãŠå¢å€§ãã
ããè³çåžé床ã¯åå絊è ã«ããããŸãå€åæ
åã«ãã€ãŠãå€åããã第ïŒè¡šã«ã¯ïŒçš®ã®åžé
ã®çµæã瀺ããã§ã¯ãã¹ãã¬ãããããŒãŒæ
åæ§å絊è ã«ã¹ãã¬ãããããŒãŒ2.5åäœãšå
æã«ã¢ã³ããªãã¢ã€ã¢ãŒãæäžãããéçžã«ã©
ã ããéããã¢ã³ããªãã¢ã€ã¢ãŒã®åç»1.0ml
ãåçµä¹Ÿç¥ããççé£å¡©æ°Ž0.3mlã«å溶解ããã
æ瀺ããåç»0.1mlãæ瀺ããããã«ççé£å¡©
æ°Žã§åžéãã泚å°ãããã§ã¯ãPPDæåæ§
å絊è ã«æšæºAplisol PPD1/10åžé液0.05ml
ããã¢ã³ããªãã¢ã€ã¢ãŒã®æ瀺ããççé£å¡©æ°Ž
åžé液0.1mlãŸãã¯å¯Ÿç §ãšããŠççé£åæ°Ž0.1ml
ãšãšãã«æ³šå°ããã ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ããã€ç©è³ªã¯æ°Žæº¶æ¶²
ãããšãŒãã«ã§æœåºã§ãããæœåºå¯èœãªæŽ»æ§ã¯
æ倧å¹æãåŸãã«åžéãèŠãããããããªã
ããã©ã®ã¢ã³ããªãã¢ã€ã¢ãŒããšãŒãã«æœåºã
ããã®ãã¯äžæã§ãããäžè¿°ã®ã¢ãžãŠã¬ãŒã¿ãŒ
ã®éçžã¯ãããã°ã©ãã€ãŒã«ããåé¢ã¯æ¬æè¡
åéã§å ¬ç¥ã®åçš®éçžã«ã©ã ææãçšããŠå®æœ
ã§ããã溶åºç¶æ ã¯å€åããããäžèšã¢ãžãŠã¬
ãŒã¿ãŒã®åé¢ã«æé©ãªæ¡ä»¶ã¯æ¬æè¡åéã«ãã
ãéåžžã®ç¥èãæããè ã«ã¯å®¹æã«æ±ºå®ã§ãã
ãã®ã§ããã  éæåç»ã®åç»å éæåç»ã¯ããããã·ã¢ãã¿ã€ãäžã¯ãã
ãã°ã©ãã€ãŒã«ãã€ãŠããã«åç»åã§ãããç²
æ«ãé€å»ããã®ã¡ããããããããããã·ã¢ã
ã¿ã€ããïŒïœïŒéçé žã¢ã³ã¢ããŠã ã§å¹³è¡¡å
ãã1.5Ã20cmã«ã©ã ã«å å¡«ãããåçµä¹Ÿç¥ãã
0.05Méçé žã¢ã³ã¢ããŠã ã«å解ããåç»ã
ã«ã©ã ã«é©çšãããã«ã©ã ã¯0.05Mã0.2Mé
çé žã¢ã³ã¢ããŠã åŸé ïŒ115mlïŒã§ãã€ãã§
0.2Mã0.6Méçé žã¢ã³ã¢ããŠã åŸé ïŒ65mlïŒ
ã§æº¶åºãããåïŒmlã®åç»ã260nïœã®åžåã
ãã³ããã¬ã¹ã«ãã³ãšã®åå¿æ§ã§ã¢ãã¿ãŒã
ããã»ãŒå šåŸé ã«ããããåãã©ã¯ã·ãšã³ãïŒ
åãã€åããŠæ¡åãããåããåç»ã«ã€ããŠã
å絊è ãæåæ§ã瀺ããæåãšãšãã«ç®å 泚å°
ããŠçç©æŽ»æ§ã調ã¹ããçµæã第ïŒè¡šã«ç€ºãã
çžå¯ŸDHå¿çã¯ã硬çµé åã®çŽåŸã25ããã³43
æéã«æž¬å®ããŠmmã§è¡šããæååç¬ã泚å°ãã
å Žåã®å¯Ÿç §åå¿éšäœãšæ¯èŒããŠç¬¬ïŒè¡šã«ç€ºã
ãã0.1Mãš0.15Mã®éçé žã¢ã³ã¢ããŠã ã®é
ã«æº¶åºããåç»ïŒïŒïŒããã³ïŒïŒïŒã¯ãå°ãªã
ãšã43æéãDHåå¿ã匷åã«æå¶ããã72æ
éåŸã«ã¯ïŒïŒïŒããã³ïŒïŒïŒã®åç»ã泚å°ãã
éšäœã«10mmÃ10mmã®åå¿ãã¿ããããã®æå¶æŽ»
æ§ã¯æéããã€ãšå¯éæ§ããã€ããšã瀺ããŠã
ãã äŸ ïŒ ç¹åŸŽããã³å¯Ÿç §å®éš  äŸ1Bã§çœè¡çæœåºæ¶²ã補é ãããšåæ§ã«ã
ãŠéæèµ€è¡çæœåºæ¶²ã補é ãããåå¥éæã
SephadexGâ10ã«ã©ã ã¯ãããã°ã©ãã€ãŒã
äŸïŒã«èšèŒãããšåæ§ã«ããŠå®æœãããåŸãã
ãåç»ã«ã¯ãå ç«ã¢ãžãŠã¬ãŒã¿ãŒæŽ»æ§ã¯èªãã
ããªãã€ãããããã€ãŠã芳å¯ãããçç©æŽ»æ§
ã¯ãæœåºããã³ç²Ÿè£œå·¥çšã§å°å ¥ããããã®ã§ã¯
ãªãã€ããããã«ãè¡å°æ¿æœåºæ¶²ãåäžã®ç²Ÿè£œ
å·¥çšã«ä»ããããã¢ãžãŠã¬ãŒã¿ãŒæŽ»æ§ã¯ã¿ãã
ãªãã€ãã粟補ã¢ã³ããªãã¢ã€ã¢ãŒã®äžéšã¯å
ã¯ãããã°ã©ãã€ãŒã«ä»ããããã¯ããã®ç²Ÿè£œ
æãšã»ãŒåãæåã瀺ããã  茞éå åã«é¢ããå è¡æè¡ã®èšè¿°ããã芳å¯
ãããå絊è ã®æåæ§å¢å€§ããäŸäžå·®ã«ã¯æ€å°
ã§ããªãã€ãäœã¬ãã«ã®æåæ§ã®èŒžéã«ããã
æ¿çž®ãããŠå絊è ã«ãããŠæåæ§ã®å¢å€§ãšããŠ
çŸããã®ã§ã¯ãªããšããããšããã§ããéãæ
çœã«ããããšãéèŠã§ãã€ãããã®å Žåã«çšã
ãå®éšæ¹æ³ã¯ãå°åçã«å±åšããããšãæãã
ãªæåãŸãã¯å»åŠçã«è¿œè·¡ã§ããèµ·æºã®æåã«
ã€ããŠè©Šéšããæ¹æ³ããããçµæ žèã®ç²Ÿè£œã¿ã³
ãã¯èªå°äœãPPDã¯å»åŠçã«è¿œè·¡å¯èœã§ãã
ã€å°åçã«å±åšãããPPDã«å¯Ÿããæåæ§ã¯
BCGïŒBacille CalmetteâGuerinïŒã§ã¯ã¯ãã³
åãããåæŽã®ããåäœã«çããããã¯æ¬§å·ã§
ã¯çµæ žã«å¯Ÿããå ç«ãä»äžããããåºç¯ã«çšã
ãããŠãããããããªãããç±³åœã§ã¯èš±å¯ãã
ãããšããªãããã¹ããã©ãºãã³ã¯å°åçã«å±
åšããæåã§ããããã¹ããã©ãºãã³ã«å¯Ÿãã
æåæ§ã¯ç±³åœåéšãç±åž¯å°æ¹ã«å€ãããã¹ãã
ã©ãºãçã¯ãã®å°æ¹ã®é¢šåç ã§ããã欧å·ã«ã¯
ãªãã å¯Ÿç §å®éšã§ã¯ãäŸäžè ã¯ç±³åœåéšçãŸãã§ã
ãã¹ããã©ãºãã³ã«ã¯ç®èè©Šéšã§æåæ§ã瀺ã
ããPPDã«ã¯åå¿ããªãè ãéžãã ãå絊è
ã¯ãã€ãšè±åœã«äœãã§ããŠãPPDã«å¯Ÿããç®
èè©Šéšã§æåæ§ã瀺ãããBCG泚å°ã®åæŽã
ãã€ãããã®å®éšã«çšããã¢ã³ããªãã¢ã€ã¢ãŒ
ãã¬ãã¬ãŒã·ãšã³ã¯äžè¿°ã®ããã«Sephadex 
â10åç»å·¥çšã«ãã粟補ããããçã80cmã«ã©
ã ãçšããŠåé¢çšåºŠã®äœããã®ãšãããããã
ã€ãŠãè©Šéšç©è³ªã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒãïŒã
ãã³ïŒ³ãµãã¬ããµãŒã®æ··åç©ã§ãããã«ããã¬
ã¹ã«ãã³åå¿æ§ç©è³ªãå«ãã§ãããããããªã
ããçµæã¯ãã¬ããŒã·ãšã³äžã«èŒžéå å掻æ§ã
ãªãããšã蚌æãšããŠéèŠã§ããã çµæã¯ç¬¬ïŒè¡šã«ç€ºããïŒåã®å絊è ããã
ããïŒçš®é¡ã®ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯
ïŒSephadexã«ã©ã ïŒïŒããã³ïŒïŒåç»ïŒã§è©Šéš
ãããããã¬ã¹ã«ãã³åå¿æ§ã«åºã¥ã2.4mgã®
åãã©ã¯ã·ãšã³ãåç¬ã«ãŸãã¯PPD25åäœãš
ãšãã«æ³šå°ãããã¯ããã®æ³šå°ãã14æéåŸ
ã«ãæåã泚å°ããªãã€ãéšäœã«ããã¹ããã©
ãºãã³ã0.1mlã®ãã¹ããã©ãºãã³æåïŒPark
âDavis Corp.ãDetroitãMich.ãççé£å¡©æ°Ž
ïŒïŒïŒïŒïŒïœïŒïœåžé液ãšããŠåžè²©ïŒãææŠãããã
PPDãŸãã¯ãã¹ããã©ãºãã³åç¬ã泚å°ãã
å¯Ÿç §éšäœãé©åœãªæéã«æºåããã第ïŒè¡šã«
ã¯ãç®èåå¿ã®åŒ·åºŠãã泚å°éšäœã«å²ã硬çµé
åã®çŽåŸïŒmmïŒã§ç€ºããããŒã¿ã¯ãå絊è ãã
çœè¡çæœåºæ¶²åç»ã®æ³šå°åãåŸããããããã¹
ããã©ãºãã³ãšåå¿ããèœåããããªãã€ãã
ãšã瀺ããŠãããã¢ã³ããªãã¢ã€ã¢ãŒã®ä¿é²ã
ãã³å¢åŒ·ã®äž¡å¹æãèªãããããäžæ¹ããã¹ã
ãã©ãºãã³æåæ§ã®èŒžéã¯ã¿ãããªãã  æ¬çºæã®ã¢ããªãã¢ã€ã¢ãŒæŽ»æ§ã®éèŠãªç¹
ã¯ãè©Šéšãããã¹ãŠããä¿é²ïŒã¢ã³ããªãã¢ã€
ã¢ãŒïŒïŒããã³å¢å€§ïŒã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒ
掻æ§ãªãã³ã«ã¢ã³ããªãã¢ã€ã¢ãŒïŒãå«ããŠå š
身çã«æå¹ãªããšã§ãããããã«ãå šèº«çå¹æ
ã¯ç¡æäœæ§æ£è ïŒçŸæ£ã§æ£åžžãªå ç«å¿çãæ¶å€±
ããæ£è ïŒã«ãèªããããšãã§ããã BCGã®æ¢åŸããããçŸåšã¯çŸæ£ã®ããPPD
ã«éåå¿æ§ã§ããæ£è ããäžè¿°ã®äŸ2Bã®ã¢ã³
ããªãã¢ã€ã¢ãŒã10ã100åã®é«çšéç®äžæ³šå°
ãããšãããPPDã«å¿çã瀺ãããã«ãªã€ãã
æåã«å¯Ÿããå¿çã¯ã¢ã³ããªãã¢ã€ã¢ãŒã®æ³šå°
éšäœã«å±éãããªãã€ãã å šèº«çå¹æã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒãçšããäž
é£ã®å®éšã§åçã«ç€ºãããããµã«ã³ã€ããŒã·ã¹ã«
ïŒå¹Žé眹æ£ããå šæåã«å¯Ÿããå¿çãèãã匱ã
ãªã€ãŠããæ£è ã®äŸã瀺ãã以äžã«è©Šéšãè¡ã€
ããè©Šéšç¬¬ïŒæ¥ã«ãæ£è ã«ç Žå·é¢šãããœã€ããã
åç¬ããã³çš®ã ã®åžé床ã§ã¢ã³ããªãã¢ã€ã¢ãŒïŒ
ãšãšãã«æäžãããçµæã¯ã第ïŒè¡šã«ç€ºããã
ã«ãç Žå·é¢šãããœã€ãåç¬ã§ã¯ç¡¬çµã®ãªã匱ãçº
èµ€åå¿ããã¢ã³ããªãã¢ã€ã¢ãŒïŒãšãšãã«æäžã
ããšãã¯ããããªå¢å€§ã瀺ãããããããªããã
ã©ã®è©Šéšéšäœã«ã硬çµã¯ãªããæ£è ãé©åœã«å¿ç
ããŠããªãããšã瀺ããŠãããè©Šéšç¬¬ïŒæ¥ãæ£è
ã«éçžã¯ãããã°ã©ãã€ãŒåç»ïŒïŒããã®ã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒããçŽïŒÃ108ã®çœè¡çããæœåº
ãããçžåœéãç®äžæ³šå°ãããè©Šéšç¬¬ïŒæ¥ã«ãæ£
è ã«å床ãç Žå·é¢šãããœã€ãããåç¬ã«ãŸãã¯æ°
çš®ã®åžé床ã®ã¢ã³ããªãã¢ã€ã¢ãŒïŒãšãšãã«åå
åæ§æäžããããã®ãšãã¯ãã¢ã³ããªãã¢ã€ã¢ãŒ
ïŒã«æçãªåå¿ããã€ãŠã第ïŒè¡šã«ç€ºãããã«ç¡¬
çµãèªããããããã®çµæã¯ç¬¬ïŒæ¥ã«æäžããã¢
ã³ããªãã¢ã€ã¢ãŒïŒã®å šèº«çå¹æã«ãã€ãŠä¿®é£Ÿã
ããæåã«å¯Ÿããå¿çãå¢å€§ããããšã瀺ããŠã
ãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã®å šèº«çå¹æã¯ãæ£è ã®
æ«æ¢¢è¡ãªã³ãçã®in vitroã«ããã掻æ§åã«å¯Ÿã
ãå¿çã®æž¬å®ã«ãã€ãŠãæããã§ããããªã³ãç
掻æ§åã¯ããç¥ãããçŸè±¡ã§ãããæ£åžžäººã®æ«æ¢¢
è¡ãªã³ãçãµã³ãã«ããæ€ç©ããã²ã³ããã€ããž
ãã°ã«ããã³ïŒPHAïŒãªã©ã®å ¬ç¥æŽ»æ§åå€ã«ã
ã现èå¹é€ã§å¢æ®ãèªçºãããå¢æ®é床ã¯å¹å°ã
ãåè£çŽ°èãžã®3Hâãããžã³åã蟌ã¿ã«ã€ãŠè¡š
ããããè©Šéšæ³ã¯OppenheimãJ.J.ãïŒIn Vitro
Methods of Cell Mediated and Tumor
ImmunityïŒBloomãDaviaç·šïŒ573ã585é ã
Academic PressãNew YorkãN.Y.ïŒ1976ïŒã«
èšèŒãããŠããã æ«æ¢¢ãªã³ãçãµã³ãã«ã¯äžèšè©Šéšã®ç¬¬ïŒæ¥ãã
ã³ç¬¬ïŒæ¥ã«æ¡åããå皮掻æ§åå€ã«å¯Ÿããå¿çã
枬å®ãããçµæã¯ç¬¬ïŒè¡šã«ç€ºãã第ïŒæ¥ã«ã¯ãªã³
ãçã¯æ£åžžã®å¿çã¬ãã«ããããªãäœãã€ããã
第ïŒæ¥ã«ã¯ïŒçš®ã®æŽ»æ§åå€äžã®ïŒçš®ã«å¯Ÿããæ£åžž
ãŸãã¯å¢å€§ããå¿çã瀺ãããããªãã¡ãã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒã®ç®äžæ³šå°ã«å¯Ÿããå šèº«çå¿çã
çããã äžè¿°ã®å®éšã§ããã¿èããã²ã³ã¯Gibco
LaboratoriesãGrand IslandãN.Y.ãPHAãã
ã³ã³ã³ã«ãããªã³ïŒ¡ã¯Difco Laboratoriesã
DetroitãMich.ããåŸããçµæã¯ç¬¬ïŒè¡šã«ã3Hâ
ãããžã³åã蟌ã¿ãã«ãŠã³ãïŒåã§ç€ºããã äŸ ïŒ åå¿é¡è ã«ã€ããŠã®å®éšçµæãããééºäŒæ§ã®
ç¡æäœæ§ãŸãã¯å ç«æ©èœäœäžç¶æ ã®å絊è ã®å ç«
å¿çãäžè¿°ã®ã¢ã³ããªãã¢ã€ã¢ãŒã§å¢å€§ã§ããã
ãšãæããã§ãããå¿é¡è ã«ã€ããŠã®äžéšã®å®éš
çµæã¯Sephadex â10ã¯ãããã°ã©ãã€ãŒã«ã
粟補ç©è³ªã§ãã¢ã³ããªãã¢ã€ã¢ãŒã®æ··åç©ãšèã
ãããç©è³ªãçšããŠè¡ããããæ²»çæ¹æ³ã®å¥œãŸã
ãæ æ§ã¯æ¬¡ã®ãšããã§ããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒãïŒã¯éçžã¯ãããã°ã©
ãã€ãŒãçšããäŸïŒã«èšèŒããããã«èª¿è£œã粟補
ããã掻æ§åç»ãéããåçµä¹Ÿç¥ããççé£å¡©æ°Ž
ãŸãã¯çççã«èš±å®¹ãããããŒã¯ã«ã«å溶解ã
ããæå¹éãããšãã°ïŒÃ107ã®çœè¡çãã粟補
ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒãïŒã«çžåœããéã
å«ã0.1mlãç®äžæ³šå°ãããå ç«å¿çã®å¢å€§ã¯ã
æåæ§ãã€ããšãããã€ãŠããæåã«å¯Ÿããæ£è
ã®åå¿æ§ãã¢ã³ããªãã¢ã€ã¢ãŒã®æäžååŸã§æ¯ã¹
ãŠã¢ãã¿ãŒãããã¢ã³ããªãã¢ã€ã¢ãŒã¯ææã®å¹
æã«å¿ããŠãåç¬ãŸãã¯é åæäžãããã¢ã³ããª
ãã¢ã€ã¢ãŒã®æäžã«ãã€ãŠçããç³»ã®ä¿®é£Ÿã®ç¹ç¶
ã¯æ£è éã§ç°ãªããäžè¿°ã®é©åœãªæåæ§è©Šéšã«ã
ãåšæçã«ã¢ãã¿ãŒããªããã°ãªããªããææã®
å ç«åŒ·åãç¶æããããã«ã¯ãå»åž«ã®å€æã«ã
ããæäžãããè¿ãã äŸ ïŒ ã¢ã³ããªãã¢ã€ã¢ãŒã¯ãåç¬ã«ãŸãã¯é åã
ãŠã匱ãã¯ã¯ãã³ã«å ç«å¿çãçãããããã«äœ¿
çšã§ãããå€ãã®ç åäœãããšãã°æ°çš®ã®ãããŠ
çèå€çš®ããã¹ããã©ãºãçãã«ã³ãžãçãçã
ãèã¯ãäžéšã®æ£è ã§ã¯åŒ·ãå ç«å¿çãèªçºããª
ãããããããã®çš®ã®æ£è ã«å ç«æ©èœãäžããæº
足ã§ããã¯ã¯ãã³ã¯ç¥ãããŠããªãããã®çš®ã®è
ã®ææã¯ããšãã«ãçååŠçæ³ãå ç«æå¶å€çæ³
ãåããŠããæ£è ã«ãšã€ãŠã¯å±éºã§ããã匱ãæ
åã«å¯Ÿããæ£è ã®å ç«å¿çãå¢åŒ·ããããšã«ã
ããäžè¿°ã®ã¢ã³ããªãã¢ã€ã¢ãŒã®ïŒçš®ãŸãã¯ïŒçš®
以äžã®æäžã¯ããã®çš®ã®ç åäœã«å¯Ÿããã¯ã¯ãã³
ã®è£œé ãå¯èœã«ãããååŠçæ³ãŸãã¯ç§»æ€æè¡ã
åããããšããæ£è ã¯ãæ²»çåã«ããã¹ããã©ãº
ãçãã«ã³ãžãçã«çœ¹æ£ãããããªããªãããã«
ã¯ã¯ãã³åããããšãã§ããã ã¯ã¯ãã³ã¯ãå ¬ç¥æ¹æ³ã«ããé©åœãªæžæ¯ããã³
éå¢æ®åããæ¹æ³ã§èª¿è£œããææã®ç åäœã®æå
ããäŸïŒã«èšèŒã®æ¹æ³ã§è£œé ããã¢ã³ããªãã¢ã€
ã¢ãŒïŒãïŒãšåããŠè£œé ãã®ã奜ãŸãããã¯ã¯ã
ã³ã¯åžžæ³ã«ãã€ãŠæäžããã äžè¿°ã®ããã«äœ¿çšããã°ãã¢ã³ããªãã¢ã€ã¢ãŒ
ïŒãïŒã¯ãå»åŠçäºé²æ³ã®ç¯å²ãæ¡å€§ããå ç«æ§
æåã®å¯èœæ§ãåºããããšãæåŸ ã§ããã äŸ ïŒ é節ãªãããã«ããç®èåå¿ãŸãã¯ä»ã®æ¥è§Šé
ææ§åå¿ã¯ïŒ³ãµãã¬ããµãŒåŠçœ®ã§äºé²ããããæ¥
觊ç®èåå¿ããšãã°ããããä»ã®ã¢ã¬ã«ã²ã³ã«å¯Ÿ
ããåå¿ã®äž»èŠéšåã¯DHåå¿ã§ããããšãç¥ã
ããŠããŠããã®çš®ã®æ²»çã¯æ¬¡ã®ããã«å®æœãã
ãããµãã¬ããµãŒã¯äŸïŒã«èšèŒããããã«ããŠ
粟補ã§ãããéçžã¯ãããã°ã©ãã€ãŒã§åŸããã
掻æ§åç»ãéããåçµä¹Ÿç¥ããã€ãã§ãã³ãŒã«ã
ã¯ãªãŒã åºå€çµæç©ã®ãããªå±ææäžã«é©ããè»
èã«å°å ¥ãããåå¿ãããšãã°çµç¹ãŸãã¯èåšç§»
æ€ã®ããã«å šèº«æ§ã®å Žåã¯ãéçµå£æäžã奜ãŸã
ããåäŸäžè ã«ãã€ãŠãµãã¬ããµãŒæŽ»æ§ã®åçã¯
å€åããã®ã§ãé©çšéã¯æŽ»æ§åäœã§è¡šãå¿ èŠãã
ããïŒãµãã¬ããµãŒåäœã¯ããDHåå¿ã®ç¡¬çµã®
çŽåŸãïŒmmäœäžãããã®ã«å¿ èŠãªæå°éãšå®çŸ©ã
ããããã®å®çŸ©ãçšããŠãèšåºçã«å¿ èŠãã€ãŠå€§
çšéãæäžããå Žåã«ã¯100cm2ãããå°ãªããšã
ïŒåäœã®å²åã§çšãããåŠçœ®ã¯å±éºãããéãç¶
ããå°ãªããšãïŒæ¥ã«ïŒåã®ééã§è¡ãããèšåº
äžå¿ èŠãªãã³ããã«é »åã«è¡ãããšãã§ãããå
æ£è ã®åå¿ã¯ãæ£è ã®æåã«å¯Ÿããæåæ§ã®çš
床ãããã³ãµãã¬ããµãŒã«å¯Ÿããåå¿ã«ããå€å
ããããã®çš®ã®çµæç©ã«ã¯ãã¹ããã€ããŸãã¯ä»
ã®æççå€ãå ããŠãæ²»çå¹æãå¢åŒ·ãããããš
ãæå©ã§ããã äŸ ïŒ é節ãªãããããã³ä»ã®æ¥è§Šç®èåå¿ã¯ãäŸïŒ
ã«èšèŒããæ¹æ³ã§è£œé ãããµãã¬ããµãŒã«ãã
é²æ¢ã§ããããã®å Žåããç®èåå¿ã®DHæåã
ãã®æ²»çæ³ã®æå¹æ§ãæ瀺ãããããããã·ã¢ã
ã¿ã€ãã¯ãããã°ã©ãã€ãŒããåŸããã掻æ§åç»
ãéããåçµä¹Ÿç¥ããå±ææäžã«é©ããè»èçµæ
ç©ã«å°å ¥ããããåå¿ãå šèº«çãªå Žåãããšãã°
çµç¹ãŸãã¯ç®è移æ€ã§ã¯ãéçµå£æäžã奜ãŸã
ããæäžéããã³æäžæ¹æ³ã¯ãäŸïŒã«è¿°ã¹ããšã»
ãŒåãã§ããã ãµãã¬ããµãŒãšïŒ³ãµãã¬ããµãŒã¯ãå¥åã«ãŸ
ãã¯åäžçµæç©ã«æ··åããŠé©çšã§ããã æ¯æ§ æ¬çºæã«ããããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒã¯ãã
ãããäžèšãããããªäººäœç©è³ªã®æœåºç©ã§ããã
ãã®æ¯æ§ã¯æ€åºã§ããªãçšäœããåæœåºç©ã®è©Šéš
ã«ãããŠããæ¯æ§ãããæ害ãªäœçšã¯èŠãåºãã
ãªãã€ãã äžè¬ççµè« å ç«ç³»ã«ãããäžè¿°ã®ã¢ãžãŠã¬ãŒã¿ãŒã¯ã倩ç¶
ã«ãããŠå ç«ã®èª¿æŽããçŽæ¥çŽ°èå ç«ã«ãããã
ã³å€åéæ¥çã«äœæ¶²æ§å ç«ã«ã圱é¿ããŠå¶ãã§ã
ãç©è³ªãšèããããããã®ç©è³ªã¯é«çŽåºŠã«èª¿è£œã
ããã®ã§ããã®æ§è³ªãç¹å®ããããšãã§ãããã
ã®æ§è³ªã¯ãå è¡æè¡ã«å ±åãããŠãã茞éå åã
ãã®éšååç»ãšã¯å šãç°ãªããäºæãã¬çžç°ã瀺
ãããæ¬çºæã®ã¢ã³ããªãã¢ã€ã¢ãŒããã³ãµãã¬
ããµãŒã¯ãåçš®ã®å ç«æ©èœäº¢é²ããã³äœäžç¶æ ã
åããæ£è ã®æ²»çã«äœ¿çšã§ããããã®ç©è³ªã¯ç¹ç°
çãªæ§è³ªãæããè ãšããããããæ£åžžäŸäžè ã
ãåé¢ã§ãããããã€ãŠããŒã«ããåæãã倧èŠ
æš¡ãªç²Ÿè£œã容æã§ããç¹ã§ãšãã«éèŠã§ãããæ¬
çºæã®ã¢ãžãŠã¬ãŒã¿ãŒã¯ãã®çç©æŽ»æ§ããã³ç©ç
æ§ç¶ã§å®çŸ©ããããã®ã§ãã€ãŠãå¿ ãããåäžå
åŠç©è³ªããæ§æããããã®ã§ã¯ãªãã æ¬çºæã以äžãç¹å®ã®å¥œãŸããæ æ§ãåç §ããŠ
説æããããæ¬çºæã®ç²Ÿç¥ããã³ç¯å²ããéžè±ã
ãããšãªãããã«æ¹å€ãå¯èœãªããšã¯åœç¶ã§ã
ããæ¬çºæã¯ãäžè¬ã«æ¬çºæã®åçã«ãããããŸ
ãæ¬çºæã®å±ããæè¡ç¯å²å ã§å ¬ç¥ãæ £çšã®å®å
ã«ããæ¬çºæããã®å€æŽã«åºã¥ããã¹ãŠã®æ¹å€ã
䜿çšãŸãã¯é©çšãå å«ãããããšãã°ãéæãã
ã³éæèã«ããéæãæ¬æ现æžã§ã¯æ¡çšããŠãã
ãããã®èªã¯ååããã³ïŒãŸãã¯çç©æŽ»æ§ãããµ
ã€ãºããã³ïŒãŸãã¯ééã§åé¢ããåçæ¹æ³ãå
å«ãããããªãã¡ãéæã®èªã¯ãéå€éãè¶ é
å¿ããã³é»æ°æ³³åãå å«ãããã®ã§ããã
å®è³ªçã«å«ãŸãããã㊠() ããçœè¡çæœåºç©ã®éæç©ããã²ã«æ¿Ÿéã
ãã³ãªã¯ã¿ãã·ã«ã·ã©ã³ã«ã©ã ãçšããéçžé«
é液äœã¯ãããã°ã©ãã€ãŒã§æ°Žäžã®ãšã¿ããŒã«
åŸé ã«ãã溶åºããããšã«ããåŸãããšãã§
ãããã€ãŸãã () 次ã®ããããã®ãšã¿ããŒã«æ¿åºŠç¯å²ã0.0ã
0.4ïŒ ã36ã40ïŒ ã72ã76ïŒ ã85ã89ïŒ ã94ã
95ïŒ ã97ã99ïŒ ããã³100ïŒ ãæãã溶åºç»å
ãšããŠåèšåŸé ãããããã溶åºããããšãã§
ããããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã0.0ã0.4ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ã
æãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒ
é ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã36ã40ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã72ã76ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã85ã89ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã94ã95ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé
ã®ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã100ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæã
ã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ãã
ã¢ã³ããªãã¢ã€ã¢ãŒïŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé ã®
ã¢ãžãŠã¬ãŒã¿ãŒã ïŒ ãããã97ã99ïŒ ã®ãšã¿ããŒã«æ¿åºŠç¯å²ãæ
ãã溶åºç»åãšããŠåŸé ãã溶åºããããšãã§ã
ãâãµãã¬ããµãŒã§ããè«æ±ã®ç¯å²ç¬¬ïŒé ã®ã¢
ãžãŠã¬ãŒã¿ãŒã ïŒ ããçœè¡çæœåºç©ãããããçäœã®å ç«ç³»ã®
çŽæ¥ãŸãã¯éæ¥å¿çã«åœ±é¿ããæ§è³ªãæããå ç«
ç³»ã¢ãžãŠã¬ãŒã¿ãŒã補é ããæ¹æ³ã§ãã€ãŠããã®
ã¢ãžãŠã¬ãŒã¿ãŒã¯ããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿
æ§ã®ç©è³ªãå®è³ªçã«å«ãŸãããããŠ(1)ããçœè¡ç
æœåºç©ãéæååééççŽ3500ã®éæèã§éæ
ãã(2)éæç©ãã²ã«æ¿ŸéããŠè€æ°åã®åç»ã«åç»
åãã(3)ã¢ãžãŠã¬ãŒã¿ãŒç¢ºèªåç»ãéžæããŠé
ãã(4)éããããã¢ãžãŠã¬ãŒã¿ãŒç¢ºèªåç»ãéçž
ã¯ãããã°ã©ãã€ãŒã«ã©ã ã«ä»ãã(5)ã«ã©ã ãæ°Ž
äžã®ãšã¿ããŒã«åŸé ã§æº¶åºããããšãç¹åŸŽãšã
ããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒã®è£œé æ¹æ³ã ïŒïŒ 掻æ§æåãšã㊠() ååéã3500ããå°ããã () ããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿æ§ã®ç©è³ªã
å®è³ªçã«å«ãŸãããã㊠() ããçœè¡çæœåºç©ã®éæç©ããã²ã«æ¿Ÿéã
ãã³ãªã¯ã¿ãã·ã«ã·ã©ã³ã«ã©ã ãçšããéçžé«
é液äœã¯ãããã°ã©ãã€ãŒã§æ°Žäžã®ãšã¿ããŒã«
åŸé ã«ãã溶åºããããšã«ããåŸãããšãã§
ãããã€ãŸãã () 次ã®ããããã®ãšã¿ããŒã«æ¿åºŠç¯å²ã0.0ã
0.4ïŒ ã36ã40ïŒ ã72ã76ïŒ ã85ã89ïŒ ã94ã
95ïŒ ã97ã99ïŒ ããã³100ïŒ ãæãã溶åºç»å
ãšããŠåèšåŸé ãããããã溶åºããããšãã§
ããããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒãå«æãããã
ãã以åæŽé²ãããæåã«å¯Ÿããããå ç«ç³»å¿
çãå¢å€§ãããã¯æžå°ãããå»è¬çµæç©ã çºæã®èæ¯ ããå ç«ç³»ã¯ããããŠè€éã§ãçŸåšã§ãå®å šã«
ã¯ç解ãããŠããªããçŸåšã§ã¯ïŒçš®ã®äž»èŠãªæ
æ§ãããªãã¡ã埪ç°æäœã«ãã€ãŠä»²ä»ããã液äœ
æ§å ç«ãšãå称ã®ãšãããªã³ã现èã«ãã€ãŠä»²ä»
ããã现èæ§å ç«ãšããããšèããããŠãããäœ
液æ§å ç«ã¯ãããéå ç«å絊è ã«è¡æž å ç«ã°ãã
ãªã³ã«ãã€ãŠéæ¬ããããã®ãããªè¡æž ã仲ä»ã
ã茞éã«ãã€ãŠå ç«å¿çãçããããã¯å€ãã®å Ž
åå³æçã«çããã现è仲ä»å ç«ã¯æªæ¢¢è¡çœè¡ç
ã«ãã€ãŠèŒžéãããã现èã«ãã€ãŠèŒžéãããå
ç«å¿çã¯ãæ°æéãšããæéãçµãŠç·©åŸã«çºçŸã
ãã 现è仲ä»å ç«ã®ä»£è¡šçãªçºçŸã¯é 延åéææ§å
å¿ã§ãããæ¬æ现æžã§ã¯DHãšç¥ãããDHç®è
åå¿ã¯ãé©åœãªæåãç®äžæ³šå°ãããå Žåã«èªã
ãããã24ã48æé以å ã«ãå±æçççïŒçºèµ€ïŒ
ããã³è «è¹ãšè¥åïŒç¡¬çµïŒããæåæ§ã®é«ãåäœ
ã«èªããããæåæ§ã®çšåºŠã¯åå¿ã®ãµã€ãºããã³
匷床ã«ãã€ãŠæž¬å®ããããDHåå¿ã¯ãŸããç¹åŸŽ
çãªçµç¹åŠçæèŠããšãã«ççé åã«ãããè¡ç®¡
åšå²ã«ãªã³ãçããã³åçã®æµžæœ€ãçãããDH
åå¿ã®éšäœã«ã¿ããã现èã¯ãæªæ¢¢è¡çœè¡ç矀ã«
ç±æ¥ãããã®ã§ããã 现è仲ä»å ç«ã®æ©æ§ã¯ããŸã å®å šã«ã¯ããã€ãŠ
ããªããå¿çã仲ä»ãã现èã¯ãæåã®ææŠã«ã
ãŸããŸãªæ¹æ³ã§å¿çã§ããããã®çš®ã®å¿çã«ã¯ã
äžããããæåã«å¯ŸããŠç¹ç°çãªæåæ§ããã€çŽ°
èã®å¢æ®ãåçš®ã®å ç«æ©èœã仲ä»ãã现èããšã
ã°æäœã®èªå°ããã³å¢å ãç°ç©çŽ°èãè «çã«å¯Ÿã
ãåå¿ãå«ãŸããããããã®å¿çãã¿ãŒã³ã®è³ªã
ãã³éã¯å€ãã®å åãããšãã°èžè ºãå¯è ç®è³ªã®
ãã«ã¢ã³ãã€ã³ã¿ãŒããšãã³ããã®ä»ã®çŽ°èæ§å¿
çã®å¥å¹äœããšãã°ãã¹ã¿ãã³ãã»ãããã³ãã
ãã¹ã¿ã°ã©ã³ãžã³ã«ãã€ãŠåœ±é¿ãããã æ¬çºæã¯ãçœè¡çã®éææœåºæ¶²ããåé¢ããã
现è仲ä»å ç«å¿çã«åŒ·åã«åœ±é¿ããå ç«ç³»ã¢ãžãŠ
ã¬ãŒã¿ãŒã®çºèŠã«åºã¥ããã®ã§ãããããã¯ãç¹
ç°çæåã«å¯Ÿããéå°åå¿ãŸãã¯äžé©åœãªåå¿ã«
ããåçš®èšåºçç¶ã®æ²»çããã³ããçš®ã®ã¢ã¬ã«ã®
ãŒçç¶ã®ç·©åã«æçšã§ããã åŸæ¥æè¡ 1954幎ãH.S.Lawrenceã¯ãããã«ã¯ãªã³æå
æ§äŸäžè ã®çœè¡çãã調補ãã溶解質ãããã«ã¯
ãªã³éåå¿å絊è ã«ãã®æåæ§ãéã¶ããšãã§ã
ãããšãå ±åãããJ.Clin.Invest.33ã951
ïŒ1954ïŒãããã®ä»äºã«ã€ããŠã®æè¿ã®ç·èª¬ãšããŠ
LawrenceãH.S.ïŒThe Harvey Lactures68ã
239ïŒ1974ïŒããŸããã®æç¹ã§ã®è«æãéãããã®
ãšããŠã¯ãM.S.AscherãA.A.GottliebãC.H.
Kirkpatrickç·šïŒTransfer FactorïŒBasic
Properties and ClinicalApplicationsã
Academic PressãInc.ãNew YorkïŒ1976ïŒãã
ã³A.Kahnãç·šïŒImmune Regulators in
Transfer FactorãAcademic PressãInc.ã
New YorkïŒ1976ïŒãããããã®æåæ§ã®èŒžéã¯
çœè¡ç溶解質äžã®å åã«ãããã®ãšæšæž¬ãããã
ã®åŸã茞éå åãšããæ©èœçãªå称ãä»ããã
ïŒB.AmosãH.Koprowskiç·šïŒCellâBound
Antibodiesäžã§NajarianãJ.S.ãFeldmanãJ.D.
ã®è«æã«å¯Ÿããæ¹è©ã§LawrenceãH.S.ã«ããïŒã
ãã®èŒžéå åã«ããçŸåã¯ããã§ããã¿ãããã
ãã®ããã掻æ§ã®æ ¹æºãåé¢ããæ§ç¶ãæããã«
ããç 究ã¯åŸã ã«ããé²ãŸãªãã€ãã 茞éå åãæ確ã«ããã«ã¯ãïŒåã®æ£è ãããª
ãã¡äžããããæåã«å¯ŸããŠDHåå¿ã瀺ãããš
ãããã€ãŠããäŸäžè ãšãåäžæåãææŠãããŠ
ãDHåå¿ãèµ·ãããªãïŒãã®æåã«å¯Ÿãã现è
仲ä»å ç«ããããªããšèããããïŒããšãããã€
ãŠããå絊è ã確å®ããå¿ èŠããããäŸäžè ã®è¡
液ãã調補ããçœè¡çãç Žå£ãã现èå 容ç©ãé
æãããæ¿çž®ããéæç©ãé©åœãªç·©è¡æ¶²ã«ãšãã
å絊è ã®åè ãŸãã¯ä»ã®äŸ¿å©ãªéšäœã«ç®äžæ³šå°ã
ããçŽïŒæ¥åŸãå絊è ã®åäžéšäœãŸãã¯ä»ã®éšäœ
ã«ããã®æåãç®äžæ³šå°ããŠææŠããããå žåç
ãªDHåå¿ã¯çŽïŒé±åŸã«èŠ³å¯ãããããã®ããã«
ããŠèŒžéãããå ç«ã¯ãå絊è ã«ïŒå¹Žéãããä¿
æããããšããã 茞éå åã®ç²Ÿè£œããã³åå®ã®äœæ¥ã¯ãããã«äŒŽ
ãæ§é çãªããååŠçåºæºããªãããããŸã粟補
åŸã«èªããããçŸåãæåã®éæç©ã«ããèªå°ã
ããçŸè±¡ãšè³ªçã«ç°ãªãå Žåãå€ããããé²æ©ã
劚ããããŠããã茞éå åã®èªã粟補ãã¬ãã¬ãŒ
ã·ãšã³ã«ã€ããŠãçšãããããŸãDHç®èåå¿ä»¥
å€ã®åºæºã§ã¢ãã¿ãŒãããŠæç®äžã«çŸããããã
ã®èªããå®éãåäžã®çååŠçå®äœãæããŠãã
ã®ãããããã¯åäžã®çååŠçæ©èœãè¡šã掻æ§ã«
察ããŠçšãããŠããã®ããæçã§ã¯ãªããæ¬æ现
æžã«ãããŠã¯ã茞éå åã®èªã¯Lawrenceã«ãã€
ãŠåé¢ãããLawrenceã«ãã€ãŠæåã«ç¹åŸŽã¥ã
ããã掻æ§ããªãã¡ç¹å®ã®æåã«å¯Ÿããå ç«ãé«
床ã®æåæ§ããã€äŸäžè ããæåæ§ããããªãå
絊è ãžèŒžéããèœåããã€ç²çœè¡ç溶解ç©ã«éå®
ããŠçšããããšã«ããã ãã茞éå åã®ãããŸã§ã®åå¥åã§ã¯ãåçš®ã®
掻æ§ç©è³ªã®ååšãæããã«ãããŠããã
VandenbarkãA.A.ããJ.Immunol.118ã636
ïŒ1977ïŒãã¯ãçœè¡çæœåºæ¶²ã®éæç©ãSephadex
â25ïŒPharâmaciaãInc.ãUppsalaãSweden
ã®åæšåïŒã¯ãããã°ã©ãã€ãŒã«ä»ããçµæãå ±
åããŠãããin vivoã«ãããçç©æŽ»æ§ã¯å åŠå¯
床254nïœãŸãã¯280nïœã«ç€ºãïŒåã®äž»ããŒã¯ã«
ã®ã¿èªãããããïŒã€ã®ããŒã¯ãã©ã¯ã·ãšã³ã¯ã
æååå¿æ§äŸäžè ãããããŸã§ã¯éåå¿æ§ã§ãã€
ãå絊è ã«ãææãªç®èè©Šéšåå¿æ§ã茞éãããš
å ±åãããŠãããä»æ¹ã®ããŒã¯ã¯èªçºæŽ»æ§ïŒæå
ãå ããªãå Žåã®ç®èåå¿ïŒãçãããŸãæåãš
çµåãããšç®èåå¿ãææã«å¢å€§ããããåããŒ
ã¯ãã©ã¯ã·ãšã³ã¯çé»éæãŸãã¯ïŒïŒ é ¢é žããã
ã¯ïŒïŒ ã¡ã¿ããŒã«ã®æº¶åªç³»ãçšãããªã¯ã¿ãã·ã«
ã·ã©ã³æš¹èå å¡«ã«ã©ã äžéçžã¯ãããã°ã©ãã€ãŒ
ã«ãã€ãŠããã«åå¥åããããããããªãããã
ã®ååå¥ååŸã®çç©æŽ»æ§è©Šéšã®çµæã¯å ±åãããŠ
ããªãã GottliebãA.A.ãïŒTransfer FactorïŒBasic
Properties and Clinical Applicationsã263é ïŒ
ã¯çœè¡çéæç©åç»åã®ã¢ãã¿ãªã³ã°ã®æ段ãšã
ãŠããã¬ã¹ã«ãã³ãçšãããããã¬ã¹ã«ãã³
ãHoffmanâLaRocheãInc.ãNutleyãN.J.ã
BohlenãP.ãïŒArch.BiochemãBiophys.155ã
213ïŒ1973ïŒãã¯äžçŽã¢ããåºãæããç©è³ªãšåå¿
ãã匷ãè¢å ããã€çæç©ãäžããããã«ãã€ãŠ
ã¿ã³ãã¯ããã³ä»ã®äžçŽã¢ããåºããã€ååç©ã®
é«æ床å®éãå¯èœã§ãããéæãããçœè¡çæœåº
ç©è³ªãSephadex â10ïŒPharmaciaãInc.ã
UppsaleãSwedenã®åæšåïŒã«ã©ã ã§åç»åã
ããšãããçç©æŽ»æ§ã¯ããã¬ã¹ã«ãã³åå¿æ§äž»ã
ãŒã¯ã«ã€ããŠèªãããããæåãå ããŠãå ããª
ããŠããé 延åéææ§åå¿ãèªãããããã®å¿ç
ã¯æåååšæã®æ¹ã幟å倧ããã€ãã éæãããçœè¡çæœåºç©ã¯GottliebãA.A.ãã«
ããããã«åç»åãããJ.Reticuloendothelial
Soc.21ã403ïŒ1977ïŒã«å ±åãããŠãããæœåºç©ã¯
ãŸãã衚瀺ãããéæååéããããçŽ12000ã
ãã³3500ã®éæèãçšããŠãååéåå¥éæã«ä»
ãããåŸè ã®èãééãããååéç¯å²3500æªæº
ã®ç©è³ªãåç»ãååéç¯å²3500ã12000ã®ç©è³ª
ãåç»ãšåã¥ãããäž¡åç»ãSephadex â10
äžã²ã«éã«ä»ãããçç©æŽ»æ§ã¯ãã®å Žåããã
ãã¬ã¹ã«ãã³åå¿æ§ããŒã¯åç»ã«èªãããããã
ãããªããã掻æ§ã¯äŸäžè ã®å ç«ç¶æ ã®æ©èœã§ã¯
ãªãããã§ãã€ããããããïŒçš®ã®ç°ãªãäœçšã
èªããããã第äžã®äœçšã¯ãæåã®æ·»å ãªãããŸ
ãäŸäžè ããã³å絊è ã®å ç«ç¶æ ãšã¯ç¡é¢ä¿ãª
DHåå¿ã®èªå°ã§ãã€ãããã®çš®ã®æŽ»æ§ãæ¬æ现
æžã§ã¯ãã®ã¡ã«å®çŸ©ããããã«ã€ã³ããŠãŒãµãŒãš
åŒã¶ã第äºã®æŽ»æ§ã¯ãäŸäžè ãæåæ§ãæããã
ãããŸã§æŽé²ãããããšã®ãªãæåã«å¯Ÿããç®å
åå¿ã®å¢å€§ã§ãã€ãããã®ãããã¬ã¹ã«ãã³åå¿
æ§ã¯ãããã°ã©ãã€ãŒåç»ã«èªãããã掻æ§ã¯ã
å絊è ããã§ã«æåæ§ãæããæåã«å¯ŸããDH
åå¿ãå¢å€§ããããã§ãã€ãããããã®å Žåãã
äŸäžè ã®æåæ§ãšã¯ç¡é¢ä¿ã®ããã§ãã€ããã
ã©ã¯ã·ãšã³ãããã«ããããã·ã¢ãã¿ã€ãã¯ãã
ãã°ã©ãã€ãŒã«ãã€ãŠåç»ãããšãããæ·»å æå
ãªãã«DHåå¿ãçããçç©æŽ»æ§ã¯ãããã¬ã¹ã«
ãã³ãšã®åå¿ã§æ€ç¥ãããäž»ããªãããããã©ã¯
ã·ãšã³ã«ã¯ãªãã€ãã ããã«J.Immunol.124ã885ïŒ1980ïŒã«ã¯ã
GottliebãA.A.ãã«ãããã€ã³ããŠãŒãµãŒïŒæå
ãæ·»å ããªãã§DHåå¿ãçããïŒããã³ã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒå絊è ãæåæ§ãæããæåã®å
åšäžã«DHåå¿ãçããïŒããé·ã150cmã
Sephadex â10ã«ã©ã ã§åç»åããå Žåã®ããŒ
ã¿ã瀺ãããŠãããã¢ã³ããªãã¢ã€ã¢ãŒã¯äž»ãã
ã¬ã¹ã«ãã³åå¿æ§åç»ã«ååšããããã€ã³ããŠãµ
ãŒã¯ãã®åç»ã«ã¯ãªãã€ããããã«ããããã·ã¢
ãã¿ã€ããçšããŠåç»ããããã¢ã³ããªãã¢ã€ã¢
ãŒã®æŽ»æ§ã¯ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ã«çãŸã€
ããå¯Ÿç §æ¯èŒè©Šéšã«ããããã®æŽ»æ§ã¯ãåäžåŠçœ®
ãæœããèµ€è¡ç溶解ã«ãããŸãåäžç²Ÿè£œæäœãè¡
ã€ãé£å¡©æ°Žã«ããªãããšã確èªãããã GottliebãA.A.ãã¯ãImmune Regulators in
Transfer FactorãA.KahnãC.Kirkpatrickã
Hillç·šãAcademic PressãInc.ãNew York
ïŒ1979ïŒã339é ããšé¡ããè«æäžã§ãããŒã¿ã¯ç€º
ããŠããªããããµãã¬ããµãŒãšåŒã°ããå¥ã®æŽ»æ§
ããªãŒã°ã¡ã³ã¿ãŒæŽ»æ§ããããããã·ã¢ãã¿ã€ã
ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠåé¢ã§ããããšã瀺
åããŠããããªãŒã°ã¡ã³ã¿ãŒã¯ïŒ³éæåç»ã«çºèŠ
ãããåžžã«äž»ããã¬ã¹ã«ãã³åå¿æ§åç»ã«ååšã
ãããã®ãªãŒã°ã¡ã³ã¿ãŒã¯ã以åã«BCGã«æŽé²
ãããç¡æäœæ£è ã«å šèº«æäžãããšæå¹ã§ãããš
èãããããããã«ãéæåç»ã«èªãããããµ
ãã¬ããµãŒæŽ»æ§ã¯ãããããã·ã¢ãã¿ã€ãã¯ãã
ãã°ã©ãã€ãŒã«ãããŠãããã¬ã¹ã«ãã³åå¿æ§ç©
質ã®å Žåããé«ãå¡©æ¿åºŠã§æº¶åºãããšè¿°ã¹ãããŠ
ãããéæçœè¡çæœåºç©ã®åç»åãè©Šã¿ãããä»
ã®ç 究ãšããŠã¯ãWilsonãG.B.ããJ.Lab.Clin.
Med.93ã819ïŒ1979ïŒãã®in vitroã«ãããŠçœè¡ç
ã®éèµ°ã«åœ±é¿ããïŒçš®ã®æŽ»æ§ãããªãã¡ïŒçš®ã®æ
åéäŸåæ§æŽ»æ§ïŒæåãªãã§å¿çãçããïŒãïŒ
çš®ã®æåäŸåæ§ç¹ç°çã€ã³ããã¿ãŒããã³ïŒçš®ã®
æåäŸåæ§ãšã³ãã³ãµãŒã«ã€ããŠã®å ±åãããã
æåäŸåæ§ã€ã³ããã¿ãŒã¯ãé©åœãªäŸäžè ç¹ç°æ§
ã®æåã®ã¿ãin vitroã®çœè¡çéèµ°ã®ææãªé»å®³
ãçããã®ã§ã茞éå åãšå ±éã®æ§è³ªããã€ãŠã
ããæåäŸåæ§ã®çœè¡çé走匷åã¯ãæåç¹ç°æ§
ã«é¢ããç¹åŸŽã¥ãããªãããŠããªããããããªã
ããäžèšæŽ»æ§ãããå ç«ç³»ã®in vivoæ©èœã«äœã
ãã®é¢ä¿ãæããã®ãã©ããããŸããã®æ²»ççæ
çšæ§ãšã®é¢é£ã«ã€ããŠã¯ãå šãç¥ãããŠããªãã çºæã®èŠçŽ æ¬çºæã¯ããå ç«ç³»ã®ã¢ãžãŠã¬ãŒã¿ãŒã«é¢ã
ãããã詳现ã«ã¯ãæ¬çºæã¯ïŒïŒååéã3500
ããå°ãããïŒïŒããã¬ã¹ã«ãã³ã«æ¬è³ªçã«å
å¿æ§ã®ç©è³ªãå®è³ªçã«å«ãŸãããããŠïŒïŒãã
çœè¡çæœåºç©ã®éæç©ããã²ã«æ¿Ÿéããã³ãªã¯ã¿
ãã·ã«ã·ã©ã³ã«ã©ã ãçšããéçžé«é液äœã¯ãã
ãã°ã©ãã€ãŒã§æ°Žäžã®ãšã¿ããŒã«åŸé ã«ãã溶åº
ããããšã«ããåŸãããšãã§ããããå ç«ç³»ã¢ãž
ãŠã¬ãŒã¿ãŒã«é¢ããããã«ãŸãæ¬çºæã¯ãã®ãã
ãªããã¬ã¹ã«ãã³ã«æ¬è³ªçã«åå¿æ§ã®ç©è³ªãå®è³ª
çã«å«ãŸãªããããçäœã®å ç«ç³»ã®çŽæ¥ãŸãã¯é
æ¥å¿çã«åœ±é¿ããæ§è³ªãæããå ç«ç³»ã¢ãžãŠã¬ãŒ
ã¿ãŒãããçœè¡çæœåºç©ãã補é ããæ¹æ³ã«é¢
ãããã®æ¹æ³ã¯(1)ããçœè¡çæœåºç©ãéæååé
éççŽ3500ã®éæèã§éæãã(2)éæç©ãã²ã«æ¿Ÿ
éããŠè€æ°åã®åç»ã«åç»åãã(3)ã¢ãžãŠã¬ãŒã¿
ãŒç¢ºèªåç»ãéžæããŠéãã(4)éããããã¢ãžãŠ
ã¬ãŒã¿ãŒç¢ºèªåç»ãéçžã¯ãããã°ã©ãã€ãŒã«ã©
ã ã«ä»ãã次ãã§(5)ã«ã©ã ãæ°Žäžã®ãšã¿ããŒã«åŸ
é ã§æº¶åºããããšãç¹åŸŽãšããæ¹æ³ã§ãããæ¬æ
现æžã«ãããã¢ãžãŠã¬ãŒã¿ãŒã®èªã¯ãåç©ããã
ã¯ããçäœããã®éšåãŸãã¯ããããåŸãããæ
åã®ãäžèšçäœã以åã«æŽé²ãããããšãããæ
åã«å¯Ÿããå¿çãããªãã¡äžèšåç©ãããã¯ãã
ã®å ç«ç³»æ©èœã«ç¹ç°çã«åž°ããããšãã§ããå¿ç
ã«ãçŽæ¥ãŸãã¯éæ¥çã«äœçšããç©è³ªãšå®çŸ©ãã
ãããããã€ãŠãå ç«å¿çã«å¯Ÿããäœçšãå«ãã
äžè¬çäœçšãæããç©è³ªã¯ãããã«å®çŸ©ããã¢ãž
ãŠã¬ãŒã¿ãŒã®èªã«ã¯å å«ãããªããæ¬æ现æžã«è¿°
ã¹ãã¢ãžãŠã¬ãŒã¿ãŒã¯DHç®èåå¿è©Šéšã«ãããŠ
掻æ§ãçºçŸããããããã€ãŠããã®äž»äœçšã¯çŽ°è
仲ä»å ç«ç³»ã«å¯Ÿãããã®ãšèãããããããããª
ãããããã«è¿°ã¹ãã¢ãžãŠã¬ãŒã¿ãŒã¯å šå ç«ç³»ã«
åºç¯ãªäœçšãæããäœæ¶²æ§å ç«ç³»ã«ãäœçšããã
ãšããããæ¬æ现æžã«ãããŠè«ããã«éãã茞é
å åãã€ã³ããŠãŒãµãŒãã¢ã³ããªãã¢ã€ã¢ãŒãã
ã³ãµããã¬ããµãŒã®èªã¯ãããããç®èåå¿ã«ã
ããDHå¿çã«é¢é£ããããããã®æŽ»æ§ãšå®çŸ©ã
ããã 茞éå åã®èªã¯äžè¿°ã®ç²çœè¡çæœåºæ¶²ã®æœåºç©
ã瀺ãã茞éå å掻æ§ã¯ãäžããããæåã«å¯Ÿã
ãŠæåæ§ãæããããšãããã€ãŠããäŸäžè ã®çœ
è¡çãã茞éå åãã¬ãã¬ãŒã·ãšã³ã調補ããå
äžæåã«æåæ§ã®ãªãããšãããã€ãŠããå絊è
ã«ç®äžæ³šå°ããå Žåã«çºçŸãããå絊è ã«ãã®åŸ
ãã®æåãææŠããããšDHå¿çã芳å¯ãããã
å絊è ã¯ãæ£åžžæã茞éå å掻æ§ã泚å°ããªãå Ž
åãå¿çãçããªãã茞éå åã¯ãäžããããæ
åã«ä»¥åæŽé²ãããŠããªãå絊è ã«ãäœçšãèªã
ãããããšãããäžè¿°ã®ã¢ãžãŠã¬ãŒã¿ãŒã§ã¯ãª
ãããããã茞éå åã®äœçšã¯äžããããæåã«
é¢ããŠç¹ç°çã§ããããããã«è¿°ã¹ãã¢ã³ããªã
ã¢ã€ã¢ãŒããã³ãµãã¬ããµãŒã¯ãå絊è ã以åã«
æŽé²ãããæåã«éç¹ç°çã«äœçšããã ã€ã³ããŠãŒãµãŒã¯ãæåã®æ·»å ãªããäŸäžè ã
ãã³å絊è ã®æåæ§ãšã¯ç¡é¢ä¿ã«DHå¿çãçã
ã掻æ§ãšå®çŸ©ãããã ã¢ã³ããªãã¢ã€ã¢ãŒã¯ãå絊è ãæåæ§ãæã
ãæåã®æ³šå°åŸã«ãæ£åžžãã倧ããªå¿çã®ç£çã
ç¹åŸŽãšãããã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ã¯äŸäžè ã®
ç¹ç°çå ç«æåæ§ã«ã¯äŸåããªãã ãµãã¬ããµãŒæŽ»æ§ã¯ãå絊è ãæåæ§ãæãã
æåãšãµãã¬ããµãŒãåæã«æ³šå°ããå Žåãå絊
è ã«æ£åžžããå°ããDHå¿çãçãããšããçµæ
ã«ãã€ãŠèŠ³å¯ãããã æ¬çºæã«ãããŠãããå ç«ç³»ã®ã¢ãžãŠã¬ãŒã¿ãŒ
ã¯çœè¡çæœåºæ¶²ã®éæç©ããåé¢ããããïŒçš®ã®
ã¢ãžãŠã¬ãŒã¿ãŒã¯ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ãæ
ããïŒçš®ã¯ãµãã¬ããµãŒæŽ»æ§ãæãããã¢ã³ããª
ãã¢ã€ã¢ãŒã¯ãç¡æäœç¶æ ããã³å ç«æ©èœäœäžç¶
æ ã®æ²»çã«å±æçãŸãã¯å šèº«çã«çšããŠæçšãšè
ããããäžæ¹ããµãã¬ããµãŒã¯å±æçæäœäº¢é²ç¶
æ ããšãã°ãããã«ããé害ã®æ²»çã«æçšã§ã
ãããããã®ã¢ã³ããªãã¢ã€ã¢ãŒã¯ã¢ã³ããªãã¢
ã€ã¢ãŒïŒãïŒãšåœåããããµãã¬ããµãŒã¯ïŒ³âãµ
ãã¬ããµãŒããã³ïŒ¬âãµãã¬ããµãŒãšåœåããã 奜ãŸããæ æ§ã®è©³çŽ°ãªèª¬æ æ¬çºæã¯å ç«å¿çãã¢ãžãŠã¬ãŒãããæ©èœãã
ã€ç©è³ªã®çºèŠã«åºã¥ããã®ã§ãããçŸåšã®æè¡ã§
ã¯ãããåäœã以åã«æŽé²ãããæåã«å¯Ÿããå¿
çãå¢åŒ·ãŸãã¯æå¶ããã¢ãžãŠã¬ãŒã¿ãŒã®åå®ã
å¯èœã§ãããããããªããããã®çš®ã®ç©è³ªã«ãã€
ãŠãåçš®ã®ä¿®é£Ÿãããæ©èœãçŸãããããšãã°ã
åå¿ã®ç¹ç¶ãæåæ§ã®éŸå€ãããã³ççããªã³ã
çå¢æ®ãããã¯åŸªç°æäœç£ççã®å¿çã®çš®é¡ã§ã
ãããã®çš®ã®ä¿®é£Ÿæ©èœã¯ãããæ€ç¥ããã³å®éã
ãããã«çšããè©Šéšç³»ã«ãã€ãŠå®çŸ©ãããããšã¯
æããã§ãããæ¬çºæã®ã¢ãžãŠã¬ãŒã¿ãŒã«ã¯DH
å¿çã®ã¢ã³ããªã€ãã¢ã€ã¢ãŒããµãã¬ããµãŒãå«
ãŸããã°ããã§ãªããä»ã®é©åœãªè©Šéšç³»ã§æ€ç¥ã
å®éãããå ç«ä¿®é£Ÿã®ä»ã®è¡šçŸãå å«ãããã æ¬æ现æžã«è¿°ã¹ãã¢ãžãŠã¬ãŒã¿ãŒã¯ããããã€
ãŠãå ç«ç³»ã®æåéã®çŽ°èéäŒéã®èªç¶æ段ãæ§
æããã¢ãžãŠã¬ãŒã¿ãŒç©è³ªã®ç³»ã®äžéšã§ãããª
ãããã®å Žåãå ç«å¿çã®ç¶æ ã¯çµ¶ããåœé¢ã®æ
åææŠã®ã¬ãã«ããã³æŽ»æ§ã«å¿ããŠã¢ãã¿ãŒã
ãã修食ãããããããã€ãŠãæ¬çºæãããã®çš®
ã®ã¢ãžãŠã¬ãŒã¿ãŒç³»ã®ååšãæããã§ãã以äžã
ä»ã®ã¢ãžãŠã¬ãŒã¿ãŒãçºèŠãããããšãããåŸ
ããä»ã®ç²Ÿè£œæè¡ããã³ä»ã®è©Šéšæäœãçšããä»
åŸã®ç 究ãããã®çš®ã®ã¢ãžãŠã¬ãŒã¿ãŒã®åå®ãã
ã³ç²Ÿè£œãå°ãã§ããããããããªãããæ¬çºæã¯
ãã®çš®ã®ã¢ãžãŠã¬ãŒã¿ãŒã®ååšãæããã«ããå
çš®ã®å ç«æ§é¢é£ç¶æ ã®æ²»çã«æçšãªæ°ãããäºæ
ããªãæ§è³ªãæããæ°çš®ã®ã¢ãžãŠã¬ãŒã¿ãŒã®åé¢
ããã³ç¹åŸŽã¥ããå§ããŠè¡ãããšã«ããããã®çš®
ã®çºèŠãžã®éãéããã®ã§ããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãäžããããæåã«å¯Ÿ
ããæåæ§ãæããå絊è ã®DHç®èåå¿ã«å¯Ÿã
ãŠä¿é²ããã³å¢åŒ·å¹æã瀺ãç¹ãç¹åŸŽãšãããæ
åãšãšãã«æäžãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã«ã
ã€ãŠçããåå¿ã¯ãç®äžæ³šå°åŸçŽïŒã14æéã§åŒ·
床ãããŒã¯ã«éãã以åŸæ¥éã«æ¶éããïŒäžæ¹ã
ã¢ã³ããªãã¢ã€ã¢ãŒïŒããªãå Žåã«ã¯ãæåã®æ³š
å°åŸ24ã30æéã§ãæ£åžžã®DHå¿çã¯ããŒã¯ã«é
ããïŒãæ¬çºæã®ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãæ¬çº
æã®ä»ã®ã¢ãžãŠã¬ãŒã¿ãŒããããªã¯ã¿ãã·ã«ã·ã©
ã³ã«ã©ã ãçšãïŒã100ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«
âæ°ŽåŸé ã§æº¶åºããéçžã¯ãããã°ã©ãã€ãŒã«ã
ãåé¢ã§ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ã«ã©ã ã
ããå°ãªããšãæ°Žäž15ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«ã§
溶åºããããã®ã¢ããªãã¢ã€ã¢ãŒã®å€§éšåã¯æ°Žäž
çŽ15ïŒ ïŒïœïŒïœïŒããçŽ20ïŒ ïŒïœïŒïœïŒãšã¿ããŒ
ã«ïŒããŒãã³ãšã«ããŒæ¿åºŠæž¬å®è£ 眮ã®èªã¿åãæ¿
床ïŒäžã«æº¶åºããããåŸããã溶åºç»åã®å±æç
枬å®å€1.3324ã1.3326ããèšç®ããããšã¿ããŒã«
æ¿åºŠã¯ïŒã0.4ïŒ ã§ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒ
ã¯ããã¬ã¹ã«ãã³ãšã¯ã»ãšãã©åå¿ãããããã¬
ã¹ã«ãã³åå¿æ§ã®äž»ããŒã¯ãšã¯éçžã¯ãããã°ã©
ãã€ãŒã§åé¢ããããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ã
衚瀺ã®ååééæéç3500ã®éæèãééããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒããæåã«å¯Ÿããå¿çã®
ä¿é²ããã³å¢åŒ·ãçããããä¿é²ã®çšåºŠã¯ã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒã«å¯Ÿããå¿çãããããããªãã
å°ãããåå¿éšäœã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒæå
ã«ããå Žåãããå±éãããããªãé·æéïŒïŒæ¥
ãŸã§ïŒç¹ç¶ãããé©ãã¹ãããšã¯ãæ倧å¢åŒ·æŽ»æ§
ãé©çæ¿åºŠã«ãããŠã®ã¿èªããããè³é©æ¿åºŠãè¶
ãããšå¢åŒ·äœçšãäœäžããã°ãããDHå¿çã®æ
å¶ãçãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãªã¯ã¿ãã·
ã«ã·ã©ã³ããå°ãªããšã45ïŒ ïŒïœïŒïœïŒãšã¿ããŒ
ã«â氎溶液ã«ãã€ãŠæº¶åºãããã®ã¢ã³ããªãã¢ã€
ã¢ãŒã®å€§éšåã¯æ°ŽäžçŽ45ïŒ ïŒïœïŒïœïŒãçŽ53ïŒ
ïŒïœïŒïœïŒãšã¿ããŒã«ïŒããŒãã³ãšã«ããŒæ¿åºŠæž¬
å®è£ 眮ã®èªã¿åãæ¿åºŠïŒäžã«æº¶åºããããåŸãã
ã溶åºç»åã®å±æç枬å®å€1.3428ã1.3440ããèš
ç®ããããšã¿ããŒã«æ¿åºŠã¯36ã40ïŒ ã§ããããã
ã¬ã¹ã«ãã³ãšã¯åå¿ãããçœè¡çæœåºæ¶²ã®éæç©
ããåé¢ãããä»ã®ã¢ãžãŠã¬ãŒã¿ãŒããã³ãã®æœ
åºæ¶²ã«ãããããã¬ã¹ã«ãã³åå¿æ§ç©è³ªã®äž»ããŒ
ã¯ãããéçžã¯ãããã¯ã©ãã€ãŒã«ãã€ãŠåé¢ã
ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®ååéããã³ãµã€
ãºã¯ã衚瀺ã®ååééæéççŽ3500ã®éæèãé
éããçšåºŠã§ããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒïŒããã³ïŒã¯ãæåã«
察ããå¿çã®å¢åŒ·ããããããåžéç 究ã«ãã
ã°ãã¢ã³ããªãã¢ã€ã¢ãŒïŒããã³ïŒã®æŽ»æ§ã¯åžé
ã«ãã€ãŠå¢åŒ·ããããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æŽ»
æ§ãå¢åŒ·ãããããããŒã¿ã¯å¹ŸåãããŸãã§ã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒïŒããã³ïŒã¯ããªã¯
ã¿ãã·ã«ã·ã©ã³ãããããããå°ãªããšã70ïŒ
ïŒïœïŒïœïŒã80ïŒ ïŒïœïŒïœïŒããã³89ïŒ ïŒïœïŒïœïŒ
ãšã¿ããŒã«â氎溶液ã«ãã€ãŠæº¶åºããããããã
ã®ã¢ã³ããªãã¢ã€ã¢ãŒã®å€§éšåã¯ã以äžã®ãšã¿ã
ãŒã«âæ°Žæ¿åºŠç¯å²ïŒããŒãã³ãœã³ãšã«ããŒæ¿åºŠæž¬
å®è£ å®è£ 眮ã®èªã¿åãæ¿åºŠïŒã§æº¶åºãããïŒã¢ã³
ããªãã¢ã€ã¢ãŒïŒã¯70ïŒ ïŒïœïŒïœïŒã74ïŒ ïŒïœïŒ
ïœïŒãã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯80ïŒ ïŒïœïŒïœïŒã
84ïŒ ãïŒïœïŒïœïŒãã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯89ïŒ
ïŒïœïŒïœïŒã94ïŒ ïŒïœïŒïœïŒãåŸãããå溶åºç»å
ã®å±æç枬å®å€1.3531ã1.3543ã1.3567ã1.3580
ããã³1.3592ã1.3596ããèšç®ããããšã¿ããŒã«
æ¿åºŠã¯ããããã72ã76ïŒ ã85ã89ïŒ ããã³94ã
95ïŒ ã§ããããããã®ã¢ããªãã¢ã€ã¢ãŒã¯ããã
ãããã¬ã¹ã«ãã³ãšåå¿æ§ã瀺ããããã¹ãŠãã
ããããŸãæ¬æ现æžã«è¿°ã¹ãä»ã®ã¢ãžãŠã¬ãŒã¿ãŒ
ãããéçžã¯ãããã°ã©ãã€ãŒã«ãã€ãŠåé¢ã§ã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒïŒããã³ïŒã¯ããã
ãã衚瀺éæååééççŽ3500ã®éæèãééã
ãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯DHåå¿ã«ãããŠæå
ã«å¯Ÿãå¢åŒ·å¿çãçããå šèº«äœçšãæããããæ
ããã«ãããŠãããã¢ã³ããªãã¢ã€ã¢ãŒïŒãé€ã
æ¬æ现æžèšèŒã®å¢åŒ·æ§ã¢ãžãŠã¬ãŒã¿ãŒã®å€§éšåã«
å ±éããŠããç¹ã¯ãæ倧å¿çã®ããã®è³é©çšéã
ããç¹ã§ãããã¯åé¢ããããµã³ãã«ãåžéããŠ
ãããªããå¹æãæ¯èŒããããšã«ãã確èªãã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãªã¯ã¿ãã·ã«ã·ã©ã³
ãã100ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«ïŒããŒãã³ãšã«
ããŒæ¿åºŠæž¬å®è£ 眮ã®èªã¿åãæ¿åºŠïŒã§æº¶åºãã
ããåŸããã溶åºåç»ã®å±æç枬å®å€1.3610ã
1.3620ããèšç®ããããšã¿ããŒã«æ¿åºŠã¯100ïŒ ã§
ããããã®ã¢ã³ããªãã¢ã€ã¢ãŒã¯ããã¬ã¹ã«ãã³
ãšåå¿ãããæ¬æ现æžã«èšèŒã®ä»ã®ã¢ãžãŠã¬ãŒã¿
ãŒãšã¯éçžã¯ãããã°ã©ãã€ãŒã«ãã€ãŠåé¢ã§ã
ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®ååéããã³ãµã€ãº
ã¯ã衚瀺éæååééççŽ3500ã®éæèãééã
ãçšåºŠã§ããã ãµãã¬ããµãŒã¯è¡šç€ºéæååééç3500ã®é
æèãééããéæç©ããåé¢ãããããµãã¬
ããµãŒã¯ãéçžã¯ãããã°ã©ãã€ãŒã«ããïŒã
100ïŒ ïŒïœïŒïœïŒãšã¿ããŒã«âæ°ŽåŸé ã§æº¶åºããŠ
åå®å¯èœã§ãããå°ãªããšãéšåçã«ã¢ã³ããªã
ã¢ã€ã¢ãŒïŒããã³ïŒããåé¢ã§ããããµãã¬ã
ãµãŒã¯ãªã¯ã¿ãã·ã«ã·ã©ã³ããæ°Žäžãšã¿ããŒã«67
ïŒ ã100ïŒ ïŒïœïŒïœïŒã®ç¯å²ã§æº¶åºããã96ïŒ
ïŒïœïŒïœïŒã99ïŒ ïŒïœïŒïœïŒïŒããŒãã³ãšã«ããŒæ¿
床枬å®è£ 眮ã®èªã¿åãæ¿åºŠïŒã§æº¶åºããåç»ã«æ
çã«ååšããããã®åç»ã®å±æç枬å®å€1.3602ã
1.3606ããèšç®ããããšã¿ããŒã«æ¿åºŠã¯97ã99ïŒ
ã§ããããµãã¬ããµãŒã¯éçžã¯ãããã°ã©ãã€
ãŒã«ãããäž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãšã®å
é¢æ§ããå€æããŠãããã¬ã¹ã«ãã³ãšåå¿ããŠè¢
å ãçããããšã¯ãªããDHç®èåå¿ã®æå¶ã¯ã
ãµãã¬ããµãŒãå絊è ãDHå¿çã瀺ãè©Šéšæ
åã®æ³šå°åãŸãã¯ãã®æ³šå°ãšåæã«æ³šå°ããå Žå
ã«çºçŸãããæå¶ã¯å¯éæ§ã§ãçæéäœçšåã§ã
DHã®çºçŸããçŽ72æéé 延ããããã¢ã³ããªã
ã¢ã€ã¢ãŒïŒããµãã¬ããµãŒãšåæã«æ³šå°ãããš
æå¶ã¯èªããããªãã ãµãã¬ããµãŒã¯ã衚瀺éæååééç12000
ã®éæèãééããããéæååééçé3500ã®
èã§ã¯éæãããªãçœè¡çæœåºåç»äžã«ååšã
ãããµãã¬ããµãŒã®æŽ»æ§ã«äŒŒãŠããµãã¬ããµ
ãŒæŽ»æ§ã¯å¯éæ§ã§ãæå¶å¹æã¯çŽ72æéç¹ç¶ã
ãããµãã¬ããµãŒã¯ããããã·ã¢ãã¿ã€ãã¯ã
ããã°ã©ãã€ãŒã«ããäž»ããã¬ã¹ã«ãã³åå¿æ§ã
ãŒã¯ããåé¢ãããããšããå€æããŠãããã¬ã¹
ã«ãã³ãšåå¿ããªãã 以äžã®å®æœäŸäžã®æäœã¯ãããäŸäžè ããåŸã
ããææãããã³ããå絊è ã«å¯Ÿããè©Šéšã«ã€ã
ãŠè¿°ã¹ããã®ã§ãããçšããæäœããã³è©Šè¬ã¯ã
ããã®æ²»ççšã®ç¡èãéæ¯æ§çæç©ãåŸãããã
ãã«éžæãããç¹å®ã®æåã«å¯ŸããäŸäžè ããã³
å絊è ã®æåæ§ã¯ãããããè©Šéšããã äŸ ïŒ ç²Ÿè£œæäœ ïŒ¡ çœè¡çã®èª¿è£œ çœè¡çã¯ãå šè¡ãµã³ãã«ã®åç»åãŸãã¯çœè¡
çæ³³åã®ãããããçšããæšæºæ¹æ³ã§èª¿è£œã
ããåè ã®æ¹æ³ã§ã¯ãå šè¡ãµã³ãã«450mlã
MacrodexïŒPharmacia Corporationã
PiscatawayãN.J.ã®åæšåãççé£å¡©æ°ŽäžïŒ
ïŒ ïŒïœïŒïœïŒããã¹ãã©ã³70ïŒäž1xgã§æ²éã
ããŠåç»åããçœè¡çããèµ€è¡çãåé¢ããã
ãã®æ¹æ³ã§çŽïŒãïŒÃ109ã®çœè¡çãååãã
ããçœè¡çæ³³åã¯å€§éã®çŽ°èãåŸãå Žåã«å¥œãŸ
ããã€ããHaemoneticsïŒHaemonetics
Corp.ãBraintreeãMass.ã®åæšåïŒ30så现
èåé¢æ©ã䜿çšããããã®ç³»ã«ã¯ãæ«æ¢¢è¡ãã
ã®çœè¡çã®ååããã³æ²éã«ããæçµçœè¡çã
ã¬ãã¬ãŒã·ãšã³ããã®èµ€è¡çã®é€å»ãå¹æçã«
ããããã46.7ïŒ ã¯ãšã³é žäžãããªãŠã
ïŒHaemoneticsãBraintreeãMassãïŒ30c.c.ãã
ã³500mlã®ïŒïŒ ïŒïœïŒïœïŒVoltexïŒMcGaw
Co.ãIrvineãCalif.ã®åæšåïŒãé«ååéãã³
ãã³ãã¬ãã¬ãŒã·ãšã³ãäžå¡ãããããããã®
å Žåãã37âã§60åéã€ã³ããŠããŒãããã®
ã¡ãçœè¡çã«å¯ãã è¡æŒ¿ãåŸããããè¡æŒ¿ã
400xgã§15åéé æ²åŸã0.5Mé£å¡©æ°Žã§ïŒåæŽæµ
ããŠçœè¡çãååãããæŽæµåŸãçœè¡çãã¬ã
ããâ20âã§åçµä¿åããã现èåé¢æ©ãïŒå
äœåãããŠãçœè¡çã®å¹³ååéã¯ïŒÃ1010åã§
ãã€ãã  éæ çœè¡çæœåºæ¶²ã¯æ» èç¶æ ã§èª¿è£œãããçœè¡ç
ãã¬ãããïŒïœïŒéçé žã¢ã³ã¢ããŠã 10mlã«å
æžæ¿ãããã©ã€ã¢ã€ã¹âã¢ã»ãã³æµŽäžã§10åå
çµãè解ãããè¿ããã溶解ç©ããŸããéæå
åééç12000ã®ã»ã«ããŒã¹éæããŠãŒã
ïŒArthur H.ThomasãInc.ãChicagoãIll.ïŒã
çšããïŒïœïŒéçé žã¢ã³ã¢ããŠã ã«å¯ŸããŠéæ
ãããç·©è¡æ¶²ãïŒå亀æããéæ液ãåããŠå
çµä¹Ÿç¥ããå°å®¹éã®éçé žã¢ã³ã¢ããŠã ã«å溶
解ããéæååééç3500ã®ã»ã«ããŒã¹ããŠãŒ
ããçšããïŒïœïŒéçé žã¢ã³ã¢ããŠã ã«å¯ŸããŠ
ååãšåæ§ã«éæããã第ïŒã®éæã«ãããæ®
ç液ãæ¬æ现æžã§ã¯ïŒ¬åç»ãéæ液ãåç»ãš
åŒã¶ãååç»ã次ã®äœ¿çšãŸã§â20âã§åçµä¿å
ããã  ã²ã«é Sephadex â10ïŒPharmaciaãInc.ã
UppsalaãSwedenã®åæšåïŒãïŒïœïŒéçé ž
ã¢ã³ã¢ããŠã äžã§äžå€èšæœ€ãããã€ãã§ãªãŒã
ã¯ã¬ãŒãã§åŠçããã埮ç²æ«ãé€å»ããã®ã¡ã
1.5cmÃ151cmã«ã©ã ã«å å¡«ããïŒïœïŒéçé žã¢
ã³ã¢ããŠã ã§å¹³è¡¡åãããå溶解ããåç»ã®
ããã¬ã¹ã«ãã³åå¿æ§ç©è³ª400mgãBohlenãP.
ãïŒArch.Biochem.Biophys.155ã213ïŒ1973ïŒ
ã«ãããããå®éåºæºãšããŠã®ãŠã·è¡æž ã¢ã«ã
ãã³ã«åºã¥ãããã«ã©ã ã«è² è·ããããµã³ãã«
ã¯ïŒïœïŒéçé žã¢ã³ã¢ããŠã ã«ãããæµé13
mlïŒæã§æº¶åºãããïŒã«ã©ã 容éïŒ254mlïŒã
0.8mlã®ãã©ã¯ã·ãšã³ãšããŠæ¡éãããåãã©
ã¯ã·ãšã³100ÎŒããšã€ãŠã254nïœã«ããã玫
å€ç·åžåããã³ããã¬ã¹ã«ãã³ãšã®åå¿æ§ã調
ã¹ããçµæã¯ç¬¬ïŒå³ã«ç€ºããšããã§ããã äž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãåŸãããã
ãã®ãã¿ãŒã³ã¯äŸäžè éã§å€åã¯ãªãã€ããã
ãã¬ã¹ã«ãã³åå¿æ§ãšã®é¢ä¿ã§ã®ã¢ãžãŠã¬ãŒã¿
ãŒæŽ»æ§ã®äœçœ®ã¯äžé£ã®10ååžé液ã«ããã€ãŠ
DHå¿çã枬å®ããŠæããã«ãããDHå¿çã®
æ§è³ªã¯åžéã«ãã€ãŠå šãäºæãã¬æ¹åã«å€åã
ããããã¬ã¹ã«ãã³ããŒã¯ã®é åã®éåžéãµã³
ãã«ã¯ãæååç¬ã«å¯Ÿããå¯Ÿç §å¿çã«æ¯ã¹ãŠæ
åã«å¯ŸããDHå¿çãäœäžããã10-2ããã³
10-3ã®åžéã§ãé©ãã¹ãããšã«ãDHå¿çã¯å¯Ÿ
ç §ã«æ¯ãå¢åŒ·ããããããã«é©ãã¹ãããšã«ã
10-5ã®ãªãŒããŒã«åžéãããšDHå¿çã®æå¶ã
èªããããããã®ãããªç°åžžãªå¿çæ§ã瀺ãå
ç»ããæ¬æ现æžã§ã¯ã¢ãžãŠã¬ãŒã¿ãŒç¢ºèªåç»ãš
åŒã¶ããã®åç»ãéžã³ããã«ç²Ÿè£œããããã®ã
ããªå®éšãããåé¡ã®æŽ»æ§ïŒã¢ãžãŠã¬ãŒã¿ãŒç¢º
èªåç»ïŒã¯äž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãšã
ãã«å ç«ã€å°ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ãå«
ãé åã«ååšããããšãããã€ãã次ã®ç²Ÿè£œå·¥
çšã§ã¯ãåç»ïŒïŒïŒãïŒïŒïŒïŒç¬¬ïŒå³ã«ç€ºãïŒ
ãéããåçµä¹Ÿç¥ããããã®åç»ã®äž¡åŽã«ãã
ã«åéåç»ãåºããã°æçµåçãæ¹è¯ãããå¯
èœæ§ããããæé©ã®åç»éžæã¯ãŸã 確å®ããŠã
ãªãã äžéšã®å®éšã§ã¯ããã€ãšçãïŒ80cmïŒ
SephadexGâ10ã«ã©ã ãçšããŠã²ã«éãè¡
ã€ããé·ãã«ã©ã ã®æ¹ãåé¢ãæ¹åãããç¹ã
é€ããçµæã¯ã»ãŒåæ§ã§ãã€ãããšãã«ãé·ã
ã«ã©ã ã§ã¯ãäž»ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯ã
ãæåéäŸåæ§ã®ã€ã³ããŠãŒãµãŒãåé¢ãã
ãã ã²ã«éã«ä»£ããŠãæé€ååééç5000ã®ã¹
ã«ãã³åããªã¹ãã¬ã³ãžããã«ããŒã³
ïŒShodex â802ïŒïœãæåé»å·¥è£œïŒã®ïŒÃ25
cmã«ã©ã ãçšããæµé0.8mlïŒåã®æ°Žã§æº¶åºã
ãé«éã²ã«æé€ã¯ãããã°ã©ãã€ãŒã«ãã粟補
ããããšãå¯èœã§ãã€ãã  éçžã¯ãããã°ã©ãã€ãŒ ãªã¯ã¿ãã·ã«ã·ã©ã³ã®ã«ã©ã ãçšããïŒã
100ïŒ ïŒïœïŒïœïŒåŸé ã®ãšã¿ããŒã«æ°Žæº¶æ¶²ã§æº¶
åºããéçžé«å§æ¶²äœã¯ãããã°ã©ãã€ãŒã«ãã
ããã«ç²Ÿè£œãè¡ã€ããã«ã©ã ã«ãµã³ãã«30mg
ïŒããã¬ã¹ã«ãã³åå¿æ§ã«åºã¥ããŠïŒãè² è·ãã
æµé0.5mlïŒåã§æº¶åºããïŒmlåç»ãéããã
äžéšã®ãã¬ãã¬ãŒã·ãšã³ã§ã¯ããšã¿ããŒã«âæ°Ž
åŸé ã«ç¶ããŠã100ïŒ ãšã¿ããŒã«ã«ããåé床
ã§æº¶åºãè¡ã€ãã åãã©ã¯ã·ãšã³ãåçµä¹Ÿç¥ããççé£å¡©æ°Ž
0.5mlã«å溶解ãããåãã©ã¯ã·ãšã³0.1mlãã
ãããããå容è ãæåæ§ã瀺ãããšã確èªã
ãæåãšãšãã«ç®å 泚å°ãã24æéåŸã®ç®èå
å¿ã調ã¹ããçµæã第ïŒå³ã«ç€ºãã 第ïŒå³ã«ç€ºãåé¢ã«ãããæåã¹ãã¬ããã
ããŒãŒïŒSKïŒã«æåæ§ã瀺ããªãäŸäžè ãã
ç©è³ªãåŸããå容è ã¯ã¹ãã¬ãããããŒãŒã«æ
åæ§ã瀺ãããšãããã€ãŠãããå容è ããã¢
ãžãŠã¬ãŒã¿ãŒã®ãªãå Žåã«ç€ºãSKã«å¯Ÿããç®
èåå¿ã第ïŒå³ã«æ°Žå¹³ãªç·ãšããŠç€ºããããã®
ç·ããäžã«ããã°ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ãã
ã以äžã®å¿çã¯æ£åžžããäœãããµãã¬ããµãŒæŽ»
æ§ã瀺åãããåèã®ããã第ïŒå³ã«ãããã¬
ã¹ã«ãã³åå¿ç©è³ªãªãã³ã«åçš®ã®å°ååïŒã»ã
ããã³ããã¹ã¿ãã³ãã¢ã¹ã³ã«ãã³é žããã³ã
ã³ã¢ããããã³ãªã³é žãã€ããã³ãŒããŸã³ïŒã§
è¡ç®¡åå¿æ§ãççèªçºæ§ãŸãã¯æççæ§ãç¥ã
ããŠããç©è³ªãå«ãåç»ã®äœçœ®ã瀺ããå®ç·ã¯
ååç»ã®æº¶åºãããŸãŸã®æ¿åºŠã§ã®ç®èåå¿æ§ã
瀺ããŠããã ååç»ã®çµæããæ°çš®ã®åžé床ã§æäžããé
ååç»ïŒïŒãïŒïŒïŒïŒïŒãïŒïŒïŒïŒïŒãïŒïŒïŒ
ãšæ¯èŒãããåžé床ãé«ãã»ã©ãéã«ã10ã20
ã®éååç»ã§ã¯æ倧ã®ã¢ããªãã¢ã€ã¢ãŒæŽ»æ§ã
瀺ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æ倧掻æ§ã瀺
ãåç»ïŒããªãã³ã«åç»ïŒïŒã®åžéå¹æãã
SKã«å¯ŸããŠæåæ§ã瀺ãåäœã§æž¬å®ãããçµ
æã¯ãæåããã³ã¢ãžãŠã¬ãŒã¿ãŒæ³šå°åŸïŒïŒïŒ
ïŒããã³24æéã®çºèµ€ããã³ç¡¬çµé åã®çžŠæšªã
mmã§ç€ºãããã¢ãžãŠã¬ãŒã¿ãŒã¯ççé£å¡©æ°Žã§åž
éããããã®ããŒã¿ã¯ç¬¬ïŒè¡šã«ç€ºãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã®å ŽåïŒç¬¬ïŒå³ã®åç»
ïŒïŒãè©Šéšããå šåžé床ã§åŒ·ãä¿é²ããå¢åŒ·äœ
çšãèªããããæ€èšããå šæ¿åºŠã§è©Šéšéšäœã®é£œ
åã瀺ããŠãããããããªãããåç»ïŒïŒã§
ã¯ã10ã1000ååžéã§ã®ã¿ææãªå¢åŒ·ãèªãã
ãããããã€ãŠãã¢ã³ããªãã¢ã€ã¢ãŒïŒæŽ»æ§ã«
ã¯æçãªè³é©æ¿åºŠãåŸããããããçšåºŠã®ä¿é²
ãã¿ãããããã¢ã³ããªãã¢ã€ã¢ãŒïŒã»ã©æç
ã§ã¯ãªãã€ãã 第ïŒå³ã®éåžéãµã³ãã«ã«ã€ããŠã®æž¬å®ã§åŸ
ãããã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ã®ããšïŒããŒã¯
ã¯ãå¿ ããããå šãã¬ãã¬ãŒã·ãšã³ã«ãããã¢
ã³ããªãã¢ã€ã¢ãŒã®çã®äœçœ®ã瀺ããã®ã§ã¯ãª
ããããã«ã¯ããã€ãã®çç±ãããã第äžã«ã
äŸäžè ã«ããçœè¡çäžã®ã¢ãžãŠã¬ãŒã¿ãŒæ¿åºŠã
ç°ãªããã§ãããçœè¡çäžã«ä»ã®ç©è³ªãããã
ããããã¬ãã¬ãŒã·ãšã³ã«åœ±é¿ããå Žåãã
ããè©Šéšããå容è åŽã®çç©åŠé©ãªå€åãã
ããæåŸã«ãã¢ã³ããªãã¢ã€ã¢ãŒïŒã®å Žåãæ¿
床ã«ãã€ãŠéã®å¹æã瀺ãããšãé¢ä¿ããããš
ãã«ç¬¬ïŒå³ã«ãããŠãåç»ïŒïŒãïŒïŒã®é åã§
掻æ§ãäœäžããã®ã¯ããã®é åã§ã¯ã¢ã³ããªã
ã¢ã€ã¢ãŒãäžèšè³é©æ¿åºŠã«ãã€ãçµæã§ããã
ãšã¯æçã§ãããé©åœã«åžéããå Žåãã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒã®æŽ»æ§ããŒã¯ã¯åç»ïŒïŒãïŒïŒ
ã®é åã«èªããããã¹ãã§ããããã®çµè«ã第
ïŒå³ã«ç¹ç·ã§ç€ºãããããã¯ã¢ã³ããªãã¢ã€ã¢
ãŒïŒæŽ»æ§ãè³é©åžéã«ãããŠæž¬å®ãããšããŠã®
æšæž¬æ²ç·ã§ããã åç»ïŒïŒãïŒïŒã«ã¯ïŒ³ãµãã¬ããµãŒæŽ»æ§ãã¿
ããããæåãšåæã«æ³šå°ãããšããµãã¬ã
ãµãŒã¯æ³šå°ïŒãŸãã¯24æéåŸã®DHå¿çã®çºçŸ
ãå¹æçã«é²æ¢ãããããã«å¯Ÿããæååç¬ã
泚å°ããå Žåã«ã¯ã24æéåŸã«æçãªDHå¿ç
ãèªããããã¢ã³ããªãã¢ã€ã¢ãŒïŒãŸãã¯ïŒã
ååšãããšããã§ã¯ããã€ãšåŒ·ãå¿çããèªã
ããããçµæã第ïŒå³ã«ç€ºããæ£è ã®å·Šè ã«ã
第ïŒå³ã«ç€ºã溶åºåŸé ã®åç»ãéãïŒïŒ10ãã
ã³ïŒïŒ100ã«åžéãããã®ããæ£è ã®è ã«ç€ºã
ãããã«HPâPKâïŒã«ã¯HPâïŒïŒåç»ïŒã
ïŒïŒãåãïŒãHPâPKâïŒã«ã¯HPâïŒïŒåç»
ïŒïŒãïŒïŒãåãïŒãHPâPKâïŒã«ã¯HPâ
ïŒïŒåç»ïŒïŒãïŒïŒãåãïŒãPPDãšæ··åããŠ
äžé£ã«ç®äžæ³šå°ãããPPDåç¬ã®å¯Ÿç §ã®æ³šå°
ã¯æ£è ã®å³è ã«è¡ã€ããHPâïŒããã³HPâ
ïŒã泚å°ããéšäœã§ã¯ããã®åç»äžã®ã¢ã³ããª
ãã¢ã€ã¢ãŒã«ãããå¯Ÿç §ã«æ¯ã¹ãŠççã®å¢åŒ·ã
芳å¯ããããããããªãããHPâïŒåŠçéšäœ
ã§ã¯ãååšãããµãã¬ããµãŒã®æŽ»æ§ããã®åç»
ã®ã¢ã³ããªãã¢ã€ã¢ãŒã®æŽ»æ§ãäžåããšæã
ããççã¯äœäžããããµãã¬ããµãŒæŽ»æ§ã¯å€§
éšåã®äŸäžè ã§ãéçžã¯ãããã°ã©ãã€ãŒã®ã
ãŒã«ããåç»ïŒïŒãïŒïŒã«ã¿ãããããµãã¬
ããµãŒæŽ»æ§ãåäžã®åç»ããšãã°ç¬¬ïŒå³ã®åç»
ïŒïŒã«èªããããå Žåããã€ããããããªã
ããå šãã¬ãã¬ãŒã·ãšã³ã§åžžã«åäžãã©ã¯ã·ãš
ã³ã«ãµãã¬ããµãŒæŽ»æ§ãã¿ãããã®ã¿ã§ãªãã
ãã®ãããªæŽ»æ§ã®ååšã¯äŸäžè éã§å·®ãã¿ãã
ãã éçžã¯ãããã°ã©ãã€ãŒã«ããåé¢ãã20ã
ã30ãŸã§ã®é åã®åãã©ã¯ã·ãšã³ã«ã€ããŠæ°çš®
ã®åžéãè¡ã枬å®ãããšãã¢ã³ããªãã¢ã€ã¢ãŒ
ïŒïŒïŒããã³ïŒã®ååšã確èªããããã¢ã³ããª
ãã¢ã€ã¢ãŒïŒã®æŽ»æ§ããŒã¯ã¯åç»ïŒïŒããã³ïŒ
ïŒãã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æŽ»æ§ã¯åç»ïŒïŒã«
éãŸããã¢ã³ããªãã¢ã€ã¢ãŒïŒã®æŽ»æ§ã¯äž»ãšã
ãŠåç»ïŒïŒããã³ïŒïŒã«ååšããããµãã¬ã
ãµãŒã¯åç»ïŒïŒããã³ïŒïŒã«èªãããããã¯ã
ããã°ã©ãã€ãŒã®ä»£è¡šççµæã第ïŒå³ã«ç€ºãã
第ïŒå³ã§ã¯ãå¯Ÿç §ã«å¯ŸããDHå¿çã®å€åã
ïŒïœÃïœïŒâïŒa*Ãb*ïŒã«ããç®èåå¿ã®çšåºŠã§
ããããããïœããã³ïœã¯åç»ïŒæåã®æ³šå°ã«
ãã€ãŠçããçºèµ€éšäœã®çŽåŸããããã«çŽäº€ã
ã軞ã«ãã€ãŠæž¬å®ããŠmmã§è¡šç€ºããå€ã§ããã
a*ããã³b*ã¯æååç¬ã泚å°ããŠçããå¯Ÿç §
éšäœã§ã®çžåœããçŽåŸã§ãããããªãã¡ããã®
ç®èåå¿ã®çšåºŠã¯æååç¬ãã³æåãšã¢ãžãŠã¬
ãŒã¿ãŒã®æ··åã«ãããç å€ã®é¢ç©ã®å·®ã«ã»ãŒçž
åœãããåç»ïŒïŒããã³ïŒïŒã«ã¿ãããå¯Ÿç §ã¬
ãã«ïŒããå°ããªå€ã¯ãµãã¬ããµãŒæŽ»æ§ããïŒ
ãã倧ããå€ã¯ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ã瀺
ãã第ïŒå³ã«ç€ºããå®éšã§ã¯å¥æ°çªå·ã®åç»ã®
ã¿æž¬å®ããŠããããšãèæ ®ãããšã第ïŒå³ã®ã
ã¿ãŒã³ã¯ç¬¬ïŒå³ã®å Žåã«é¡äŒŒããŠããã ãšã¿ããŒã«âæ°ŽåŸé ããšã¿ããŒã«æ¿åºŠ99.9ïŒ
ã«éããã®ã¡ã100ïŒ ãšã¿ããŒã«ã«ããæµé0.5
mlïŒåã§æº¶åºããïŒmlåç»ãéãããšãéçžã«
ã©ã ããã¢ã³ããªãã¢ã€ã¢ãŒïŒã溶åºãããã
ã®æ¡ä»¶ã§ã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯åç»ïŒïŒã
ïŒïŒã«æ€åºãããèŠããã®æ¿åºŠãæ倧ã«ãªãã®
ã¯åç»ïŒïŒã§ãã€ãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã¯ãå絊è ãæåæ§ã
瀺ãæåã«å¯Ÿããå¿çãä¿é²ãå¢å€§ããããïŒ
Ã108ã®çœè¡çããäžè¿°ã®ç²Ÿè£œæ³ã§çæããçš
éã§ã以åã«æŽé²ãããæåã«å¯Ÿããå¿çãçŸ
æ£ã«ããäœäžããæ£è ã®DHå¿çãæ¹åããå Ž
åã«ããå埩ããããäžè¬çã«ãã¢ã³ããªãã¢
ã€ã¢ãŒïŒã«å¯Ÿããå¿çã¯åžéã«ãã€ãŠå¢å€§ãã
ããè³çåžé床ã¯åå絊è ã«ããããŸãå€åæ
åã«ãã€ãŠãå€åããã第ïŒè¡šã«ã¯ïŒçš®ã®åžé
ã®çµæã瀺ããã§ã¯ãã¹ãã¬ãããããŒãŒæ
åæ§å絊è ã«ã¹ãã¬ãããããŒãŒ2.5åäœãšå
æã«ã¢ã³ããªãã¢ã€ã¢ãŒãæäžãããéçžã«ã©
ã ããéããã¢ã³ããªãã¢ã€ã¢ãŒã®åç»1.0ml
ãåçµä¹Ÿç¥ããççé£å¡©æ°Ž0.3mlã«å溶解ããã
æ瀺ããåç»0.1mlãæ瀺ããããã«ççé£å¡©
æ°Žã§åžéãã泚å°ãããã§ã¯ãPPDæåæ§
å絊è ã«æšæºAplisol PPD1/10åžé液0.05ml
ããã¢ã³ããªãã¢ã€ã¢ãŒã®æ瀺ããççé£å¡©æ°Ž
åžé液0.1mlãŸãã¯å¯Ÿç §ãšããŠççé£åæ°Ž0.1ml
ãšãšãã«æ³šå°ããã ã¢ã³ããªãã¢ã€ã¢ãŒæŽ»æ§ããã€ç©è³ªã¯æ°Žæº¶æ¶²
ãããšãŒãã«ã§æœåºã§ãããæœåºå¯èœãªæŽ»æ§ã¯
æ倧å¹æãåŸãã«åžéãèŠãããããããªã
ããã©ã®ã¢ã³ããªãã¢ã€ã¢ãŒããšãŒãã«æœåºã
ããã®ãã¯äžæã§ãããäžè¿°ã®ã¢ãžãŠã¬ãŒã¿ãŒ
ã®éçžã¯ãããã°ã©ãã€ãŒã«ããåé¢ã¯æ¬æè¡
åéã§å ¬ç¥ã®åçš®éçžã«ã©ã ææãçšããŠå®æœ
ã§ããã溶åºç¶æ ã¯å€åããããäžèšã¢ãžãŠã¬
ãŒã¿ãŒã®åé¢ã«æé©ãªæ¡ä»¶ã¯æ¬æè¡åéã«ãã
ãéåžžã®ç¥èãæããè ã«ã¯å®¹æã«æ±ºå®ã§ãã
ãã®ã§ããã  éæåç»ã®åç»å éæåç»ã¯ããããã·ã¢ãã¿ã€ãäžã¯ãã
ãã°ã©ãã€ãŒã«ãã€ãŠããã«åç»åã§ãããç²
æ«ãé€å»ããã®ã¡ããããããããããã·ã¢ã
ã¿ã€ããïŒïœïŒéçé žã¢ã³ã¢ããŠã ã§å¹³è¡¡å
ãã1.5Ã20cmã«ã©ã ã«å å¡«ãããåçµä¹Ÿç¥ãã
0.05Méçé žã¢ã³ã¢ããŠã ã«å解ããåç»ã
ã«ã©ã ã«é©çšãããã«ã©ã ã¯0.05Mã0.2Mé
çé žã¢ã³ã¢ããŠã åŸé ïŒ115mlïŒã§ãã€ãã§
0.2Mã0.6Méçé žã¢ã³ã¢ããŠã åŸé ïŒ65mlïŒ
ã§æº¶åºãããåïŒmlã®åç»ã260nïœã®åžåã
ãã³ããã¬ã¹ã«ãã³ãšã®åå¿æ§ã§ã¢ãã¿ãŒã
ããã»ãŒå šåŸé ã«ããããåãã©ã¯ã·ãšã³ãïŒ
åãã€åããŠæ¡åãããåããåç»ã«ã€ããŠã
å絊è ãæåæ§ã瀺ããæåãšãšãã«ç®å 泚å°
ããŠçç©æŽ»æ§ã調ã¹ããçµæã第ïŒè¡šã«ç€ºãã
çžå¯ŸDHå¿çã¯ã硬çµé åã®çŽåŸã25ããã³43
æéã«æž¬å®ããŠmmã§è¡šããæååç¬ã泚å°ãã
å Žåã®å¯Ÿç §åå¿éšäœãšæ¯èŒããŠç¬¬ïŒè¡šã«ç€ºã
ãã0.1Mãš0.15Mã®éçé žã¢ã³ã¢ããŠã ã®é
ã«æº¶åºããåç»ïŒïŒïŒããã³ïŒïŒïŒã¯ãå°ãªã
ãšã43æéãDHåå¿ã匷åã«æå¶ããã72æ
éåŸã«ã¯ïŒïŒïŒããã³ïŒïŒïŒã®åç»ã泚å°ãã
éšäœã«10mmÃ10mmã®åå¿ãã¿ããããã®æå¶æŽ»
æ§ã¯æéããã€ãšå¯éæ§ããã€ããšã瀺ããŠã
ãã äŸ ïŒ ç¹åŸŽããã³å¯Ÿç §å®éš  äŸ1Bã§çœè¡çæœåºæ¶²ã補é ãããšåæ§ã«ã
ãŠéæèµ€è¡çæœåºæ¶²ã補é ãããåå¥éæã
SephadexGâ10ã«ã©ã ã¯ãããã°ã©ãã€ãŒã
äŸïŒã«èšèŒãããšåæ§ã«ããŠå®æœãããåŸãã
ãåç»ã«ã¯ãå ç«ã¢ãžãŠã¬ãŒã¿ãŒæŽ»æ§ã¯èªãã
ããªãã€ãããããã€ãŠã芳å¯ãããçç©æŽ»æ§
ã¯ãæœåºããã³ç²Ÿè£œå·¥çšã§å°å ¥ããããã®ã§ã¯
ãªãã€ããããã«ãè¡å°æ¿æœåºæ¶²ãåäžã®ç²Ÿè£œ
å·¥çšã«ä»ããããã¢ãžãŠã¬ãŒã¿ãŒæŽ»æ§ã¯ã¿ãã
ãªãã€ãã粟補ã¢ã³ããªãã¢ã€ã¢ãŒã®äžéšã¯å
ã¯ãããã°ã©ãã€ãŒã«ä»ããããã¯ããã®ç²Ÿè£œ
æãšã»ãŒåãæåã瀺ããã  茞éå åã«é¢ããå è¡æè¡ã®èšè¿°ããã芳å¯
ãããå絊è ã®æåæ§å¢å€§ããäŸäžå·®ã«ã¯æ€å°
ã§ããªãã€ãäœã¬ãã«ã®æåæ§ã®èŒžéã«ããã
æ¿çž®ãããŠå絊è ã«ãããŠæåæ§ã®å¢å€§ãšããŠ
çŸããã®ã§ã¯ãªããšããããšããã§ããéãæ
çœã«ããããšãéèŠã§ãã€ãããã®å Žåã«çšã
ãå®éšæ¹æ³ã¯ãå°åçã«å±åšããããšãæãã
ãªæåãŸãã¯å»åŠçã«è¿œè·¡ã§ããèµ·æºã®æåã«
ã€ããŠè©Šéšããæ¹æ³ããããçµæ žèã®ç²Ÿè£œã¿ã³
ãã¯èªå°äœãPPDã¯å»åŠçã«è¿œè·¡å¯èœã§ãã
ã€å°åçã«å±åšãããPPDã«å¯Ÿããæåæ§ã¯
BCGïŒBacille CalmetteâGuerinïŒã§ã¯ã¯ãã³
åãããåæŽã®ããåäœã«çããããã¯æ¬§å·ã§
ã¯çµæ žã«å¯Ÿããå ç«ãä»äžããããåºç¯ã«çšã
ãããŠãããããããªãããç±³åœã§ã¯èš±å¯ãã
ãããšããªãããã¹ããã©ãºãã³ã¯å°åçã«å±
åšããæåã§ããããã¹ããã©ãºãã³ã«å¯Ÿãã
æåæ§ã¯ç±³åœåéšãç±åž¯å°æ¹ã«å€ãããã¹ãã
ã©ãºãçã¯ãã®å°æ¹ã®é¢šåç ã§ããã欧å·ã«ã¯
ãªãã å¯Ÿç §å®éšã§ã¯ãäŸäžè ã¯ç±³åœåéšçãŸãã§ã
ãã¹ããã©ãºãã³ã«ã¯ç®èè©Šéšã§æåæ§ã瀺ã
ããPPDã«ã¯åå¿ããªãè ãéžãã ãå絊è
ã¯ãã€ãšè±åœã«äœãã§ããŠãPPDã«å¯Ÿããç®
èè©Šéšã§æåæ§ã瀺ãããBCG泚å°ã®åæŽã
ãã€ãããã®å®éšã«çšããã¢ã³ããªãã¢ã€ã¢ãŒ
ãã¬ãã¬ãŒã·ãšã³ã¯äžè¿°ã®ããã«Sephadex 
â10åç»å·¥çšã«ãã粟補ããããçã80cmã«ã©
ã ãçšããŠåé¢çšåºŠã®äœããã®ãšãããããã
ã€ãŠãè©Šéšç©è³ªã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒãïŒã
ãã³ïŒ³ãµãã¬ããµãŒã®æ··åç©ã§ãããã«ããã¬
ã¹ã«ãã³åå¿æ§ç©è³ªãå«ãã§ãããããããªã
ããçµæã¯ãã¬ããŒã·ãšã³äžã«èŒžéå å掻æ§ã
ãªãããšã蚌æãšããŠéèŠã§ããã çµæã¯ç¬¬ïŒè¡šã«ç€ºããïŒåã®å絊è ããã
ããïŒçš®é¡ã®ããã¬ã¹ã«ãã³åå¿æ§ããŒã¯
ïŒSephadexã«ã©ã ïŒïŒããã³ïŒïŒåç»ïŒã§è©Šéš
ãããããã¬ã¹ã«ãã³åå¿æ§ã«åºã¥ã2.4mgã®
åãã©ã¯ã·ãšã³ãåç¬ã«ãŸãã¯PPD25åäœãš
ãšãã«æ³šå°ãããã¯ããã®æ³šå°ãã14æéåŸ
ã«ãæåã泚å°ããªãã€ãéšäœã«ããã¹ããã©
ãºãã³ã0.1mlã®ãã¹ããã©ãºãã³æåïŒPark
âDavis Corp.ãDetroitãMich.ãççé£å¡©æ°Ž
ïŒïŒïŒïŒïŒïœïŒïœåžé液ãšããŠåžè²©ïŒãææŠãããã
PPDãŸãã¯ãã¹ããã©ãºãã³åç¬ã泚å°ãã
å¯Ÿç §éšäœãé©åœãªæéã«æºåããã第ïŒè¡šã«
ã¯ãç®èåå¿ã®åŒ·åºŠãã泚å°éšäœã«å²ã硬çµé
åã®çŽåŸïŒmmïŒã§ç€ºããããŒã¿ã¯ãå絊è ãã
çœè¡çæœåºæ¶²åç»ã®æ³šå°åãåŸããããããã¹
ããã©ãºãã³ãšåå¿ããèœåããããªãã€ãã
ãšã瀺ããŠãããã¢ã³ããªãã¢ã€ã¢ãŒã®ä¿é²ã
ãã³å¢åŒ·ã®äž¡å¹æãèªãããããäžæ¹ããã¹ã
ãã©ãºãã³æåæ§ã®èŒžéã¯ã¿ãããªãã  æ¬çºæã®ã¢ããªãã¢ã€ã¢ãŒæŽ»æ§ã®éèŠãªç¹
ã¯ãè©Šéšãããã¹ãŠããä¿é²ïŒã¢ã³ããªãã¢ã€
ã¢ãŒïŒïŒããã³å¢å€§ïŒã¢ã³ããªãã¢ã€ã¢ãŒïŒïŒ
掻æ§ãªãã³ã«ã¢ã³ããªãã¢ã€ã¢ãŒïŒãå«ããŠå š
身çã«æå¹ãªããšã§ãããããã«ãå šèº«çå¹æ
ã¯ç¡æäœæ§æ£è ïŒçŸæ£ã§æ£åžžãªå ç«å¿çãæ¶å€±
ããæ£è ïŒã«ãèªããããšãã§ããã BCGã®æ¢åŸããããçŸåšã¯çŸæ£ã®ããPPD
ã«éåå¿æ§ã§ããæ£è ããäžè¿°ã®äŸ2Bã®ã¢ã³
ããªãã¢ã€ã¢ãŒã10ã100åã®é«çšéç®äžæ³šå°
ãããšãããPPDã«å¿çã瀺ãããã«ãªã€ãã
æåã«å¯Ÿããå¿çã¯ã¢ã³ããªãã¢ã€ã¢ãŒã®æ³šå°
éšäœã«å±éãããªãã€ãã å šèº«çå¹æã¯ã¢ã³ããªãã¢ã€ã¢ãŒïŒãçšããäž
é£ã®å®éšã§åçã«ç€ºãããããµã«ã³ã€ããŒã·ã¹ã«
ïŒå¹Žé眹æ£ããå šæåã«å¯Ÿããå¿çãèãã匱ã
ãªã€ãŠããæ£è ã®äŸã瀺ãã以äžã«è©Šéšãè¡ã€
ããè©Šéšç¬¬ïŒæ¥ã«ãæ£è ã«ç Žå·é¢šãããœã€ããã
åç¬ããã³çš®ã ã®åžé床ã§ã¢ã³ããªãã¢ã€ã¢ãŒïŒ
ãšãšãã«æäžãããçµæã¯ã第ïŒè¡šã«ç€ºããã
ã«ãç Žå·é¢šãããœã€ãåç¬ã§ã¯ç¡¬çµã®ãªã匱ãçº
èµ€åå¿ããã¢ã³ããªãã¢ã€ã¢ãŒïŒãšãšãã«æäžã
ããšãã¯ããããªå¢å€§ã瀺ãããããããªããã
ã©ã®è©Šéšéšäœã«ã硬çµã¯ãªããæ£è ãé©åœã«å¿ç
ããŠããªãããšã瀺ããŠãããè©Šéšç¬¬ïŒæ¥ãæ£è
ã«éçžã¯ãããã°ã©ãã€ãŒåç»ïŒïŒããã®ã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒããçŽïŒÃ108ã®çœè¡çããæœåº
ãããçžåœéãç®äžæ³šå°ãããè©Šéšç¬¬ïŒæ¥ã«ãæ£
è ã«å床ãç Žå·é¢šãããœã€ãããåç¬ã«ãŸãã¯æ°
çš®ã®åžé床ã®ã¢ã³ããªãã¢ã€ã¢ãŒïŒãšãšãã«åå
åæ§æäžããããã®ãšãã¯ãã¢ã³ããªãã¢ã€ã¢ãŒ
ïŒã«æçãªåå¿ããã€ãŠã第ïŒè¡šã«ç€ºãããã«ç¡¬
çµãèªããããããã®çµæã¯ç¬¬ïŒæ¥ã«æäžããã¢
ã³ããªãã¢ã€ã¢ãŒïŒã®å šèº«çå¹æã«ãã€ãŠä¿®é£Ÿã
ããæåã«å¯Ÿããå¿çãå¢å€§ããããšã瀺ããŠã
ãã ã¢ã³ããªãã¢ã€ã¢ãŒïŒã®å šèº«çå¹æã¯ãæ£è ã®
æ«æ¢¢è¡ãªã³ãçã®in vitroã«ããã掻æ§åã«å¯Ÿã
ãå¿çã®æž¬å®ã«ãã€ãŠãæããã§ããããªã³ãç
掻æ§åã¯ããç¥ãããçŸè±¡ã§ãããæ£åžžäººã®æ«æ¢¢
è¡ãªã³ãçãµã³ãã«ããæ€ç©ããã²ã³ããã€ããž
ãã°ã«ããã³ïŒPHAïŒãªã©ã®å ¬ç¥æŽ»æ§åå€ã«ã
ã现èå¹é€ã§å¢æ®ãèªçºãããå¢æ®é床ã¯å¹å°ã
ãåè£çŽ°èãžã®3Hâãããžã³åã蟌ã¿ã«ã€ãŠè¡š
ããããè©Šéšæ³ã¯OppenheimãJ.J.ãïŒIn Vitro
Methods of Cell Mediated and Tumor
ImmunityïŒBloomãDaviaç·šïŒ573ã585é ã
Academic PressãNew YorkãN.Y.ïŒ1976ïŒã«
èšèŒãããŠããã æ«æ¢¢ãªã³ãçãµã³ãã«ã¯äžèšè©Šéšã®ç¬¬ïŒæ¥ãã
ã³ç¬¬ïŒæ¥ã«æ¡åããå皮掻æ§åå€ã«å¯Ÿããå¿çã
枬å®ãããçµæã¯ç¬¬ïŒè¡šã«ç€ºãã第ïŒæ¥ã«ã¯ãªã³
ãçã¯æ£åžžã®å¿çã¬ãã«ããããªãäœãã€ããã
第ïŒæ¥ã«ã¯ïŒçš®ã®æŽ»æ§åå€äžã®ïŒçš®ã«å¯Ÿããæ£åžž
ãŸãã¯å¢å€§ããå¿çã瀺ãããããªãã¡ãã¢ã³ã
ãªãã¢ã€ã¢ãŒïŒã®ç®äžæ³šå°ã«å¯Ÿããå šèº«çå¿çã
çããã äžè¿°ã®å®éšã§ããã¿èããã²ã³ã¯Gibco
LaboratoriesãGrand IslandãN.Y.ãPHAãã
ã³ã³ã³ã«ãããªã³ïŒ¡ã¯Difco Laboratoriesã
DetroitãMich.ããåŸããçµæã¯ç¬¬ïŒè¡šã«ã3Hâ
ãããžã³åã蟌ã¿ãã«ãŠã³ãïŒåã§ç€ºããã äŸ ïŒ åå¿é¡è ã«ã€ããŠã®å®éšçµæãããééºäŒæ§ã®
ç¡æäœæ§ãŸãã¯å ç«æ©èœäœäžç¶æ ã®å絊è ã®å ç«
å¿çãäžè¿°ã®ã¢ã³ããªãã¢ã€ã¢ãŒã§å¢å€§ã§ããã
ãšãæããã§ãããå¿é¡è ã«ã€ããŠã®äžéšã®å®éš
çµæã¯Sephadex â10ã¯ãããã°ã©ãã€ãŒã«ã
粟補ç©è³ªã§ãã¢ã³ããªãã¢ã€ã¢ãŒã®æ··åç©ãšèã
ãããç©è³ªãçšããŠè¡ããããæ²»çæ¹æ³ã®å¥œãŸã
ãæ æ§ã¯æ¬¡ã®ãšããã§ããã ã¢ã³ããªãã¢ã€ã¢ãŒïŒãïŒã¯éçžã¯ãããã°ã©
ãã€ãŒãçšããäŸïŒã«èšèŒããããã«èª¿è£œã粟補
ããã掻æ§åç»ãéããåçµä¹Ÿç¥ããççé£å¡©æ°Ž
ãŸãã¯çççã«èš±å®¹ãããããŒã¯ã«ã«å溶解ã
ããæå¹éãããšãã°ïŒÃ107ã®çœè¡çãã粟補
ãããã¢ã³ããªãã¢ã€ã¢ãŒïŒãïŒã«çžåœããéã
å«ã0.1mlãç®äžæ³šå°ãããå ç«å¿çã®å¢å€§ã¯ã
æåæ§ãã€ããšãããã€ãŠããæåã«å¯Ÿããæ£è
ã®åå¿æ§ãã¢ã³ããªãã¢ã€ã¢ãŒã®æäžååŸã§æ¯ã¹
ãŠã¢ãã¿ãŒãããã¢ã³ããªãã¢ã€ã¢ãŒã¯ææã®å¹
æã«å¿ããŠãåç¬ãŸãã¯é åæäžãããã¢ã³ããª
ãã¢ã€ã¢ãŒã®æäžã«ãã€ãŠçããç³»ã®ä¿®é£Ÿã®ç¹ç¶
ã¯æ£è éã§ç°ãªããäžè¿°ã®é©åœãªæåæ§è©Šéšã«ã
ãåšæçã«ã¢ãã¿ãŒããªããã°ãªããªããææã®
å ç«åŒ·åãç¶æããããã«ã¯ãå»åž«ã®å€æã«ã
ããæäžãããè¿ãã äŸ ïŒ ã¢ã³ããªãã¢ã€ã¢ãŒã¯ãåç¬ã«ãŸãã¯é åã
ãŠã匱ãã¯ã¯ãã³ã«å ç«å¿çãçãããããã«äœ¿
çšã§ãããå€ãã®ç åäœãããšãã°æ°çš®ã®ãããŠ
çèå€çš®ããã¹ããã©ãºãçãã«ã³ãžãçãçã
ãèã¯ãäžéšã®æ£è ã§ã¯åŒ·ãå ç«å¿çãèªçºããª
ãããããããã®çš®ã®æ£è ã«å ç«æ©èœãäžããæº
足ã§ããã¯ã¯ãã³ã¯ç¥ãããŠããªãããã®çš®ã®è
ã®ææã¯ããšãã«ãçååŠçæ³ãå ç«æå¶å€çæ³
ãåããŠããæ£è ã«ãšã€ãŠã¯å±éºã§ããã匱ãæ
åã«å¯Ÿããæ£è ã®å ç«å¿çãå¢åŒ·ããããšã«ã
ããäžè¿°ã®ã¢ã³ããªãã¢ã€ã¢ãŒã®ïŒçš®ãŸãã¯ïŒçš®
以äžã®æäžã¯ããã®çš®ã®ç åäœã«å¯Ÿããã¯ã¯ãã³
ã®è£œé ãå¯èœã«ãããååŠçæ³ãŸãã¯ç§»æ€æè¡ã
åããããšããæ£è ã¯ãæ²»çåã«ããã¹ããã©ãº
ãçãã«ã³ãžãçã«çœ¹æ£ãããããªããªãããã«
ã¯ã¯ãã³åããããšãã§ããã ã¯ã¯ãã³ã¯ãå ¬ç¥æ¹æ³ã«ããé©åœãªæžæ¯ããã³
éå¢æ®åããæ¹æ³ã§èª¿è£œããææã®ç åäœã®æå
ããäŸïŒã«èšèŒã®æ¹æ³ã§è£œé ããã¢ã³ããªãã¢ã€
ã¢ãŒïŒãïŒãšåããŠè£œé ãã®ã奜ãŸãããã¯ã¯ã
ã³ã¯åžžæ³ã«ãã€ãŠæäžããã äžè¿°ã®ããã«äœ¿çšããã°ãã¢ã³ããªãã¢ã€ã¢ãŒ
ïŒãïŒã¯ãå»åŠçäºé²æ³ã®ç¯å²ãæ¡å€§ããå ç«æ§
æåã®å¯èœæ§ãåºããããšãæåŸ ã§ããã äŸ ïŒ é節ãªãããã«ããç®èåå¿ãŸãã¯ä»ã®æ¥è§Šé
ææ§åå¿ã¯ïŒ³ãµãã¬ããµãŒåŠçœ®ã§äºé²ããããæ¥
觊ç®èåå¿ããšãã°ããããä»ã®ã¢ã¬ã«ã²ã³ã«å¯Ÿ
ããåå¿ã®äž»èŠéšåã¯DHåå¿ã§ããããšãç¥ã
ããŠããŠããã®çš®ã®æ²»çã¯æ¬¡ã®ããã«å®æœãã
ãããµãã¬ããµãŒã¯äŸïŒã«èšèŒããããã«ããŠ
粟補ã§ãããéçžã¯ãããã°ã©ãã€ãŒã§åŸããã
掻æ§åç»ãéããåçµä¹Ÿç¥ããã€ãã§ãã³ãŒã«ã
ã¯ãªãŒã åºå€çµæç©ã®ãããªå±ææäžã«é©ããè»
èã«å°å ¥ãããåå¿ãããšãã°çµç¹ãŸãã¯èåšç§»
æ€ã®ããã«å šèº«æ§ã®å Žåã¯ãéçµå£æäžã奜ãŸã
ããåäŸäžè ã«ãã€ãŠãµãã¬ããµãŒæŽ»æ§ã®åçã¯
å€åããã®ã§ãé©çšéã¯æŽ»æ§åäœã§è¡šãå¿ èŠãã
ããïŒãµãã¬ããµãŒåäœã¯ããDHåå¿ã®ç¡¬çµã®
çŽåŸãïŒmmäœäžãããã®ã«å¿ èŠãªæå°éãšå®çŸ©ã
ããããã®å®çŸ©ãçšããŠãèšåºçã«å¿ èŠãã€ãŠå€§
çšéãæäžããå Žåã«ã¯100cm2ãããå°ãªããšã
ïŒåäœã®å²åã§çšãããåŠçœ®ã¯å±éºãããéãç¶
ããå°ãªããšãïŒæ¥ã«ïŒåã®ééã§è¡ãããèšåº
äžå¿ èŠãªãã³ããã«é »åã«è¡ãããšãã§ãããå
æ£è ã®åå¿ã¯ãæ£è ã®æåã«å¯Ÿããæåæ§ã®çš
床ãããã³ãµãã¬ããµãŒã«å¯Ÿããåå¿ã«ããå€å
ããããã®çš®ã®çµæç©ã«ã¯ãã¹ããã€ããŸãã¯ä»
ã®æççå€ãå ããŠãæ²»çå¹æãå¢åŒ·ãããããš
ãæå©ã§ããã äŸ ïŒ é節ãªãããããã³ä»ã®æ¥è§Šç®èåå¿ã¯ãäŸïŒ
ã«èšèŒããæ¹æ³ã§è£œé ãããµãã¬ããµãŒã«ãã
é²æ¢ã§ããããã®å Žåããç®èåå¿ã®DHæåã
ãã®æ²»çæ³ã®æå¹æ§ãæ瀺ãããããããã·ã¢ã
ã¿ã€ãã¯ãããã°ã©ãã€ãŒããåŸããã掻æ§åç»
ãéããåçµä¹Ÿç¥ããå±ææäžã«é©ããè»èçµæ
ç©ã«å°å ¥ããããåå¿ãå šèº«çãªå Žåãããšãã°
çµç¹ãŸãã¯ç®è移æ€ã§ã¯ãéçµå£æäžã奜ãŸã
ããæäžéããã³æäžæ¹æ³ã¯ãäŸïŒã«è¿°ã¹ããšã»
ãŒåãã§ããã ãµãã¬ããµãŒãšïŒ³ãµãã¬ããµãŒã¯ãå¥åã«ãŸ
ãã¯åäžçµæç©ã«æ··åããŠé©çšã§ããã æ¯æ§ æ¬çºæã«ããããå ç«ç³»ã¢ãžãŠã¬ãŒã¿ãŒã¯ãã
ãããäžèšãããããªäººäœç©è³ªã®æœåºç©ã§ããã
ãã®æ¯æ§ã¯æ€åºã§ããªãçšäœããåæœåºç©ã®è©Šéš
ã«ãããŠããæ¯æ§ãããæ害ãªäœçšã¯èŠãåºãã
ãªãã€ãã äžè¬ççµè« å ç«ç³»ã«ãããäžè¿°ã®ã¢ãžãŠã¬ãŒã¿ãŒã¯ã倩ç¶
ã«ãããŠå ç«ã®èª¿æŽããçŽæ¥çŽ°èå ç«ã«ãããã
ã³å€åéæ¥çã«äœæ¶²æ§å ç«ã«ã圱é¿ããŠå¶ãã§ã
ãç©è³ªãšèããããããã®ç©è³ªã¯é«çŽåºŠã«èª¿è£œã
ããã®ã§ããã®æ§è³ªãç¹å®ããããšãã§ãããã
ã®æ§è³ªã¯ãå è¡æè¡ã«å ±åãããŠãã茞éå åã
ãã®éšååç»ãšã¯å šãç°ãªããäºæãã¬çžç°ã瀺
ãããæ¬çºæã®ã¢ã³ããªãã¢ã€ã¢ãŒããã³ãµãã¬
ããµãŒã¯ãåçš®ã®å ç«æ©èœäº¢é²ããã³äœäžç¶æ ã
åããæ£è ã®æ²»çã«äœ¿çšã§ããããã®ç©è³ªã¯ç¹ç°
çãªæ§è³ªãæããè ãšããããããæ£åžžäŸäžè ã
ãåé¢ã§ãããããã€ãŠããŒã«ããåæãã倧èŠ
æš¡ãªç²Ÿè£œã容æã§ããç¹ã§ãšãã«éèŠã§ãããæ¬
çºæã®ã¢ãžãŠã¬ãŒã¿ãŒã¯ãã®çç©æŽ»æ§ããã³ç©ç
æ§ç¶ã§å®çŸ©ããããã®ã§ãã€ãŠãå¿ ãããåäžå
åŠç©è³ªããæ§æããããã®ã§ã¯ãªãã æ¬çºæã以äžãç¹å®ã®å¥œãŸããæ æ§ãåç §ããŠ
説æããããæ¬çºæã®ç²Ÿç¥ããã³ç¯å²ããéžè±ã
ãããšãªãããã«æ¹å€ãå¯èœãªããšã¯åœç¶ã§ã
ããæ¬çºæã¯ãäžè¬ã«æ¬çºæã®åçã«ãããããŸ
ãæ¬çºæã®å±ããæè¡ç¯å²å ã§å ¬ç¥ãæ £çšã®å®å
ã«ããæ¬çºæããã®å€æŽã«åºã¥ããã¹ãŠã®æ¹å€ã
䜿çšãŸãã¯é©çšãå å«ãããããšãã°ãéæãã
ã³éæèã«ããéæãæ¬æ现æžã§ã¯æ¡çšããŠãã
ãããã®èªã¯ååããã³ïŒãŸãã¯çç©æŽ»æ§ãããµ
ã€ãºããã³ïŒãŸãã¯ééã§åé¢ããåçæ¹æ³ãå
å«ãããããªãã¡ãéæã®èªã¯ãéå€éãè¶ é
å¿ããã³é»æ°æ³³åãå å«ãããã®ã§ããã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14973780A | 1980-05-14 | 1980-05-14 | |
| US25688681A | 1981-05-06 | 1981-05-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57500611A JPS57500611A (ja) | 1982-04-08 |
| JPH0453848B2 true JPH0453848B2 (ja) | 1992-08-27 |
Family
ID=26846987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56501991A Expired - Lifetime JPH0453848B2 (ja) | 1980-05-14 | 1981-05-14 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0042064B1 (ja) |
| JP (1) | JPH0453848B2 (ja) |
| AU (1) | AU555652B2 (ja) |
| CA (1) | CA1163194A (ja) |
| DE (1) | DE3176443D1 (ja) |
| DK (1) | DK214481A (ja) |
| FI (1) | FI78483C (ja) |
| IE (1) | IE53572B1 (ja) |
| IL (1) | IL62870A (ja) |
| NO (1) | NO156516C (ja) |
| WO (1) | WO1981003279A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468379A (en) * | 1982-05-06 | 1984-08-28 | Endeavor Corp. | Leukocyte extracts for affecting the immune system |
| US4616079A (en) * | 1984-08-24 | 1986-10-07 | Imreg, Inc. | Immunoamplifiers and processes for the extraction thereof |
| CA1286989C (en) * | 1985-12-26 | 1991-07-30 | A. Arthur Gottlieb | Immunoamplifiers and related compositions |
| EP0247538A3 (en) * | 1986-05-28 | 1989-08-30 | Imreg, Inc. | Immunosuppressor and method of extraction thereof |
| GB8614733D0 (en) * | 1986-06-17 | 1986-07-23 | Lefesvre A | Aids treatment |
| CA2086610A1 (en) * | 1990-07-02 | 1992-01-03 | Charles H. Kirkpatrick | Transfer factor and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991182A (en) * | 1971-10-19 | 1976-11-09 | The Regents Of The University Of California | Transfer factor |
| US4132776A (en) * | 1978-02-15 | 1979-01-02 | University Patents, Inc. | Delivery of immunologically active components of transfer factor |
| US4180627A (en) * | 1978-08-17 | 1979-12-25 | The United States Of America As Represented By The Secretary Of Agriculture | Process for in vivo transfer of cell-mediated immunity in mammals with alcoholic precipitates of Bovine Transfer factor |
| NO793412L (no) * | 1978-10-25 | 1980-05-06 | Benzon As Alfred | Fremgangsmaate for fremstilling av overfoeringsfaktor mot patogene antigener |
-
1981
- 1981-05-13 FI FI811473A patent/FI78483C/fi not_active IP Right Cessation
- 1981-05-13 NO NO811626A patent/NO156516C/no unknown
- 1981-05-13 IE IE1075/81A patent/IE53572B1/en not_active IP Right Cessation
- 1981-05-14 AU AU70578/81A patent/AU555652B2/en not_active Ceased
- 1981-05-14 WO PCT/US1981/000640 patent/WO1981003279A1/en unknown
- 1981-05-14 DE DE8181103702T patent/DE3176443D1/de not_active Expired
- 1981-05-14 IL IL62870A patent/IL62870A/xx unknown
- 1981-05-14 JP JP56501991A patent/JPH0453848B2/ja not_active Expired - Lifetime
- 1981-05-14 CA CA000377601A patent/CA1163194A/en not_active Expired
- 1981-05-14 DK DK214481A patent/DK214481A/da not_active Application Discontinuation
- 1981-05-14 EP EP81103702A patent/EP0042064B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| WO1981003279A1 (en) | 1981-11-26 |
| CA1163194A (en) | 1984-03-06 |
| AU7057881A (en) | 1981-11-19 |
| IL62870A (en) | 1985-03-31 |
| JPS57500611A (ja) | 1982-04-08 |
| DK214481A (da) | 1981-11-15 |
| EP0042064A3 (en) | 1983-01-19 |
| AU555652B2 (en) | 1986-10-02 |
| NO156516C (no) | 1987-10-07 |
| IL62870A0 (en) | 1981-07-31 |
| EP0042064A2 (en) | 1981-12-23 |
| NO811626L (no) | 1981-11-16 |
| IE811075L (en) | 1981-11-14 |
| FI78483B (fi) | 1989-04-28 |
| DE3176443D1 (en) | 1987-10-22 |
| FI78483C (fi) | 1989-08-10 |
| EP0042064B1 (en) | 1987-09-16 |
| NO156516B (no) | 1987-06-29 |
| IE53572B1 (en) | 1988-12-21 |
| FI811473L (fi) | 1981-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4468379A (en) | Leukocyte extracts for affecting the immune system | |
| Vowels et al. | Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne | |
| DE69133485T2 (de) | Verwendung von Staphylococcus Enterotoxin Homologe fÃŒr Krebs-Therapie | |
| US4250084A (en) | Purified thymic hormone (THF), its preparation and pharmaceutical compositions containing it | |
| ANTONIADES et al. | Studies on the state of insulin in blood: Properties of circulating âfreeâ and âboundâ insulin | |
| DK172578B1 (da) | IgE-bindingsfaktorer fra kolostrum fremgangsmåder til fremstilling deraf, anvendelse af disse faktorer samt farmaceutisk pr | |
| JPH0453848B2 (ja) | ||
| JPS6053009B2 (ja) | èçãŠã€ã«ã¹ïœã«ããæ¥æ§ãŸãã¯æ ¢æ§ã®æææ²»ççšã®æ°èŠå»è¬ | |
| Keiser et al. | âNonspecificâ stimulation of lymphocyte transformation by cellular fractions and acid extracts of group A streptococci | |
| US4001080A (en) | Production of immunological materials | |
| Burnett et al. | Some immunological aspects of sea nettle toxins | |
| US4148886A (en) | Polypeptide possessing thymic activity | |
| Bout et al. | Purification, immunochemical and biological characterization of malate dehydrogenase ofSchistosoma mansoni | |
| Richter et al. | Studies on the allergens of ragweed pollen: A review | |
| EP0200090A2 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
| Burnett et al. | A comparison of the toxicology of the nematocyst venom from sea nettle fishing and mesenteric tentacles | |
| Herz | On the effects of tannic acid on erythrocyte membrane acetylcholinesterase | |
| JPH0347200A (ja) | ãã«ã©ã¹ã ã®ç±æ¥ã®ç³ã¿ã³ãã¯è³ªããã®è£œé æ³åã³ãããå«æããå ç«èª¿ç¯å€ | |
| JPH0123447B2 (ja) | ||
| RU2799637C1 (ru) | СпПÑПб пПлÑÑÐµÐœÐžÑ Ð±ÐžÐŸÐ»ÐŸÐ³ÐžÑеÑкО акÑОвМПгП пепÑОЎМП-аЌОМПкОÑлПÑМПгП пÑепаÑаÑа Ма ПÑМПве Ð¿Ð»Ð°Ð·ÐŒÑ ÐºÑПвО ÑелПвека | |
| Moura et al. | Lipids from Mycobacterium leprae cell wall are endowed with an antiâinflammatory property and inhibit macrophage function in vivo | |
| Grellet et al. | An associated process for the purification of immuno globulin g, catalase, superoxide dismutase and albumin from haemolysed human placenta blood | |
| Blyth et al. | Particulate and soluble antigens of Micropolyspora faeni in experimental allergic alveolitis of the mouse | |
| Britton et al. | Grass Pollen Extracts IV. The Biological Activity of Rye Pollen Extracts and their Fractions | |
| CA1303295C (en) | Immunosuppressor and method of extraction thereof |